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Abstract 
About 95 % of nutrient protein is absorbed in the mammalian intestine as amino acids 
and tri- and dipeptides. Once absorbed by the intestine amino acids are distributed by 
the circulation throughout the body. In the kidney an ultrafiltrate of the blood plasma 
is generated from which all amino acids are reabsorbed in the proximal tubule. System 
B° is the main amino acid transport system in these two tissues for broad neutral 
amino acids. 
Four transporters B°AT1 (SLC6A19), B°AT2 (SLC6A15), B°AT3 (SLC6A18) and ASTC2 
(SCL1A5) have properties of this system when studied in isolation. B°AT1 and B°AT2 co-
transport one Na+-ion and one amino acid substrate. The low-affinity B°AT1 
transporter accepts most neutral amino acids, while the high-affinity transporter 
B°AT2 prefers branch-chained amino acids and proline. B°AT3 prefers alanine and 
glycine, but has also been reported to transport a variety of neutral amino acids. 
ASCT2 is a Na+-dependent antiporter, preferring neutral amino acids except those with 
an aromatic side-chain. However, in two studies it has been reported that amino acid 
transport of ASCT2 was inhibited also by phenylalanine. Analysis of ASCT2 function in 
vivo and in vitro, has led to the proposal that it represents the molecular correlate of 
system B° in kidney and intestine. Mutations in B°AT1, however, cause Hartnup 
disorder, a defect of neutral amino acid transport in kidney and intestine. Thus it is 
important to reconcile differences and to clarify the contribution of these amino acid 
transporters to system B°-like transport in kidney and intestine. 
Therefore, the overall aim for this thesis was to investigate the distribution and 
contribution of B°AT1 (SLC6A19), B°AT2 (SLC6A15), and ASTC2 (SCL1A5) to neutral 
amino acid transport in the kidney. 
Immunofluorescence studies revealed localisation of B°AT1 in the apical membrane of 
early (S1-S2) segments of the proximal tubule, while B°AT2 was localised to the apical 
membrane of the later (S2-S3) segments. This is consistent with physiological data 
reporting low-affinity transport in early segments and high-affinity transport in later 
segments of the proximal tubule. ASCT2 was localised in the apical membrane of S2 
segments and in the basolateral membrane of the distal tubule. 
Transport studies with renal brush border membrane vesicles revealed a dominant 
transport activity that is consistent with the properties of B°AT1. This transport activity 
was lacking in B°ATl-deficient mice. B°AT2 activity was excluded by competition 
studies with selective substrates. ASCT2 activity was excluded due to the lack of 
additional amino acid transport in brush border membrane vesicles preloaded with 
ASCT2 amino acid substrates. Therefore, it is concluded that B°AT2 and ASCT2 do not 
contribute significantly to neutral amino acid transport in the kidney. B°AT1 is the main 
transport activity for neutral amino acid transport in the kidney. 
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Chapter 1 - General Introduction 2 
1.1 Introduction 
In all animals, amino acids play a fundamental role in several biological processes, such 
as biosynthesis of proteins, cell growth and neurotransmission, just to mention a few. 
Special membrane proteins mediating amino acid transport into and out of the cell are 
necessary, as the hydrophobic nature of the membrane restricts the movement of 
amino acids across it. Hence those membrane proteins are essential for life. 
1.2 Short history of the discovery of amino acid transport systems and 
their nomenclature 
In mammalia, absorption and reabsorption of nutrients for nutrient homeostasis of the 
organism primarily takes place at two sites: in the small intestine and in the renal 
proximal tubule. Proteins are a major part of the human diet. They are taken up as part 
of our nutrition and are then partially hydrolysed by enzymes secreted by the stomach 
and intestine to form oligopeptides. These are digested further by brush border 
peptidase into amino acids, tri- and dipeptides. All three compounds are taken up by 
enterocytes of the small intestine. 
In the enterocytes, peptides are hydrolysed and the resulting amino acids are released 
together with those absorbed directly, into the blood. Through the bloodstream, the 
amino acids are transported to every tissue in the body. Protein digestion and 
absorption is an efficient process. Less than 4 % of ingested nitrogen leaves the body in 
faeces. Also, only minimal amounts of amino acids are wasted in urine due to efficient 
reabsorption of amino acids from the primary urine. As a result less than 5 % of all 
ingested amino acids are discarded (Matthews, 1991). 
Processes of nutrient into cells or across epithelial cells have been the subject of 
intensive research over several decades (reviewed in (Kilberg, 1982; Palacin et al., 
1998; Broer, 2008). Over the years, several mechanisms were discussed for those 
processes. However, it is now established that absorption of nutrients is mostly an 
active process occuring against a concentration gradient. It involves several specific 
transporters that meditate transport of amino acids, peptides, sugars, lipids and other 
nutrients for the body. 
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Already by the beginning of the twentieth century basic studies of amino acid 
transport into animal cells were conducted. In 1913, it was shown that amino acids can 
be accumulated against a concentration gradient in tissues (Van Slyke, 1913). Later, in 
the 1960s, more detailed information on transport processes in non-epithelial cells 
was elucidated by the work of the Halvor Christensen Laboratory (Oxender and 
Christensen, 1963). Their work showed that amino acid transporters are more likely to 
accept groups of similar amino acids than just single amino acids as substrates 
(reviewed in (Christensen, 1984; Christensen, 1990). Further investigations established 
a variety of transport activities using intact tissue, primary cell cultures, cell lines and 
preparations of cell membranes, such as brush border membrane vesicles or 
proteoliposomes. 
In this period, before the onset of molecular cloning, some important concepts were 
discovered. For instance, it was shown that amino acids can be taken up against a 
concentration gradient into epithelial cells and that this transport often required a 
Na+-gradient across apical membranes (Crane, 1965). Additionally, based on work in 
the 1960s, amino acid transport activities were identified and were classified as 
systems with abbreviations indicating their substrate specificity, which was usually 
broad and overlapping. This system is still in use today to describe amino acid 
transport activities in cells and tissues. Accordingly, the amino acid transport activity 
preferring leucine and other large hydrophobic neutral amino acids has been referred 
to as system L (Le Cam and Freychet, 1977). System A indicates a transporter 
preferring alanine and other small and polar neutral amino acids (Le Cam and Freychet, 
1977) and system ASC denotes an alanine, serine and cysteine preferring transporter 
(Christensen etal., 1967). 
A different nomenclature was used for systems transporting cationic amino acids and 
anionic amino acids, x denotes a transporter for anionic amino acids, while y denotes a 
cationic amino acid transporter. In this nomenclature, z refers to neutral amino acids. 
Upper case acronyms are used for Na+- dependent transporters while lower case 
acronyms are used for Na+- independent transporters, with the exception of system L 
and system T, which are in fact Na+- independent (reviewed in (Verrey et al., 2005). 
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However, many of the classic systems introduced by the Christensen's group did not 
match with the transport activities in epithelial cells, resulting in the definition of 
further systems (Broer, 2002). The new systems were referred to as the neutral system 
(B for kidney or neutral brush border (NBB) for intestine nomenclature) mediating 
transport of neutral amino acids, the basic system (b0,+), transporting cationic amino 
acids and cystine, the imino(glycine) system mediating uptake of proline, 
hydroxyproline and glycine and the acidic system (X"A,G) transporting aspartate and 
glutamate. 
In 1990 the identification of the first mammalian amino acid transporter cDNA, 
encoding a GABA transporter in the human brain (Guastella et al., 1990), started a 
cascade of efforts to identify amino acid transporter cDNAs. The cloning of the first 
gene for an a-amino acid transport protein, which mediated transport of cationic 
amino acids (Kim et al., 1991; Wang et al., 1991) was another breakthrough in this 
field. Subsequently, with the development of new molecular biological techniques 
together with the oocyte expression systems and homology screening, the door to the 
identification of genes for plasma membrane amino acid transporters was opened. It 
subsequently was shown that the cloned amino acid transporters matched the 
physiologically identified systems. Initial genomic analysis of amino acid transporter 
gene sequences demonstrated that these could be grouped into twelve solute carrier 
families (Hediger et al., 2004). However, some cloned transporters could not be 
assigned to a classic system. The human Genome Organisation (HUGO) Nomenclature 
Committee Database provides a list of transporter families of the solute carrier gene 
series. Currently it includes 48 families. 
Due to changes and inconsistency in the nomenclature, cDNA annotation is confusing 
at times. To facilitate this overview, Table 1 summarises the major amino acid 
transporter systems of mammalian epithelial cells together with their mediators, 
substrate specificity, mechanisms and mediating ions. 
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Table 1.1: Major epithelial amino acid transport systems, their substrate specificities and 
mechanisms. 
Classic 
System cDNA 
SLC 
number Amino Acid Substrates Analogues 
Mech-
anism 
Coupling 
Ions 
A SNAT1 SLC38A1 G, A, S, C, a N, H, M MeAlB S Na+ 
SNAT2 SLC38A2 G, P, A, S, C, a N, H, M MeAlB S Na+ 
SNAT4 SLC38A4 G, A, S, C, a N, M, AA+ MeAlB S Na+ 
ASC ASCT1 SLC1A4 A, S, C, T Cysteic acid A Na+ 
ASCT2 SLC1A5 A, S, C, T, Q Cysteic acid A Na+ 
asc ascl/4F2hc* SLC7A10 G, A, S, C, T D-AA° A -
B° B°AT1 SLC6A19 AA° BCH S Na+ 
B°AT2 SLC6A15 P, L, V, 1, M BCH S Na+ 
B0 + ATBC,+ SLC6A14 AA°, AA+, P- A BCH S Na+, CI" 
b°'+ rBAT/bO'+AT+ SLC7A9 R, K, 0, Cystine A -
P TauT SLC6A6 Tau, P - A S Na+, CI 
Gly B°AT3/XT2 SLC6A18 G, AA° S Na+, CI 
GlyT2 SLC6A9 G S Na+, CI" 
IMINO IMINO/SIT1 SLC6A20 P, HO-P MeAlB S Na+, CI 
L LATl/4F2hc* SLC7A5 H,M, L, 1, V, F, Y, W BCH A -
LAT2/4F2hc* SLC7A8 AA° except P BCH A 
LAT3 SLC43A1 L, 1, M, F BCH U -
LAT4 SLC43A2 L, 1, M, F BCH U -
N SNAT3 SCL38A3 a N, H S Na+ (S), H+(A) 
SNAT5 SLC38A5 a N, H, S, G S Na
+ (S), H+(A) 
PAT PAT1 SLC36A1 P, G, A, GABA, P-A MeAlB S H+ 
PAT2 SLC36A2 P, G, A S H+ 
Phe ? ? F, M -
TAT1 SLC16A1 F, Y, W U -
X AG EAAT1 S LCI A3 E, D S Na
+ (S), H+(A) 
EAAT2 SLC1A2 E, D D-Asp S Na+ (S), H+(A) 
EAAT3 SLC1A1 E,D D-Asp S Na+ (S), H+(A) 
X"c xCT/4F2hc* SLC7A11 E, C" A -
+ 
y CAT1 SLC7A1 R, K, 0, H U -
y+L y+LATl SLC7A7 K, R, a H, M, L A Na
+ (S AA°) 
y+LAT2 SCL7A8 K, R, a H, M, L, A, C A Na
+ (S AA°) 
The genes coding for a transport activity are shown. Systems are classified in the solute carrier 
(SLC) series according to www.bioparadigms.org/slc/menu.asp and the HUGO Nomenclature 
Committee database (www.genenames.org/). The amino acid substrates are given in one-
letter codes with neutral amino acids (AA°), cationic amino acids (AA+), ornithine (O) and 
hydroxyproline (HO-P). The transport mechanisms are: antiport (A), symport (S) und uniport 
(U). *Heterodimeric transporter: for achieving transport activity association with SLC3A2 is 
essential. Information presented in this table was taken from ((Broer, 2008)), with additional 
information referring to literature by (Palacin et al., 1998) and (Singer et al., 2009). 
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1.3 Organisation and anatomy of the kidney and the intestine 
As mentioned before, the two major sites for reabsorption and absorption of nutrients 
are the kidney and the small intestine. Here, transporters assist in amino acid 
absorption across epithelial cell layers into the bloodstream. It is known that 
transporter function and activity changes along the intestine and along the kidney 
nephron. (Scriver and Tenenhouse, 1985) 
Therefore, it is essential to investigate the distribution of those transporters in their 
organs, for instance by immunofluorescence to gain information about their function. 
This anatomy section will mostly refer to the human kidney and intestine since it is 
wildly described although it is generally transferrable to other mammals. In particular, 
to mice, which form the subject of the investigations described in this thesis. 
1.3.1 The kidney 
The kidney has three essential functions for the body. Firstly, it is the body's blood 
filter, removing metabolic waste products and toxins, such as creatinine and urea from 
the blood and disposing them via the urine. Secondly, it regulates electrolyte balance 
thus contributing to whole body homeostasis. Thirdly, it produces or activates 
hormones that regulate blood pressure, calcium metabolism and production of red 
blood cells (Evans etal., 1995). 
The anatomy of the kidney is shaped according to its functions. The kidneys are paired, 
bean shaped organs which are located behind the peritoneum on each side of the 
vertebral column, usually extending from the 12th thoracic to the third lumbar 
vertebra. The size of the kidney is dependent on the body weight usually forming less 
than 0.5 % of the total body weight. An average human kidney is 12 cm in length while 
a mouse kidney is less than 1 cm. 
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The macroscopic structure of the kidney is shown in Figure 1.1. Each kidney is covered 
by a fibrous capsule. The capsule contains an opening, the hilus, accommodating the 
entry point for the renal artery and nerves and the exit point for the renal vein and the 
ureter. The hilus opens up into a space referred to as the renal sinus. The renal pelvis, 
a urine filled space, with its extensions, the major and minor calyces, are part of this 
renal sinus as well as blood vessels and nerves. The kidney itself can be divided into 
two layers, the cortex and the medulla. The cortex is the more granular outer region 
and consists of glomeruli - tiny clews of capillaries and a large number of tubules 
formed from epithelial structures. The medulla is the inner region and lacks glomeruli. 
It possesses an arrangement of tubules and blood vessels. The medulla can be 
subdivided into conical renal pyramids. Usually 8 to 18 of those pyramids are found in 
one kidney. The base of each pyramid faces the cortex while the tip of each pyramid 
ends into the renal pelvis. The urine flows through perforations from the pyramids into 
the minor calyces of the renal sinus (Boron and Boulpaep, 2005). 
Medulla 
(pyramid) Cortex 
Nephron 
Renal sinus 
Renal calyx 
Papilla of pyramid 
Figure 1.1: Macroscopic structure of the kidney. 
Depicted are the different layers of the kidney, the capsule, the cortex, the medulla and the 
renal pelvis with sub-structures. Also shown is the renal pelvis making the exit and entrance to 
the kidney. 
(Figure adapted from Boron and Boulpaep, 2005) 
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The functional unit of the kidney is the nephron (Figure 1.2). Each kidney contains up 
to 1,200,000 nephrons located mainly in the cortex and the medulla. Each nephron 
consists of a cluster of blood vessels, the previous described glomerulus and a tubule, 
an epithelial structure of many different subdivisions. The two parts are connected 
with each other via the Bowman's capsule or the glomerular capsule. It contains the 
Bowman's space which is the continuation of the tubule and regulates the pressure of 
the glomerulus (Mbassa et a!., 1988). In the Bowman capsule and the Bowman space 
the filtrate enters the tubule system from the vascular system. 
The remaining part of the nephron consists of subdivisions of the tubule. The 
subdivisions are: the proximal tubulus (subdivided into the proximal convoluted tubule 
(PCT) and the proximal straight tubule (PST)), the thin descending and ascending loop 
of Henle, the thick ascending loop of Henle, the distal convoluted tubule, the 
connecting tubule and the initial collecting tubule. Each nephron individually possesses 
these subdivisions, while the following can be shared by two or more nephrons: the 
cortical collecting tubule, the outer medullary collecting duct and the inner medullary 
collection duct, which leads into the duct of Bellini. There are two types of nephrons: 
superficial nephrons, where most of the nephron is located in the cortex of the kidney 
and only short loops extend into the inner medulla and juxtaglomerular nephrons, with 
long loops that extend far into the medulla (Smith, 1951; Kriz and Bankir, 1988; Seldin, 
2000). 
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Initial collecting 
Connecting subule (ICT) K 
tubule (CNT). 
Juxtamedullary 
nephron 
Thin ascending 
Ivnb of Henle's 
loop (tALH) 
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Figure 1.2: Structure of the nephron. 
The two different types of nephrons are shown with their subdivisions glomerulus, proximal 
and distal tubulus connected by the loop of Henle and the different parts of the collecting 
duct. 
(Figure adapted from Boron and Boulpaep, 2005) 
The proximal tubulus can be further subdivided into different parts as shown in Figure 
1.3. An understanding of the structure of this subdivision is necessary to understand 
the immunolocalisation experiments and the role of amino acid transporter 
distribution in Chapter 3. In low magnification the proximal tubulus consists of the 
proximal convoluted tubulus (PCT) and the straight proximal tubulus (PST). However, 
closer examination reveals a more detailed division into segments referred to as SI , S2 
and S3. The S I segment starts at the glomerulus and contains the first portion of the 
PCT. The cells are easy to distinguish from those of the other two segments since the 
glomerulus is easy to identify in kidney sections. The S2 segment starts after the S I 
segment in the second half of the PCT and continues into the first half of the PST while 
the S3 segment covers the second half of the PST. 
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To distinguish between the S2 and the S3 segment, the cell morphology must be 
compared. From the S I to the S3 segment, the epithelial cells become progressively 
thinner. This correlates with the decrease of reabsorption rates along the tubule. 
Furthermore, the brush border membrane of the different segments is gradually less 
developed and the basolateral membrane possesses a smaller cell membrane area 
(Smith, 1951; Kriz and Bankir, 1988; Seldin, 2000; Boron and Boulpaep, 2005). It is well 
known that the distribution of the transporters in these three segments is 
characteristic for each substrate. Transporters in the earlier segments of the proximal 
tubule have high capacity and usually broader specificity but lower affinity for their 
substrates, while transporters in the later segments of the proximal tubule possess 
lower capacity but higher affinity with an usual narrower substrate specificity (Scriver 
and Tenenhouse, 1985). 
Figure 1.3: Nephron with the structure of tubule cells S2 and S3. 
Depicted is a nephron and the subdivision of the proximal tubule into the segments S I to S3 
(the black lines mark the division of the nephron into the different segments) with the 
corresponding cell structure for S2 and S3 as described in the text above. G indicates a 
glomerulus, the adjacent cell to the lef is a S I cell. 
(Figure adapted from Boron and Boulpaep, 2005) 
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1.3.2 The Intestine 
The major functions of the intestine are to absorb nutrients from digested food while 
discarding waste out of the body. The intestine is a convoluted tube extending through 
the abdominal cavity from the pyloric sphincter to the anus. It is proceeded by the 
stomach, the oesophagus and the mouth. In humans it consists of two segments, the 
small and the large intestine. The intestine averages about 8 m in human and about 
25cm in mice but it differs according to size, gender and age of the person or mouse. 
The wall of the intestine is composed of the mucosa, submucosa, muscularis and 
serosa (Figure 1.4). However, they possess structural differences in the two segments 
of the intestine. 
1.3.2.1 The small intestine 
Within the twisted loops of the small intestine, digestion is completed and absorption 
of the majority of nutrients occurs. The diameter of the small intestine is only about 
half that of the large intestine, reaching an average of 3.5 cm in human and an average 
of 2-3 mm in mice. It can be divided into three regions: the duodenum, the jejunum 
and the ileum. 
The microscopic anatomy and histology of the small intestine is highly adapted for 
nutrient absorption (Figure 1.4). The mucosa is composed of a layer of epithelium, 
lamina propria and lamina muscularis mucosae. The epithelial layer itself consists of a 
simple epithelium, which contains several different cell types. The absorptive cells 
digest and absorb nutrients while goblet cells secrete mucus lubricating the passage of 
food. The epithelial layer also contains deep crevices, which are lined with glandular 
epithelium. Cells secreting intestinal juice are referred to as intestinal glands or crypts 
of Lieberkuhn. The glands also contain paneth cells, which secret lysozyme. The lamina 
propria contains connective tissue and a mucosa associated lymphoid tissue while the 
muscularis mucosae consists of smooth muscles. 
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The submucosa of the duodenum contains special Brunner's glands, which secrete an 
alkaline mucus supporting the neutralisation of gastric acid. Generally the submucosa 
contains nerves, blood vessels and elastic fibre with collagen which maintains the 
shape of the intestine even if the intestine stretches. The muscularis of the small 
intestine consists of two layers of smooth muscles. The inner, thicker layer contains 
circular fibres while the outer, thinner layer contains longitudinal fibres. The serosa 
surrounds most of the small intestine except a portion of the duodenum. It is made up 
from loose connective tissue and is coated by the mucosa to prevent damage. 
The special structural modifications of the small intestine are revealed in the anatomy 
of the wall, which contains circular folds or so called plicae circularis, villi and microvilli. 
The circular folds are deep folds of the mucosa and submucosa. They are permanent 
and cause a spiral movement of the food pulp rather than a movement in a straight 
line, allowing more time for full nutrient absorption. 
The villi are finger-like projections of the mucosa. This structure amplifies the 
absorptive structure enormously to a total of 400 to 500 m2. The villi are large in the 
duodenum and become smaller through the intestinal system. Each villus has a cover 
of epithelial cells and a core of lamina propria. Within the lamina propria there are 
blood capillaries and lymph capillaries, the so called lacteal. Absorption of nutrients 
takes place through the epithelial cells into both blood and lymph capillaries. 
The last feature, the microvilli are a projection of the apical membrane of the absortive 
cells of the mucosa. They form the fuzzy layer of the brush border, which increases the 
absorption area further and extend into the lumen of the small intestine. The brush 
border membrane has two major roles. Firstly, it contains several enzymes assisting 
with the digestion and secondly it possesses embedded transporters important for 
absorption of the digested nutrients (Boron and Boulpaep, 2005; Marieb and Hoehn, 
2008; Tortora and Derrickson, 2009). 
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Figure 1.4: Histology of the small intestine. 
The Figure shows the four layers of the intestine, named mucosa, submucosa, muscularis and 
serosa together with the structure of the villi. 
A: Gross anatomical structure of the small intestine. 
B: Enlarged villus structure showing the localisation of the different epithelial cells. 
(Figure adapted from (Tortora and Derrickson, 2009) 
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The small intestine eventually opens into the large intestine, which will be only briefly 
mentioned here, since it is not a site of amino acid absorption, the focus of this study. 
1.3.2.2 The large intestine 
The function of the large intestine is to reabsorb some nutrients, such as short chain 
fatty acids or electrolyte and to remove the remaining water from the digested food 
and compress and discard the resulting faeces. It can be divided into four regions: 
cecum, colon, rectum and anal canal. 
The wall of the large intestine differs from the small intestine in several points. For 
instance, the large intestine does not contain any circular folds, villi or microvilli and no 
cells secreting digestive enzymes since most nutrients are absorbed before reaching 
the large intestine. Furthermore, the mucosa is thicker and the large intestine has 
deeper crypts containing a higher number of goblet cells. They produce a higher dose 
of mucus allowing an easier passage of the digested food through the large intestine 
into the anal canal before it is discarded (Tortora and Derrickson, 2009). 
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1.4 Neutral amino acid transport in kidney and intestine epithelial 
cells 
The absorption or transport of amino acids in epithelial cells of the intestine is an 
evolutionary old process and exists in most organisms, while absorption or transport of 
amino acids in the epithelial cells of the renal proximal tubule cells is an evolutionary 
late invention found in higher vertebrates. It has been shown that transport 
mechanisms are not conserved within mammalian families and can be easily adapted 
to physiological demands in evolution via mutations (Broer, 2002; Veljkovic et al., 
2004). To understand the different transport mechanisms, it is essential to investigate 
the physiology and the cells they are localised in. 
Epithelial cells possess tight junctions that form a selective barrier between the 
individual cells of the epithelium. These junctions prevent random diffusion, for 
instance, backflux of amino acids across the epithelial cell layer and they also form a 
boundary between the apical and basolateral regions of the cell membrane. In 
epithelial cells, transporters exist in two different membrane locations: the apical and 
the basolateral membrane. 
Both plasma membranes are different in almost every aspect, for instance in 
morphology, protein-, lipid-, carbohydrate-composition and transport properties. The 
transporters on the apical and basolateral membrane cooperate in the absorption of 
nutrients, albeit the apical transporters are more investigated than basolateral 
transporters due to their accessibility for studies. Vesicles derived from the basolateral 
membrane (BLMV) were introduced by Hopfer et al. (Hopfer et al., 1976) and had 
limited use. 
Transport functions across the apical membrane in the kidney are well studied. It has 
been shown that accumulation of most neutral amino acids in kidney brush border 
membrane vesicles (BBMV) requires a Na+-electrochemical gradient (Evers eta!., 1976; 
Fass et al., 1977). Proline and glycine are the exception, which transport is proton 
driven in some species. 
Chapter 1 - General Introduction 16 
Furthermore, the combined evidence from different experimental approaches (Young 
and Edwards, 1966; Young and Freedman, 1971; Silbernagl et al., 1975) led to an 
acceptance that a low affinity Na+-dependent neutral amino acid transporter (system 
B°) is present in the proximal tubule of the kidney (Doyle and McGivan, 1992a; Doyle 
and McGivan, 1992b). 
Additionally, heterogeneity of neutral amino acid transport has been reported in the 
kidney (Kragh-Hansen and Sheikh, 1984). For instance, a low affinity uptake of serine 
was observed in the PCT and a high affinity transport system was observed in the PST. 
Similar observations were made for phenylalanine (Kragh-Hansen et al., 1984) and 
branched chain amino acid transport (Jorgensen et al., 1990), suggesting that a variant 
of the system B° is expressed in the PST. Also, a system with similar characteristics to 
system ASC was reported to be present in the kidney apical membrane after 
solubilisation and reconstitution into liposomes of membrane transporters from rat 
kidney BBMV (Oppedisano et al., 2004). 
Only a limited number of studies were conducted with BLMV. A high affinity transport 
system was found in the basolateral membrane of the kidney with properties similar to 
system L. It preferred branched chain amino acids and aromatic amino acids, and was 
also inhibited by 2-Aminobicyclo[2,2,l]heptane-2-carbocylic-acid (BCH), all of which is 
consistent with a system L transporter. The transporter mechanism was that of an 
entirely Na+-independent, electroneutral uniporter (Lash and Jones, 1984). This 
transport activity has not been identified at the molecular level so far. 
In BLMV derived from rat small intestine, a Na+-independent transporter of broad 
specificity was identified by Mircheff et al. (Mircheff et al., 1980). The transporter had 
properties similar to system L. The heterodimeric LAT2/4F2 transporter has been 
identified as part of this activity (Pineda et al., 1999). 
LAT2 requires the glycoprotein heavy chain (he) 4F2hc (SLC3A2, also known as CD98), 
to be present in the basolateral membrane of kidney and intestine. It is required for 
trafficking of the transporter to the membrane (Nakamura et al., 1999; Pineda et al., 
1999; Rossier et al., 1999; Rajan et al., 2000). It transports neutral amino acids except 
proline with an antiport mechanism. 
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Transporters for neutral amino acids in the intestine have been studied in detail, 
especially that of alanine (Curran et al., 1967). Similar to the kidney apical membrane, 
transport of neutral amino acids in the intestine is Na+-dependent and no 
accumulation occurrs in the absence of Na+-ions (Cohen and Huang, 1964; Schultz et 
a I., 1967). 
Most groups have proposed one transporter for neutral amino acid transport in the 
intestinal epithelium (Newey and Smyth, 1964; Preston et al., 1974) with only 
Sepulveda and Smith (Sepulveda and Smith, 1978) proposing two transport systems for 
neutral amino acids in rabbit epithelium. BBMV studies confirmed a Na+-dependent 
transporter for most neutral amino acids. This system was named system B or NBB, to 
indicate the similarity to the kidney transporter (Satoh et al., 1989; Maenz and 
Patience, 1992). Additionally, a system ASC-like activity was detected in the rabbit 
ileum (Maenz etal., 1992; Munckand Munck, 1999). 
Neutral amino acid transporter activity was detected in the intestinal basolateral 
membrane and showed properties similar in general to those found in the kidney 
(Mircheff et al., 1980; Wilde and Kilberg, 1991). It has been reported that glutamine 
uptake across the intestinal basolateral membrane was Na+-dependent and had 
properties of system A (Taylor et al., 1989; al-Mahroos et al., 1990; Wilde and Kilberg, 
1991). 
This glutamine uptake was inhibited by other small amino acids and by the amino acid 
analogue MeAiB. It was hypothesised that the system A transporter SNAT2, which is 
expressed in the intestine (Hatanaka et al., 2000; Sugawara et al., 2000), provides this 
function. Interestingly, SNAT2 is also expressed in the renal medulla (Reimer et al., 
2000) and smaller amounts are also found in the renal cortex, but have not been 
localised further. 
Figure 1.5 gives a general overview over the described transporter system in the 
kidney and the small intestine. 
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A B 
Figure 1.5: Scheme of apical and basolateral transporter activities for neutral amino 
acid absorption. 
Neutral amino acid transporter activities involve in neutral amino acid absorption in kidney (A) 
and intestine (B). Letters inside the circles refer to the amino acid transport systems as defined 
in Table 1.1. TJ: tight junctions; AA°: neutral amino acids; Na+: sodium-ion. 
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1.4.1 Solute carrier families 
As described above, transporters in mammalian cells are categorised on the basis of 
their sequence similarity into solute carrier families (SLC). To date 48 of these families 
with a total of 368 members have been identified (Hediger et al., 2004); 
http://www.bioparadiRms.org/slc). 
Over the years, different candidates have been suggested as being involved in the B°-
like transport activity in the kidney and intestine. To date, the transporters involved in 
neutral amino acid transport belong, amongst others, to solute carrier family 1 and 
solute carrier family 6. Three members of these families will be investigated in this 
study. 
1.4.2 Solute carrier family 6 
Members of the solute carrier family 6 (SLC6), which is larger than solute carrier family 
1 and hence mentioned here first, transport amino acids, neurotransmitters, taurine 
and creatine (Chen et al., 2004). The SLC6 belongs to a larger superfamily of 
transporters with members found in all animals and some bacteria, which maintain 
sodium gradients, but is not found in plants, fungi and yeast (Saier, 2000). The SLC6 
family currently possesses 20 confirmed members and two pseudo genes. The 
members can be further classified into four subfamilies (Figure 1.6) referred to as the 
monoamine transporter branch, the GABA transporter branch, the amino transporter 
branch and the amino acid transporter branch (II), previously known as the 'orphan 
transporter branch'. Since the first members of this family to be discovered were 
transporters for GABA, noradrenaline, dopamine and serotonin, the family is referred 
to as the neurotransmitter transporter family. 
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Figure 1.6: Tree of the mouse SLC6 family. 
The tree shows all 20 members of the mouse SLC6 family (Al- A20) with their respective 
names and aliases. Note that the mouse SLC6A10, -a creatine transporter- does not have a 
correlate in the human genome. Also, in mouse the transporters members A16 and A20 seem 
to have two genes for this locus. 
(Figure is adapted from (Broer, 2006)) 
Initially it appeared that the members of the SLC6 family were Na+- and CI -dependent. 
It was also thought that the transport stoichiometry was the same for all family 
members, namely 2 Na+ : 1 CI" : 1 substrate as shown for instance for the GABA 
transporter (Loo et al., 2000). However, this notion could not be sustained when 
different transport mechanisms were elucidated (Broer, 2002). In fact, the number of 
co-transported Nations varies from one to three. 
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Furthermore, the serotonin transporter SERT also carries out K+-antiport (Rudnick, 
1998). The SLC6 members share the same predicted topology comprising twelve 
transmembrane helices and a length of approximately 500 to 700 amino acids (Chen et 
al., 2004). In 2005, the high-resolution structure of the bacterial LeuT^ transporter 
from Aquifex aeolicus was elucidated, the sequence of which is homologous to SLC6 
transporters (Yamashita et al., 2005). This allowed the generation of homology models 
for SLC6 transporters and confirmation of substrate and ion-binding sites of different 
mammalian SLC6 transporters (O'Mara et al., 2006). The SLC6 members investigated in 
this thesis are B°AT1 and B°AT2. B°AT3 will also be discussed in the context of its renal 
function. The other members are reviewed in (Broer, 2006). 
1.4.2.1 B°AT1 (SLC6A19) 
The neutral amino acid transporter B°AT1 (also previously known as XT2sl or XTRP2sl) 
is the molecular correlate of system B°. It was initially cloned from mouse kidney 
(Broer et al., 2004) and was characterised using flux studies and electrophysiological 
techniques (Bohmer et al., 2005; Camargo et al., 2005). It was named according to the 
mediated transport of a broad (B) variety of neutral (0) amino acids with a preference 
for large, aliphatic amino acids, such as leucine. The order of preference is 
methinone=leucine=isoleucine=valine>glutamine=asparagine=phenylalanine=cysteine 
=alanine>serine=glycine=tyrosine=threonine=histidine=proline>tryptophan>lysine. The 
substrate K0 5 values range from 1 mM (leucine) to 11 mM (glycine). Functional 
characterisation showed the transporter to be Na+-dependent but 
Cl'-independent. Only one Na+-ion is co-transported with the substrate. The substrate 
leucine forms part of the Na+-binding site in both the bacterial homologue LeuT and in 
B°AT1, explaining that an increase of the Na+-concentration decreases the Km of the 
substrate and vice versa (Bohmer et al., 2005). This finding is consistent with a random 
binding order, alternatively it has been suggested that the amino acid binds first to the 
transporter (Camargo et al., 2005). The role of a putative second Na+-binding site 
remains unclear (O'Mara etal., 2006). 
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In situ hybridisation and immunofluorescence analysis localised B°AT1 in the kidney 
proximal tubule (Broer et al., 2004; Romeo et al., 2006) and all parts of the small 
intestine but not the colon (Terada et al., 2005; Romeo et al., 2006). It was shown that 
its expression increases from the duodenum to the ileum in the apical membranes 
with a more distinct signal toward the villi tips. These results are consistent with the 
expression of B°AT1 in differentiated enterocytes (Broer etal., 2004). Furthermore, the 
transporter has also been detected in the spleen and lung. No splice variants of the 
transporter have been reported so far. 
The mouse and especially the human SCL6A19 protein showed very little activity in 
heterologous expressions systems. Therefore, it was a major breakthrough discovering 
that expression of B°AT1 protein in brush border membranes requires co-expression of 
collectrin (Danilczyk and Penninger, 2006; Malakauskas et al., 2007). Accordingly, 
collectrin-deficient mice showed an increased amount of neutral amino acids in the 
urine in combination with a significantly decreased amount of B°AT1 and IMINO 
(SLC6A20) in kidney BBMV. Collectrin (also known as TMEM27) is a type I membrane 
protein with a molecular weight of 27 kDa and was first localised in the collecting duct, 
which gave its name (Zhang et al., 2001). 
Experiments co-expressing B°AT1 and collectrin in Xenopus oocytes showed a five to 
ten-fold increase in transport activity (Danilczyk and Penninger, 2006). Thus, it is now 
established that B°AT1 requires heterodimerisation with collectrin to be expressed at 
the cell surface. Since collectrin is only expressed in the kidney some other auxiliary 
protein was required to express B°AT1 in the intestinal cell surface. Subsequently, the 
peptidase angiotensin-converting enzyme 2 (ACE2), a homologue of collectrin, was 
reported as the B°AT1 partner co-expressed in the intestine (Danilczyk et al., 2006; 
Kowalczuk et al., 2008; Singer et al., 2009). ACE2 is a carboxy peptidase with several 
reported functions. For instance, it cleaves the blood pressure regulating peptide 
angiotensin (II) and it is involved in peptide digestion in the intestine. 
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In 2001, Nozaki et al. mapped the Hartnup disorder gene to chromosome 5 (Nozaki et 
al., 2001). Subsequently, Kleta et al. and Seow at al. identified the SLC6A19 gene, 
which expresses B°AT1, as the gene mutated in Hartnup disorder (Kleta et al., 2004; 
Seow et al., 2004). Hartnup disorder (OMIM234500) is an autosomal recessive disorder 
of neutral amino acid transport in the small intestine and the kidney, which occurs 
with at frequency of about 1:20,000 (Levy, 2001). It was named in 1956 after the first 
described patient, Eddy Hartnup (Baron etal., 1956). Patients show a high excretion of 
neutral amino acids in the urine (aminoaciduria), which is the key diagnostic feature of 
this disease (Baron et al., 1956; Levy, 2001) but it is also associated with a number of 
additional symptoms, such as pellagra-like skin rash and temporary cerebellar ataxia 
(Baron et al., 1956). Additionally, smaller body height and weight (Scriver et al., 1987) 
have been reported. It has been shown in more recent studies that sometimes the skin 
rash or diarrhoea in infancy are the only symptoms for Hartnup disorder. To date, 21 
mutations have been identified in the B°AT1 gene causing Hartnup disorder (Azmanov 
et al., 2008) and reviewed in (Broer, 2009). These data have been collected from 20 
families. 
1.4.2.2 B°AT2 (SLC6A15) 
The neutral amino acid transporter B°AT2 (also known as SBAT1, v7-3, NTT7-3) also has 
properties similar to system B°. It was named B°AT2 for its similarities in structure and 
transport mechanism to B°AT1. B°AT2 has been analysed in two studies (Takanaga et 
al., 2005; Broer et al., 2006). It mainly transports branched chain amino acids and 
proline. Leucine, isoleucine, valine, proline and methionine are transported with high 
affinity, with half saturation constants (K0.5) ranging from 40 to 200 pM, while alanine, 
glutamine and phenylalanine were recognised with low affinity (Broer et al., 2006). 
B°AT2 is Na+-but not Cl"-dependent and its transport is electrogenic. The transport 
mechanism is comparable to that of B°AT1, co-transporting one Na+-ion with one 
substrate (Broer et al., 2006). 
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Initially, B°AT2 was described as a brain specific transporter but further reverse 
transcription-polychain reaction (RT-PCR) studies suggested additional localisation in 
mouse but not human kidney (Farmer et al., 2000; Takanaga et al., 2005; Broer et al., 
2006). The localisation of B°AT2 has been studied extensively in brain tissue (Inoue et 
al., 1996), but its localisation in the kidney has still to be investigated. Splice variants of 
B°AT2 have also been identified (Sakata et al., 1999). Recent studies on B°AT2-deficient 
mice identified respectively a 15 and 40 % reduction of proline and leucine transport 
into cortical synaptosoms in comparison to wild type control mice (Drgonova et al., 
2007) with mild physiologic effects. However, this study did not consider possible 
changes in kidney amino acid transport. 
1.4.2.3 B°AT3 (SLC6A18) 
The function of the transporter B°AT3 (also known as XT2, and previously as XTRP2 or 
ROSIT) could not be characterised for a long time. In the beginning it was only shown 
that different, shorter splice variants were generated - six in mice, for instance (Nash 
et al., 1998). Despite testing a variety of substrates (Wasserman et al., 1994), only data 
generated from experiments using B°AT3-deficient mice produced the first meaningful 
results. The mice showed elevated levels of glycine in their urine, however other 
amino acids appeared to be elevated as well (Quan et al., 2004). 
It was only recently shown that B°AT3, when co-expressed with ACE2 in Xenopus laevis 
oocytes, is a Na+-and Cl-dependent neutral amino acid transporter. It transports 
alanine=methionine>valine=isoleucine>glycine=serine=leucine. 
Concentration dependence experiments with isoleucine and glycine revealed a K0 5 for 
B°AT3 for those substrates of 0.21 mM and 0.53 mM respectively (Singer et al., 2009). 
In contrast, another recent study by Vanslambrouck et al. showed that B°AT3 
preferentially transports alanine and glycine in mice but also showed some transport 
activity for most neutral amino acids excluding proline. Alanine has a higher affinity for 
the transporter (0.9 ± 0.4 mM) compared to glycine (2.3 ± 0.4 mM). 
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Additionally, it was also shown that B°AT3 interacts with collectrin, similar to B°AT1 
(Vanslambrouck et ai, 2010). B°AT3 has been localised in both studies mainly in the 
kidney, more accurately in the brush border membranes of the late proximal tubule 
(S2, S3). Due to its mechanism it was categorised as a B°-like transporter. 
1.4.3 Solute carrier family 1 
The solute carrier family 1 (SLC1) family consists of seven members divided into two 
subfamilies: five high-affinity glutamate transporters and two neutral amino acid 
transporters (Figure 1.7). Similar to the SLC6 family, proteins related to the SLC1 family 
have been identified in some bacteria, which maintain Na+-gradients, but not in plants, 
fungi and yeast (Saier, 2000). 
(GLTl) 
Figure 1.7: Tree of the SLC1 family. 
The tree shows the SLC1 members (A1-A7) together with their common names. 
(Figure adapted from Kanai, 2004) 
The identification of the high-affinity glutamate transporters started in 1992, when 
three isoforms of transporters were independently identified. The first three members 
identified were EAAC1 (Kanai and Hediger, 1992), GLTl (Danbolt et ai, 1992) and 
GLAST (Storck et ai, 1992). After their discovery, it was possible to identify by 
sequence homology two additional glutamate transporters, named EAAT4 (Fairman et 
ai, 1995) and EAAT5 (Arriza et ai, 1997) and two Independent neutral amino acid 
transporters, referred to as ASCT1 (Arriza et ai, 1993) and ASCT2 (Utsunomiya-Tate et 
al., 1996). 
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The glutamate transporters share 44 to 55 % amino acid sequence identity with each 
other. The two neutral ASC transporters are 57 % identical, while the ASC transporters 
are 40 to 44 % identical to the glutamate transporters (Kekuda et al., 1996; 
Utsunomiya-Tate et al., 1996; Kanai and Hediger, 2004). 
The structure of the proteins belonging to the SLC1 family was first predicted to be a 
protein with either eight transmembrane helices with a unique, highly conserved long 
hydrophobic stretch near the C-terminus and a large extracellular glycosylated loop 
between the transmembrane domains three and four (Grunewald et al., 1998; 
Grunewald and Kanner, 2000) or six to ten transmembrane helices (Masson et al., 
1999). However, the high-resolution structure of the bacterial homologue from 
Pyrococcus horikoshii revealed eight transmembrane helices and three independent 
binding sites for substrates, each surrounded by two helical hairpins which assist in 
glutamate transport through the plasma membrane (Yernool et al., 2004). 
Only the neutral amino acid transporters will be further considered in this thesis. The 
other members were reviewed in Kanai, 2004. 
1.4.3.1 ASCT1 (SLC1A4) 
The amino acid transporter ASCT1 (also known as SATT) was the first transporter that 
showed ASC-like properties (Arriza et al., 1993; Shafqat et al., 1993) and was first 
cloned from mouse brain. Typically for system ASC, it transports, as its name indicates, 
L-alanine, L-serine, L-cysteine and L-threonine in a stereospecific manner. This 
transport was reported to be pH insensitive and occurred only in exchange with 
intracellular amino acids associated with one or two Nations in both directions in an 
electroneutral manner (Zerangue and Kavanaugh, 1996). It was shown that under 
some circumstances binding and transport of substrate induces inward currents. 
However, this was due to a substrate-gated anion conductance and not caused by the 
co-transport of ions (Broer et al., 2000). It is expressed in a wide variety of tissues. 
ASCT1 will not be investigated in this project but is listed here for completeness. 
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1.4.3.2 ASCT2 (SLC1A5) 
The amino acid transporter ASCT2 (also known as AAAT and hATB0) is the molecular 
correlate of the intestinal system ASC (Kekuda et al., 1996; Utsunomiya-Tate et al., 
1996) and was first cloned from mouse testis. ASCT2 mediates transport of small 
neutral amino acids such as L-alanine, L-serine, L-cysteine, L-threonine and L-glutamine 
with high affinity and Km values of about 20 |iM, while L-methionine, L-leucine, 
L-glycine and L-valine are transported with lower affinity and Km values of 300 to 500 
HM (Utsunomiya-Tate et al., 1996). However, in a two studies it was observed, that 
ASCT2 transport activity was inhibited by phenylalanine (Kekuda etal., 1996; Pollard et 
al., 2002). Since phenylalanine is a substrate for B° activity, it was hypothesised that 
ASCT2 is or is part of the B° activity observed in the kidney and intestine (Kekuda et al., 
1996; Avissar et al., 2001). 
ASCT2 has been reported Na+-dependent but not electrogenic. This apparent 
contradiction is explained by its antiport transport mechanism, involving an exchange 
of substrates and a Na+/Na+-ion exchange (Broer et al., 2000). No fixed ratio for Na+-
ion and substrate exchange has been reported (Koser and Christensen, 1971) since the 
antiport nature of the ASCT2 transporter does not allow a precise prediction for Na+-
ion transport as with amino acid co-transporters. Due to the antiport mechanism, 
ASCT2 cannot contribute to net efflux of neutral amino acids across the apical 
membrane. 
Northern blot hybridisations showed that ASCT2 is expressed in a wide range of 
tissues, mainly in kidney, large intestine, lung, skeletal muscle, testis and adipose 
tissue (Utsunomiya-Tate et al., 1996). More recent studies with immunofluorescence 
and reconstitution experiments suggest localisation of the ASCT2 transporter in the 
apical membrane of the kidney and intestine, more specifically in the proximal tubule 
and the jejunum and colon of the intestine, while the duodenum and ileum show low 
expression (Avissar et al., 2001; Oppedisano et al., 2004). In contrast, studies by Green 
et al. (2004) suggested expression of ASCT2 in the basolateral membrane within the 
kidney proximal tubule (Green etal., 2004). 
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The functional characterisation of ASCT2 in the small intestine revealed another ability 
of the transporter: it can interact with anionic amino acids at low pH. It has been 
shown that L-glutamate uptake via ASCT2 increases at lower pH, where it is 
transported with a Km value of 1.6 mM (Utsunomiya-Tate et al., 1996). 
As a result, ASCT2 might contribute more to glutamate transport than to neutral amino 
acid transport (Pontoglio et al., 1996) in the acidic microclimate of the small intestine 
but this has still to be confirmed. It has also been reported that splice variants for 
ASCT2 exist due to imprecise recognition of the first start codon (Tailor et al., 2001). 
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1.5 Methods of investigation of amino acid transporters 
The study of transporter proteins is important for our understanding of cell physiology. 
Because of the overlapping substrate specificity of transport proteins, the analysis of 
individual transporters in their natural, cellular environment can be difficult. 
Heterologous expression systems have been developed to overcome this problem and 
they are routinely used to characterise transport proteins. The most commonly used 
expression system for mammalian transport proteins is the Xenopus laevis oocyte 
expression system. BBMV, reconstituted transporters and cultured cell lines are also 
used to investigate the role of transporters. 
1.5.1 The Xenopus leavis expression system 
The oocytes of the South African clawed frog Xenopus laevis have been used as an 
expression system to study the function of membrane proteins since it was 
demonstrated that oocytes could express the p-globin gene following cRNA injection 
(Gurdon etal., 1971). 
The oocytes' ability to express large quantities of exogenous protein and their 
relatively large diameter of up to 1.3 mm are the advantages of this system. 
Furthermore, the oocytes contain enough energy and nutrition for protein synthesis 
and cell growth with little dependence on the environment. Due to these 
circumstances, the oocytes possess only a few endogenous transport proteins. Thus 
there is little interference with the transporters to be investigated. 
If the desired membrane protein is successfully trafficked into the plasma membrane 
of the oocyte, functional studies using radioactive uptake and electrophysiology can be 
performed. This system has previously been used to analyse and characterise 
transporters, for instance B°AT1 (Broer et al., 2004), B°AT2 (Broer et ai, 2006) and 
ASCT2 (Broer etal., 2000). 
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1.5.2 Brush border membrane vesicles 
Another system to characterise the function of epithelial amino acid transporters are 
BBMV. This system has been used since the 1970s (Murer et al., 1976). Apical and 
basolateral plasma membranes are different in almost every aspect, including 
morphology, protein-, lipid-, carbohydrate-composition and transport properties. 
These differences are exploited in the procedure to achieve separation of both 
membranes. The different protein to lipid ratios and the different carbohydrate 
contents result in different physical properties of the two membranes, their density 
and surface charge. These properties allow the separation of the apical and basolateral 
membrane by precipitation and centrifugation (Murer and Gmaj, 1986). During 
preparatory precipitation and centrifugation steps, an enrichment of brush border 
membranes takes place, which form vesicles. Ex vivo transport studies using 
radioactive uptake can then be performed. 
These transport studies are described more detailed in (Murer and Kinne, 1980; Murer 
et al., 1983). In general, the BBMV are suspended in a buffer of neutral pH, containing 
Mannitol HEPES and Tris. At time point zero, at which no internal Nations or 
substrates are present in the vesicles, the vesicles are added to the uptake buffer 
containing sodium and the radiolabeled substrate. The substrate and Nations then 
bind quickly to the transporter and transport into the vesicles occurs, stimulated by 
the inwardly directed Na+-gradient. This transport increases the internal Na+-ion and 
substrate concentrations in a short period of time, causing the Na+-gradient to 
dissipate. 
The process can vary in time, for instance amino acid transport is maximal after 15 
seconds (sec) (Chesney et al., 1986), while glucose uptake is maximal after 1 minute 
(min) (Murer et al., 1976). The dissipation of the Na+-gradient during transport causes 
an overshoot of amino acid uptake. After the initial overshoot is reached, the 
concentration of Nations and substrates in the vesicles equilibrates with the uptake 
buffer possibly due to the transporters involved and leakage from the vesicles. 
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As a comparison and control, the substrate transport is also investigated in an uptake 
buffer based on potassium-salt instead of sodium-salt. With an inwardly directed K+-
gradient no 'overshoot' should occur, rather the concentration of substrate within the 
vesicles should increase gradually. At the time point at which an equilibrium between 
the substrate and ion concentrations within the vesicles in the sodium and potassium 
buffers is reached, the concentrations within the vesicles should also be at equilibrium 
with the concentrations remaining in the two buffers. 
It is known that the equilibrium time point with BBMV varies with different 
transporters (Hopfer et al., 1973; Ganapathy and Leibach, 1982; Chesney et al., 1986). 
Also, the equilibrium time point of the two different uptake buffers, sodium and 
potassium, is sometimes not very congruent (Ganapathy and Leibach, 1982) but 
achieves a tolerable variance within an acceptable timeframe. Figure 1.8 shows a 
typical Na+-dependent amino acid transport into BBMV. 
Overshoot 
time 
Figure 1.8: Generic example of Na+-dependent amino acid transport measured into 
BBMV in Na+- and K+-based buffer. 
Na+-based buffer, depicted with squared, shows an overshoot after one min. While K+-based 
buffer, depicted with circles, does not show an overshoot. 
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Additionally, the potassium selective ionophore valinomycin is frequently used to 
investigate Na+-dependent transport. When vesicles are preloaded with potassium, the 
addition of valinomycin will render the membrane permeable to potassium. 
Dilution of the vesicles into K+-free buffer (a sodium buffer) will generate a K+-gradient, 
which in turn will generate a potassium diffusion potential. Substrate and ion transport 
measured in this sodium buffer will display a greater overshoot than transport in a 
sodium buffer without preloading with valinomycin and potassium. This method has 
frequently been used to identify rheogenic transport processes (Ganapathy and 
Leibach, 1982). A typical graph of Na+-dependent renal brush border membrane vesicle 
transport in the presence and absence of valinomycin is depicted in Figure 1.9. 
o-l . 1 > 1 «- 1 ! 1 ; r-0 2 4 6 8 10 
time 
Figure 1.9: Generic example of Na+-dependent amino acid transport measured with 
or without valinomycin preloaded BBMV. 
Amino acid transport with valinomycin preloaded BBMV, depicted with triangles shows a much 
higher over shoot than amino acid transport without valinomycin preloaded BBMV in Na+-
based buffer, depicted with squares. The control of amino acid uptake in unpreloaded BBMV in 
K+-based buffer shows no overshoot. 
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A major limitation in this system is that the interpretation of the data is often difficult 
since a mixture of transporters is expressed in the brush border membrane and often 
inhibitors are not available for certain transporters. Furthermore, as described earlier, 
the broad substrate specificities of the transporters are often overlapping, limiting the 
ability to determine the contribution of each transporter. Nevertheless, brush border 
membrane vesicles are frequently used for transporter investigations (Fass et al., 
1977). 
1.5.3 Epithelial cell cultures 
When the physiologist Sydney Ringer developed a salt solution containing the 
chlorides of sodium, potassium, calcium and magnesium which was suitable for 
maintaining the beating of an isolated animal heart outside of the body (Ringer, 1880), 
this breakthrough laid the foundations for establishing cell cultures. However, it 
became only a routine laboratory technique in the 1950s (Kanazawa et al., 1953) due 
to the relatively slow cell growth rate in comparison to bacteria, making cell cultures 
vulnerable to bacterial contaminations. 
More recently, epithelial cell cultures (primary cultures and immortalised cell lines) 
have come to play an important role in the characterisation of epithelial amino acid 
transporter function. The advantages of this system are that the cells are relatively 
easy to maintain, they are structurally simple and are identically. The major limitation 
is the dedifferentiation of the cultured cells which generally occurs (Verrey et al., 
2005). The opossum kidney (OK) cell line to date is the most conserved proximal tubule 
cell line and has been used to characterise the function of several amino acid 
transporters, for instance LAT2/4F2 (Fernandez et al., 2003). 
Furthermore, cell lines can be transfected or infected with transport proteins, even 
though their transfection rate can vary highly (Peel, 2004). Once transfected, the cells 
are able to express those proteins with their own machinery and subsequently the 
expressed transport proteins can be investigated. 
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1.6 Aims of this thesis: 
Which neutral amino acid transporter is the main B° transporter in the kidney and 
intestine has been the subject of controversial discussion over the past few years 
(Avissar et ai, 2001; Sundaram et a!., 2007; Broer, 2009). The main intention of this 
PhD project was to investigate the role of the three neutral amino acid transporters 
B°AT1, B°AT2 and ASCT2 in neutral amino acid transport in the kidney using different 
approaches. 
First, the localisation of B°AT1, B°AT2 and ASCT2 was determined in mouse kidney and 
intestine tissue by immunofluorescence using B°AT1, B°AT2 and ASCT2-specific 
antibodies. The exact localisation of B°AT2 in the kidney was previously unknown, 
while the localisation of B°AT1 needed to be confirmed. The localisation of ASCT2 
needed to be investigated since it was reported to be in different location. 
Second, the three neutral amino acid transporters were characterised after expression 
in Xenopus laevis oocytes to determine substrate specificity. This information was 
compared to transport data gained using BBMV of mouse kidney with the aim of 
identifying the contribution of each transporter. 
Third, a B°ATl-deficient mouse was characterised using immunofluorescence 
approaches and BBMV experiments. The BBMV results from wild type mice were 
compared with those obtained from B°ATl-deficient mice, to confirm the roles 
identified for B°AT1, B°AT2 and ASCT2. 
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2.1 Materials 
2.1.1 Enzymes, chemicals and molecular biology kits 
Restriction endonucleases and DNA modifying enzymes were purchased from New 
England Biolabs (NEB, Ipswich, USA), Roche Molecular Biochemicals (Basel, 
Switzerland), Promega (Madison, USA) and TaKaRa Technology (Shiga, Japan). 
Molecular biology grade chemicals, reagents and antibiotics were purchased from 
Sigma-Aldrich (St. Louis, USA), Invitrogen (Carlsbad, USA), AMRESCO (Solon, USA)) and 
MERCK KGaA (Darmstadt, Germany). Plasmid DNA isolation miniprep and midiprep kits 
and Endofree Plasmid Maxi Kit were purchased from either Invitrogen (Carlsbad, USA) 
or QIAGEN (Hilden, Germany). Gel extraction and PCR purification kits were obtained 
from Invitrogen (Carlsbad, USA) or Millipore (Millipore, Billerica, USA). RNA extraction 
Kit was purchased from Macherey-Nagel (Dueren, Germany). Radiolabeled 
[3,4,5-3H]L-Leucine (115.4 Ci/mmol) was purchased from MP Biomedicals, Inc. (Irvine, 
USA), L-[G-3H] Glutamine (59.0 Ci/mmol). 
2.1.2 Markers 
The lkb DNA Ladder, GeneRuler 100 bp DNA Ladder and Supercoiled DNA Ladder were 
purchased from NEB, Fermentas (Burlington, USA) and Invitrogen. 
For protein gels, SeeBlue Plus2 Prestained Standard was obtained from Invitrogen. 
2.1.3 Disposable materials 
Petri Dishes were supplied by Bacto Laboratories (Liverpool, Australia). 96-well 
microtiter plates, 0.2 mL microfuge tubes, 15 mL tubes and pipette tips were 
purchased from Sarstedt (Nuermbrecht, Germany), 1.5 mL and 2 mL tubes were 
obtained from Eppendorf (Hamburg, Germany). 50 mL Falcon tubes were purchased 
from BD Biosciences (San Jose, USA). All cell culture work equipment was obtained 
from Nalge/Nunc (Roskilde, Denmark). 
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2.1.4 Antibiotics 
The antibiotics ampicillin and kanamycin (ICN Biomedicals, Aurora, USA) were added to 
bacterial growth media at final concentrations of 100 pg/mL and 50 pg/mL, 
respectively, for propagation of Escherichia coli cultures harbouring plasmid DNA with 
their respective resistance genes. All of these antibiotics were filter sterilised (0.22 
pm). Ampicillin was stored as 50 mg/mL stock solution and Kanamycin was stored as 
20 mg/mL stock solution. 
Gentamycin was added to OR2+ at a final concentration of 10 mg/L and prepared as the 
other antibiotics. Gentamycin was stored as a 50 mg/mL stock solution. 
2.1.5 Bacterial strains and plasmids 
The Escherichia coli strains DH5a (Invitrogen) and XL1- Blue (Stratagene Inc., La Jolla, 
USA) were used as host bacteria for plasmid transformation. Following transformation, 
the E. coli strains were cultured in LB media using antibiotic resistance selection 
according to the contained plasmid. The genotypes of the E. coli strains used in this 
study are presented in Table 2.1. 
Table 2.1: Description of Bacterial Strains used in this thesis 
Bacterial Strain Genotype Source 
E. coli DH5a - F- 4>80lacZAM15 A(lacZYA-argF) U169 recAl endAl hsdR17 (rk-, mk+) phoA supE44 \- thi-1 gyrA96 relAl 
Invitrogen 
E. coli XLl-Blue 
- recAl endAl gyrA96 thi-1 hsdR17 supE44 relAl lac [F' 
proAB laclqZ A M15 TnlO (Tetr) 
Stratagene 
For short-term storage, plates with E. coli colonies were stored at 4 °C, usually up to 1 
month, after which they were autoclaved and discarded. For long-term storage a flask 
containing LB broth plus the appropriate antibiotic was inoculated from a single colony 
and vigorously shaken at 200 rpm overnight at 37 °C. The next day, a 600 pL aliquot of 
culture was mixed with 400 pL 50 % glycerol and stored at -80 °C. 
Chapter 2 - Materials and Methods 38 
The expression vectors and plasmids used in this study are detailed in Table 2.2 and in 
the appendix B respectively. The pGHJ vector was used for the expression of mRNA in 
Xenopus laevis oocytes. The multiple cloning site (MCS) in this plasmid is flanked by the 
5' and 3' untranslated regions of the Xenopus 3-globin gene, which facilitates the 
translation of injected cRNA that is produced by in vitro transcription (Liman et al., 
1992) 
The pGEX-2T vector was used for the expression of glutathione-S-transferase (GST) 
fusion proteins in E.coli., which is not part of this thesis but mentioned for 
completeness. This vector contains the foe promoter, which can be induced by IPTG. 
The pcDNA 3.1 (+) vector was used for expression of genes in mammalian cells such as 
human embryonic kidney cells (HEK) and Chinese hamster ovary cells (CHO). It has a 
human cytomegalovirus immediate-early (CMV) promoter for high-level expression in 
a wide range of mammalian cells. The multiple cloning site is in forward (+) orientation 
to facilitate the cloning and it contains a neomycin resistance gene for selection of 
stable cell lines. 
Table 2.2: Description of expression vectors used in this thesis 
Name Features Source 
pGem-He-Juel 
(pGHJ) 
- MCS flanked by the 5' and 3' untranslated 
regions of the Xenopus p-globin gene 
- p-lactamase gene for ampicillin resistance 
- T7 Promoter upstream of the 5' P-globin un-
translated region 
- SP6 Promoter downstream of the MCS 
Modified from 
pGEM 
(Liman et al., 
1992) 
pGEX-2T 
- MCS downstream of GST gene 
- tac promoter upstream of GST gene 
- p-lactamase gene for ampicillin resistance 
- /oclq gene for the control of the tac promoter 
GST Gene Fusion 
System 
(Amersham 
Biosciences) 
pcDNA 3.1 (+) 
- CMV promoter for high- level expression in a 
wide range of mammalian cells 
- 77 promotor downstream of the CMV promotor 
- Neomycin resistance for selection of stable cell 
lines, additional ampicillin resistance 
Invitrogen 
The plasmids generated or used in this study are presented in the Appendix B in detail. 
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2.1.6 Antibodies 
Antibodies used in this study and their used dilutions are presented in Appendix C. 
Primary and secondary antibodies were either produced at Pineda Antibody-Service 
(Berlin, Germany) or purchased from Vector Laboratories (Burlingame, USA), 
Pharmingen (San Diego, USA) or Invitrogen. 
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2.2 Methods- Molecular Biology: preparative DNA techniques 
2.2.1 Preparation of plasmid DNA 
Plasmids were isolated from a 5 mL overnight culture of E. coli grown in LB broth with 
the appropriate antibiotic using the PureLink Quick Plasmid Miniprep Kit (Invitrogen, 
Carlsbad, USA) or the QIAprep Spin Miniprep kit (QIAGEN, Hilden, Germany). The 
manufacturer's protocols were followed. Plasmid DNA quality and concentration was 
determined with a NanoDrop Spectrophotometer (NanoDrop Technologies, 
Wilmington, USA) as described in Section 2.3.3. 
In order to obtain larger amounts of plasmid DNA (up to 200 ^g/Midi-prep or 
750 (xg/Maxi-prep) the Qiafilter Midi and Maxi Kit (QIAGEN) was used following 
manufacturer's instructions. 
For the preparation of large quantities of plasmid DNA for mammalian cell transfection 
the endonuclease free Maxi-prep kit (QIAGEN) was used, following the manufacturer's 
instructions. 
All of these kits utilise the alkaline lysis method of plasmid DNA extraction. 
The DNA was used for cloning, expression, in vitro transcription, restriction digests, 
PGR applications and sequencing reactions. The DNA was separated on agarose gels 
(1.3.1), examined under the UV transilluminator and photographed using the GelDoc 
Imaging system described in Section 2.3.2. 
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2.2.2 DNA extraction from agarose gels 
Following agarose gel electrophoresis (Section 2.3.1) and ethidium bromide (EtBr) 
staining, the DNA band requiring purification was excised from the agarose gel using a 
clean scalpel and placed in a clean microfuge tube. This procedure was done by 
dividing the sample in an analytical and a quantitative fraction loaded into two 
adjacent lanes of the gel. Only the lane containing the analytical fraction was cut out 
and stained with EtBr. The position of the band was marked and the corresponding 
area of the unstained sample fraction was cut out without exposing to EtBr and UV 
light to avoid damage or mutation of the DNA. The excised DNA band was isolated 
from the agarose gel using either QIAquick Gel Extraction Kit (QIAGEN) or PureLink 
Quick gel Extraction Kit (Invitrogen) following manufacturer's instructions. 
DNA quality and concentration was determined with the NanoDrop 
Spectrophotometer as described in section 1.3.3. 
2.3 Molecular Biology: analytical DNA techniques 
2.3.1 Agarose gel electrophoresis 
Horizontal submerged TAE-agarose gels were run according to protocols described by 
Sambrook (Sambrook, 2001). Agarose (0.8 to 2 %) was dissolved in l x TAE buffer. One 
fifth volume of loading buffer (Fermentas) was added to samples before loading onto 
the gel. The DNA was separated at 5 to 15 V/cm 45 to 180 min. A lkb DNA Ladder, a 
lOObp DNA Ladder or a Supercoiled DNA Standard was routinely run on the agarose 
gels to determine the size and estimate the concentration of the unknown DNA on 
these gels. The 3 kb band in the 1 kb GeneRuler Fermentas DNA Ladder contained 70 
ng DNA when run at 500 pg/mL, whereas the NEB DNA Ladder contained 125 ng DNA 
when run at 500 pg/mL and 7 to 8 pL was loaded. 
l x TAE buffer 40 mM Tris-HCI 
20 mM Sodium acetate 
1 mM EDTA pH7.8 
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2.3.2 Visualisation and imaging of nucleic acids 
Following agarose electrophoresis, nucleic acids were stained in approximately 
0.5 ng/mL EtBr in ddH20 for 15 to 20 min and destained for 5-10 min in ddH20. The 
DNA was visualised by illumination on a UV transilluminator (340 nm) and 
photographed using the GelDoc Imaging system (Bio-Rad Laboratories, USA). 
2.3.3 Quantification of nucleic acids 
To quantify the amount of plasmid DNA, genomic DNA, RNA or protein the NanoDrop 
Spectrophotometer (NanoDrop Technologies, Wilmington, USA) was used. Absorbance 
at 260 nm was used to measure the concentration of DNA and RNA as described by 
Sambrook (Sambrook, 2001). It was assumed that an OD of 1.0 corresponds to 
50 |ig/mL of double-stranded DNA. The presence of proteins and other contaminations 
was estimated by measuring the A26o/28o nm ratio. A ratio of between 1.8 and 2.0 
indicates a DNA preparation largely free from contaminating proteins. RNA was 
quantified using the same procedure, where an OD of 1.0 corresponds to 40 ng/mL of 
RNA. The presence of proteins and other contaminants was estimated by measuring 
the A260/280nm ratio, where a ratio of between 1.8 and 2.0 was taken to indicate a clean 
preparation. 
2.3.4 Oligonucleatides/Primers 
All oligonucleotides of this study were custom-synthesised by Sigma-Proligo 
(Newcastle, Australia) and are listed in Appendix C. 
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2.3.5 Polymerase chain amplification (PCR) 
PCR was used to analyse expression levels of genes after reverse transcription of 
mRNA to cDNA and to amplify fragments for cloning and screening purposes. The 
amplification of DNA fragments by PCR was performed in a Corbett Research GC1-96 
thermal cycler (CR Corbett Research Life Science) as described below. 
The PfuII Ultra polymerase (Stratagene) was used in experiments where high fidelity 
amplification was required for cloning purposes, and the manufacturers' instructions 
were followed. A 10 mM mixture of the deoxyribonucleotide triphosphates (dNTPs) 
dATP, dTTP, dGTP and dCTP (Invitrogen) was made up and stored at -20 °C in aliquots. 
Template DNA concentration as well as the annealing temperature varied in individual 
sets of reactions. Generally, a PCR reaction was carried out in 0.2 mL thin- walled 
tubes, containing 1/10 volume lOx PCR buffer, lOx dNTPs stock solution in a dilution 
of 1/10, 0.5-0.6 pM primer, 1-4 U enzyme and 20-100 ng template DNA. The final 
volume was made up to either 20 pL, 50 pL (for normal PCR) or 100 pL (for RT-PCR) 
with sterile ddH20. 
Reactions were performed under the following general conditions: 
Denaturation step 95 °C 2 min 
Cycling program [28-35 cycles] 
Denaturation 95 °C 30 sec 
Annealing 56-67 °C 30 sec 
Extension 72 °C 30-200 sec 
Final extension 72 °C 10 min 
Amplification of PCR products was monitored by gel electrophoresis (1.3.1). 
In some instances a gradient PCR was carried out to determine the optimal annealing 
temperature for a given set of primers. 
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2.3.6 Restriction endonuclease digestion of DNA 
Plasmids and genomic DNA fragments were digested by incubation with 10 to 20 U of 
restriction enzyme (RE) per 0.5 to 1.0 ng DNA in the recommended restriction enzyme 
buffers supplied by the manufacturer. Restriction digests were carried out for 1 to 3 h, 
depending on the concentration of DNA to be digested at the recommended 
temperature. Restriction digests of DNA with multiple enzymes were carried out 
simultaneously if the restriction enzyme buffers were compatible. When different 
reaction buffers were required, the DNA was digested first with one restriction 
endonuclease and the buffer was adjusted accordingly to accommodate the sec 
restriction endonuclease. After restriction digests the DNA was either purified as 
described in Section 2.3.7 or extracted from agarose gel using a gel extraction kit 
before using in cloning or transformation experiments. 
2.3.7 Purification of DNA fragments 
DNA, restriction endonuclease digestions or PCR reactions were purified and 
concentrated with Microcon® centrifugal filter devices (Millipore), or a PureLink PCR 
purification kit (Invitrogen), following manufacturers' specifications. Both products are 
able to separate larger DNA fragments from proteins, salts and small (<300 bp) DNA 
fragments. 
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2.3.8 Cloning 
2.3.8.1 Dephosphorylation of linearised plasmid DNA 
Antarctic Phosphatase (NEB) treatment was used to remove 5'-phosphate groups from 
the cloning vector after restriction digestion and before ligation in cases where a single 
restriction enzyme site was used for cloning. The phosphatase treatment prevented 
preferential self-ligation of the vector backbone. 
2.3.8.2 Ligation 
To ligate fragments, 1 pL of T4 DNA Ligase of the T4 Quick Ligation Kit (NEB) was added 
to a 20 pL final reaction volume containing l x Quick Ligase buffer and vector: insert at 
a ratio of 1:3 or 1:5. Ligation reactions were carried out for 1 to 25 min at 25 °C. In 
addition to the experiment, several control ligations were performed to test the 
efficiency of the ligation reaction and the quality of the vector. These usually included 
parallel ligations in the absence of insert DNA to determine the background clones 
arising from self-ligation and inefficiently dephosphorylated vector. 
Before transformation of the ligated products, the DNA was usually concentrated using 
tRNA precipitation. 1 pL of tRNA (5 pg/pL) was added to the ligation reaction as well as 
0.5 volumes of 7.5 M ammonium acetate and 2.5 volumes of 100% ice-cold ethanol. 
After 10 min incubation at room temperature (RT), the solution was centrifuged for 
20 min at 10,000 g. The pellet was washed with 250 pL 70% ethanol and centrifuged 
again for 10 min at 10,000 g. After air drying the pellet, it was dissolved in 5 pL of 
sterile H20 and 2.5 pL was used for a transformation reaction (1.3.8.3). 
2.3.8.3 Competent bacteria and transformation 
High efficiency transformation (ca. 105 to 107 transformants/pg of circular DNA) of 
E. coli strains was achieved by electroporation using a Bio-Rad Gene Pulser 
electroporator with a Bio-Rad Pulse Controller II (Bio-Rad Laboratories, Hercules, USA). 
Precipitated DNA (2.5 pL) was mixed with a 40 pL aliquot electrocompetent DH5a 
E. coli cells (Sambrook, 2001) and left on ice for 1 min. 
Chapter 2 - Materials and Methods 46 
The mixture of cells and DNA was transferred into a cold Bio-Rad electroporator 
cuvette and subjected to an electrical pulse field (the Gene Pulser was set to 25 nF and 
2.5 kV, and the Pulse Controller was set at 200 Q, using a cuvette of 0.2 cm gap width). 
After the pulse, 750 \xl SOC media was immediately added to the cells. The mixture 
was transferred to a 15 mL tube and incubated at 37 °C for 1.5 h with moderate 
shaking to allow expression of the antibiotic resistance gene and recovery of 
transformed E. coli cells. Aliquots of the transformation mix were spread on agar 
plates with appropriate antibiotics in accordance to the resistance gene present on the 
plasmid. The agar plates were subsequently incubated at 37 °C overnight. Clearly 
visible colonies were analysed further (1.3.9). 
SOC medium 20 mM Glucose 
10 mM NaCI 
10 mM MgCI2 
10 mM MgS04 
2.5 mM KCI 
2.3.9 Rapid screening of transformed colonies 
To screen bacterial transformants for those that had taken up a recombinant vector, a 
colony cracking method was employed. Single bacterial colonies were resuspended in 
40 nL EDTA. Afterwards 40 |iL of a freshly made 2x cracking buffer for lysing the 
bacteria was added. The mixture was incubated for 5 min at RT before 10 |iL marker 
mix was added. The mixture was incubated on ice for 5 min before it was centrifuged 
for 3 min at 10,000 g. 20 \il of the supernatant was subsequently run on an agarose gel 
adjacent to a supercoiled DNA Ladder. Those plasmids containing the insert of interest 
could be discriminated by their size. 
2x cracking buffer: 0.2 g/mL Sucrose 
2 % Tryptone 
0.5 % Yeast extract 
0.5 % w/v 
0.2 M NaOH 
KCI 
Bromophenol blue 
Triton X-100 
SDS 
Marker mix: 0.5 M 
8 % v/v 
1% 
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2.3.10 Sequencing of constructs and construct analysis 
Correct constructs were confirmed by DNA sequencing. Usually a sequencing reaction 
contained of 2 pL Big Dye Terminator (BDT) v3.1, 3 pL of 5x BDT sequencing buffer 
(Applied Biosystems), 3.2 pmol of the appropriate primer, 300 ng of double stranded 
(ds) template DNA and sterile ddH20 to a final reaction volume of 20 pL. Depending on 
the gene, a T7-, SP6- or self-designed primers were used. Sequencing reactions were 
run in a PCR machine described in Section 2.3.5 under the following general 
conditions: 
Denaturation step 94 °C 5 min 
Cycling program [30 cycles] 
Denaturation 96 °C 10 sec 
Annealing 50 °C 10 sec 
Extension 60 °C 240 sec 
Holding samples 20 °C 
For purification of the reaction, 2 p i of 3 M sodium actetate (pH 5.2) and 50 pL of 
100 % ethanol was added and incubated at RT for 15 min. After centrifugation for 
20 min at 10,000 g the sample pellet was washed twice with 250 pL 70 % ethanol with 
a centrifugation of 5 min at 10,000 g after each step. The air dried sample was then 
sent to sequencing. 
Sequencing was performed at the Biomolecular Resource Facility (BRF), John Curtin 
School of Medical Research (JCSMR), (Australian National University [ANU], Canberra, 
Australia), using ABI 3730 DNA Analyser (Applied Biosystems, Foster City, USA). 
Sequences were viewed using the Chromas software program (McCarthy, 1998) and 
searches for homologue DNA sequences were carried out using the BLAST program 
through the National Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/BLAST, (Altschul eta!., 1997) 
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2.4 Protein techniques 
2.4.1 Expression and purification of protein for antibody production 
The antibodies against B°AT1, B°AT2 and ASCT2 used in this thesis were designed in 
the Broer laboratory prior to the commencement of this thesis and are mentioned 
here for completeness. 
The GST Gene Fusion System (Amersham Biosciences) was used to produce amino- and 
carboxy-terminal peptides of B°AT1 and B°AT2 (v7-3) fused to E. coli GST protein. 
These fusion proteins were used for the production of B°AT1 and B°AT2 specific 
antibodies. 
Primers used for generating those proteins are as followed: 
Name RE-site Sequence 
mBOATl-Nterminus-sense GGATCC CCCATGGTGAGGCTTGTG 
BamH\ 
mBOATl-Nterminus-antisense GAATTC ACTGGGCCTTCTTCTCCCA 
EcoR\ 
mBOATl-Cterminus-sense GGATCC CCCAAGTTCATCAGAAATTGT 
BamH\ 
mBOATl-Cterminus-antisense GAATTC AGTTCTTAAGGTCCCCA 
EcoR\ 
mV7-3Nterml-sense GCGAATTCAT ATG CCTAAGAATAG CCAAAGTG 
EcoR\ 
mV7-3Nterml-antisense GCGAATTC TTGCAGCTTACTGTTCCAGGC 
EcoR\ 
mV7-3Cterml-sense GCGAATT CGTCGCTGCAACCTCATAGAT 
EcoR\ 
mV7-3Cterml-antisense GCGAATCC CCAGTCAGACTCTGGCATATC 
EcoR\ 
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The pGEX-2T expression vector (Section 1.5) was used to produce recombinant GST 
fusion proteins using standard cloning techniques as outlined in sections 2.3.5 to 
2.3.10. Subsequently the protocol of the Bornstein Laboratory at the University of 
Washington for the preparation of bacterial expressed recombinant GST- fusion 
proteins was followed (http://depts.washington.edu/bornlab/Born-Protocol.html; 
Seattle, USA). 
Freeze dried protein samples were sent to Pineda antibody service for production of 
specific antibodies. 
The mASCT2 antibody was produced by Pineda antibody service against the peptide 
sequence: 
N-REPSGDSSATC—COOH 
2.4.2 GST-depletion of polyclonal antisera 
GST-fusion protein was used to generate an antibody against B°AT1 and B°AT2. 
Therefore the obtained serum samples contain antibodies that recognise the target 
protein and GST. To remove the antibodies that recognise GST, immobilised GST 
columns (Pierce, Rockford, USA) were used following the manufacturers' manual. 
Unbound antibodies were retained while the bound anti-GST antibodies were 
discarded. 
2.4.3 Bradford assay 
Protein concentrations were determined using the Sigma Bradford reagent with BSA 
dilutions as standard (Bradford, 1976). 
For the production of a standard curve, BSA stock solutions with 50 mg/mL, 75 mg/mL. 
100 mg/mL, 200 mg/mL, 300 mg/mL, 400 mg/mL and 500 mg/mL were made up and 
kept at -20 °C. BSA standard was thawed on ice and experimental protein samples 
were diluted as required (generally, 1:10, 1:100 and 1:1,000) and kept on ice. 30 pL of 
BSA standards or diluted protein samples were transferred to a microtiter plate in 
duplicates or triplicates. 
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Bradford reagent (270 |iL) was added to each well and reactions were mixed carefully 
before incubation for 10 to 15 min at RT. Absorbance at 595 nm was measured using a 
Bio-Tech (iQuad Microplate Spectrophotometer (Biotech Instruments, USA). The 
protein concentration of the samples were calculated by the program KC4 version 3.4 
using the generated BSA standard curve as reference. 
2.4.4 Western Blot 
2.4.4.1 Sample preparation 
After concentration estimation with the Bradford assay (2.4.3) the samples were 
prepared following the NuPAGE Technical Guide (all NuPAGE reagents were obtained 
from Invitrogen). Samples (generally containing between 1 and 2 ng/|iL protein) were 
diluted with water to a final volume of usually 20 |iL, 4x NuPAGE LDS Sample Buffer 
and lOx NuPAGE Reducing Agent. The mixture was heated for 10 min at 70 °C, briefly 
centrifuged and loaded on to the SDS-PAGE gel. 
2.4.4.2 SDS-PAGE 
NuPAGE Novex 4 to 12 % Bis-Tris 1 mm precast gels were assembled in the XCell 
Surelock Mini-Cell (Invitrogen) following the manufacturers' instructions. To this end, 
the upper chamber was filled with 200 mL l x NuPAGE MES Running Buffer containing 
500 nL NuPAGE Antioxidant. The lower chamber was filled with 700 mL of l x NuPAGE 
MES Running buffer. Samples were loaded together with a pre-stained protein Ladder 
(Invitrogen) as an indicator for protein transfer from the gel to the membrane. The 
samples were run on gels at 200 V for 40 to 60 min depending on the size of the 
protein. 
2.4.4.3 Western Immunoblot 
Western blotting was performed to detect specific protein in samples run on 
polyacrylamide gels. Proteins were transferred onto a Hybond nitrocellulose 
membrane using either the Invotrogen iBIot system or the BioRad System (2 h at 100 
V) following manufacturers' instruction. Non-specific binding was blocked by 
incubating the membrane in PBST containing 5 % skim milk powder overnight at 4 °C. 
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The membranes were washed three times with PBST for 15 min on an orbital shaker. 
The membranes where incubated for 2 h at RT with the appropriate dilution of primary 
antibody in PBST with 1.6% skim milk powder. Following three washes (15 min each) 
with PBST, the membranes were incubated on an orbital shaker for 1 h at RT in 
secondary antibody (Horseradish-peroxidise labelled donkey anti-rabbit IgG, 
Amersham Biosciences, UK) made up with 1.6% skim milk powder in PBST. 
Membranes were washed three times for 15 min in PBST. To detect the proteins on 
the membranes, the Enhanced Chemiluminescence (ECL) Western Blot Analysis System 
(Amersham Biosciences) was used. A mixture of the two detection reagents was 
applied to the washed membrane and exposed for 1 min. After removing the detection 
reagents, the chemiluminescence was detected with Hyperfilm ECL (Amersham 
Biosciences) in a dark room. The films were processed using a Kodak Processor. The 
exposure times varied depending on the intensity of the signal, usually ranging from 10 
sec to 15 min. 
2.5 Immunofluorescence 
2.5.1 Sample preparation 
Fixation of human tissue was performed following the protocol described preciously by 
Broer et al. (Broer et al., 2008). All human tissue samples were prepared by our 
collaborator in Sydney using their ethical approval from the University of Sydney. 
Fixation of mouse tissues was performed following the protocol described previously 
by Kowalczuk et al. (Kowalczuk et al., 2008). Intact kidney or intestine of C57BL6 mice 
was placed into ice-cold 0.9 % NaCl to remove the kidney capsule or rinsed with ice-
cold 0.9 % NaCl to remove all remaining faeces. The tissue specimens were placed in 
freshly made Formalin (at least 20 times the volume of the tissue) and incubated 
depending on the tissue size for 2 to 24 h. The fixation was initiated at RT and after the 
first hour the fixative was exchanged. At the end of the fixation period, tissue was 
transferred into ethanol and was processed for paraffin embedding at the Microscopy 
and Cytometry Resource Facility (MCRF) at the JCSMR. 
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Formalin (10 % neutral buffered): 100 mL Formalin (40 % formaldehyde) 
4 g NaH2P04, H20 
6.5 g Na2HP04 
1L ddH20 total volume 
2.5.2 Immunofluorescence 
Immunofluorescence was used to localise amino acid transporters in mouse tissue. The 
procedure described by Kowalczuk et al., 2008 was generally followed. However, 
several modifications for enhanced quality were acquired. These are presented in 
detail in Chapter 3. 
2.5.3 Confocal microscopy 
Confocal microscopy was carried out to examine localisation of amino acid 
transporters, transfection efficiency in mammalian cells and expression and trafficking 
of amino acid transporters in oocytes. 
A BioRad Radiance 2000 (BioRad Laboratories) or a Leica TCS SP5 (Leica Microsystems, 
Wetzlar, Germany) at the JCSMR was used to detect fluorescence. Generally, in the 
bright field microscope the vitelline layer of oocytes, the membranes of mammalian 
cells or mouse tissue was focused using a low objective lens, such as lOx objective 
lens. Image capture was then done at higher magnification. The images were viewed 
using the Laser Sharp 2000 program (BioRad Laboratories) or the LAS-AF program 
(Leica Microsystems). 
2.6 Xenopus oocyte expression 
2.6.1 In vitro transcription 
In vitro transcription was used to produce cRNA from plasmid DNA for functional 
studies in oocytes. Plasmid DNA was linearised to terminate transcription at the end of 
the cDNA. Plasmid DNA (5 ng) was linearised in an overnight digestion with a suitable 
restriction enzyme (Section 2.3.6), and then examined by agarose gel electrophoresis 
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(Section 2.3.1) for quality and completeness of the digestion reaction. Subsequently, 
the DNA was purified by extracting enzymes and proteins from the aqueous solution 
using an equal volume of phenol/chloroform (1:1) equilibrated in 1 M Tris-HCI, pH 8.0. 
The samples were mixed by vortexing, incubated for 1 min on ice and the phases were 
separated by centrifugation at 16,000 g for 5 min at RT. The upper, aqueous layer 
(approximately 100 pL) was transferred to a new tube. The DNA was then precipitated 
for 2 to 3 h at -20 °C after adding 10 pL of 2 M NaCI and 200 pL of 100% ice-cold 
ethanol. The mixture was centrifuged for 20 min at 16 000 g, the pellet was washed 
with 1 mL of 70% ethanol and centrifuged again for 10 min at 16 000 g. The dried 
pellet was dissolved in 12 pL of DEPC-treated water. The linearised and purified DNA (2 
pg) was used as template for the in vitro transcription using the mMESSAGE 
mMACHINE T7 promotor kit (Ambion Applied Biosciences, USA) following the 
manufacturers' instructions. The complementary RNA (cRNA) generated in this 
reaction was purified with a phenol/chloroform extraction, using an equal volume of 
phenol/chloroform (1:1) equilibrated in 1 M Tris-HCI, pH 8.0. The samples were 
completely mixed and the phases were separated by centrifugation at 16,000 g for 
5 min at RT. The upper, aqueous layer was transferred to a new tube and mixed again 
with an equal volume of phenol/chlorophorm. Subsequent mixing and spinning yielded 
a new aqueous phase. All two phenol layers were reextracted with 100 pL 100 mM 
Tris, pH 8.0. All three aqueous layers were combined and cRNA precipitated at -70 °C 
for at least 3 hours (h) after adding 0.5 volume 7.5 M NH4OAc and 2.5 volume ice-cold 
ethanol. The mixture was centrifuged for 35 min at 16,000g and the pellet was washed 
one with 1 mL 70% ethanol and centrifuged for 20 min at 16,000g. After drying the 
pellet in a dessiccator, it was dissolved in 20 pi of nuclease free water. The RNA was 
incubated for 3 min at 65 °C to dissolve the pellet properly and the amount of RNA in 
the sample was measured using the NanoDrop Spectrophotometer (Section 2.3.3). The 
RNA was diluted to a concentration of 1 pg/ml, dispensed into 5 pi aliquots and stored 
at -80 °C. 
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2.6.2 Oocyte preparation and injection 
Xenopus laevis oocytes were prepared as described previously (Broer, 2003). 
Female X. laevis (South African Xenopus Facility; Knysna, South Africa) were 
anaesthetised 20 to 40 min by submersion in 0.15% MS222 anaesthesia solution. 
Anaesthesia was judged complete when the frog could be turned onto its back without 
eliciting a response. The frog was placed (belly up) on an absorbance paper sheet 
placed on top of a tray of ice. A small (< 1 cm) incision was made through both the skin 
and muscle layers of the lower abdomen. Sections of ovary were removed with 
tweezers and scissors and placed into OR2" buffer. The incision was closed with one 
absorbable suture in the muscle layer, and two non-absorbable stitches in the skin 
layer. The frog was left to recover under a damp paper towel, and was submerged in 
water once awake. 
By using scissors, the removed ovary was separated into small pieces of around 50 
oocytes each. These sections were then incubated in 50 mL of 1.5 mg/mL collagenase 
D (from Clostridium histolyticum) in OR2" buffer for 2 to 4 h at 28 °C under slight 
agitation until the majority of oocytes were no longer clumped or associated with 
blood vessels or follicular cells. The collagenase was washed off with at least 500 mL 
OR2' followed by at least three rinses in OR2+ buffer. The oocytes were stored overnight 
in this buffer at 18 °C. 
On the following day, healthy oocytes of an appropriate developmental stage (stage V 
or VI; (Broer, 2003) were selected for microinjection. Oocytes were injected with 10 to 
25 ng of the appropriate cRNA. Injections were performed with a Nanoliter Injector 
(World Precision Instruments, Sarasota, USA), using capillaries pulled on a 
Flaming/Brown micropipette puller (Sutter Instrument Co., Novato, USA). Oocytes 
were maintained for up to 5 days at 18 °C in OR2+ buffer containing 50 ng/L 
gentamycin. The oocyte medium was changed daily. 
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Anaesthesia solution: 1.5 g/L 3-aminobenzoic acid ethyl ester 
1 mM NaHCOs 
OR2" buffer: 82.5 mM NaCI 
2.5 mM KCI 
1 mM MgCI2 
1 mM Na2HP04 
5 mM HEPES pH 7.8 
Collagenase D 1.5 mg/mL (Roche, USA) made in OR2" 
OR2+ buffer 82.5 mM NaCI 
2.5 mM KCI 
1 mM CaCI2 
1 mM MgCI2 
1 mM Na2HP04 
5 mM HEPES pH 7.8 
2.6.3 Total membrane preparation of oocytes for Western Blotting 
This method was used to enrich all membrane proteins from oocytes. 3 to 5 days after 
injection, 25 oocytes were homogenised in 1 mL of homogenisation buffer by 
trituration. The homogenate was spun in a microcentrifuge at 2,000 g for 10 min at 
4 °C. The supernatant was transferred to a fresh tube and spun at 14,0000 g for 30 min 
at 4 °C in a Beckman Optima MAX ultracentrifuge (Beckman, Fullerton, USA). The 
supernatant was discarded and the pellet was dissolved in 50 |il of homogenization 
buffer containing 4% SDS. The samples were then analysed on SDS-PAGE (Section 
2.4.4.2) followed by Western Immunoblot (Section 2.4.4.3). 
Homogenization buffer 50 mM Tris/HCI pH 7.6 
100 mM NaCI 
1 mM EDTA pH 8.0 
l x protease inhibitor 
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2.6.4 Immunofluorescence with oocytes 
Immunofluorescence with oocytes was performed to analyse the expression of the 
investigated amino acid transporters and the quality of the primary antibody. 
Seven to ten oocytes were incubated in 4% paraformaldehyde in PBS for 30 min with 
slow rotation. After aspirating the paraformaldehyde, the oocytes were washed three 
times for 10 min with PBS with slight rotation. Subsequently, the oocytes were 
incubated in 100% methanol for 20 min at -20 °C. After incubation, the oocytes were 
washed three times for 10 min with PBS under slow rotation. To reduce the amount of 
unspecific binding of the antibody, the oocytes were incubated in 3 % BSA, 1 % NGS 
and 0.1 % Triton-X-100 in PBS for one hour with slight rotation. The oocytes were then 
incubated in the appropriate dilution of the primary antibody (made in 1 % BSA and 
0.01 % Triton-X 100 in PBS pH7.4) for 2 h at RT. The oocytes were then washed three 
times with PBS for 10 min. Incubation with the secondary antibody (1:500 dilution 
made in 1 % BSA and 0.01 % Triton-X 100 in PBS) was carried out for 2 h with slow 
rotation in the dark to prevent bleaching of the fluorophore. Unbound antibodies were 
removed by washing with PBS three times for 10 min and the oocytes were viewed in a 
confocal microscope (Section 1.5.3). 
2.6.5 Oocyte transport assays 
Radioisotope uptake measurements were carried out in oocytes 3 to 5 days after RNA 
injection (Section 2.6.2). 
Frequently used solutions: 
ND 96; 96 mM NaCI 
2 mM KCI 
1.8 mM CaCI2 
1 mM MgCI2 
5 mM HEPES pH 7.4, titrated with NaOH 
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2.6.6 Efflux experiments 
Efflux assays were performed on groups of seven to ten oocytes, and were carried out 
at RT. The oocytes were washed twice with 4 mL ND96 transport buffer. They were 
then preloaded by incubation for 10 min in 90 (iL of uptake buffer containing 
radiolabeled and non-labelled amino acids to give a final substrate concentration of 50 
to 100 |iM. Subsequently the oocytes were washed three times with 4mL ND96 and 
the efflux experiment was commenced with the addition of lmL ND96 buffer 
containing 1 mM of non-labelled amino acid substrate. Samples were taken after 0, 5, 
10, 20 and 30 min. After 30 min, the assays were terminated by washing the oocytes 
four times in ice-cold ND96 buffer. Each oocyte was then transferred into a separate 
scintillation vial and lysed by the addition of 200 |iL of 10 % SDS. 3 mL scintillation fluid 
(Packard Biosciences, USA) was added and the radioactivity counted in a Beckman LS 
6500 scintillation counter (Beckman, USA). 
2.6.6.1 Competition experiments 
Uptake assays were performed on groups of eight to ten oocytes, and were carried out 
at RT. The oocytes were washed twice with 4 mL ND96 transport buffer. The 
competition experiment was commenced with the addition of 90 [iL ND96 containing 
50 |jM radiolabeled substrate and a non-labelled amino acid at a final substrate 
concentration of 5 mM. After 10 min, the assays were terminated by washing the 
oocytes four times in ice-cold ND96 buffer. Each oocyte was then distributed into a 
separate scintillation vial and lysed by the addition of 200 \xl of 10% SDS. 3 mL 
scintillation fluid was added and the radioactivity counted in a Beckman LS 6500 
scintillation counter. 
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2.7 Brush border membrane vesicles (BBMV) 
2.7.1 Isolation of proximal tubular brush border membrane vesicles 
For the isolation of brush-border membrane vesicles the procedure described by Biber 
et al. (Biber et al., 2007) was followed. However, several modifications for enhanced 
quality were developed. These are presented in detail in Chapter 4. 
2.7.2 Alkaline Phosphatase (AP) Assay 
To identify the enrichment of brush border membrane and therefore the quality of the 
BBMV, the enrichment of AP activity was measured. To this end, 1 ml. of AP buffer and 
100 |il_ of phosphatase substrate solution (Sigma, one tablet dissolved in 9.6 mL AP 
buffer) was incubated at 37 °C for 5 min. The reaction was started by adding 20 |iL of 
diluted vesicle sample (usually dilutions 1:10, 1:100 and 1:1000 were used) and 
incubated at 37 °C for 5 to 8 min. The reaction was stopped by adding 1 mL of 500 mM 
NaOH. The absorbance was measured at 405 nm using a Cary 50 Bio UV-Visible 
spectrophotometer (Varian, Australia). 
AP buffer: 1 M Diethanolamine 
0.5 mM MgCI2 pH 9.8 adjusted with HCI 
2.7.3 Uptake experiment with BBMV 
Radioisotope uptake measurements were carried out immediately after BBMV 
preparation in order to avoid degeneration of the vesicles at 25 °C. 
20 [ i l of vesicle solution was added to 80 nL uptake buffer containing 100 nM 
non-labelled and labelled amino acid substrates. The mixture was vortexed and after 
15 second (sec) a 20 nL sample was removed and the uptake was stopped by adding it 
to 4 mL ice-cold stopping buffer. The diluted samples were filtered using a manifold 
filtration device (Amersham Pharmacia). Subsequently, the filters were washed three 
with 4 mL stop solution. The filters were then transferred into separate scintillation 
vials and covered with 6 mL scintillation fluid. The radioactivity was counted in a 
Beckman LS 6500 scintillation counter. 
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Sodium uptake buffer was used to measure the uptake while potassium uptake buffer 
was used as a control. Two to three samples were taken for every time point and blank 
controls were measures as duplicates of filtered uptake buffer with substrate in 
respective dilution. 
Uptake buffers: 
sodium: 100 mM NaCI 
100 mM D-Mannitol 
20 mM HEPES/Tris pH 7.4 
potassium 100 mM KCI 
100 mM D-Mannitol 
20 mM HEPES/Tris pH 7.4 
Stop solution: 280 mM D-Mannitol 
20 mM HEPES/Tris pH 7.4 
2.7.4 Competition Experiments with BBMV 
Competition experiments were conducted following the same procedure as for uptake 
experiments (Section 2.7.4). 
For these experiments the uptake buffer also included one of the competing amino 
acids leucine (lOmM final concentration), glutamine (30 mM final concentration), 
proline (30 to 50 mM final concentration), phenylalanine (30 mM final concentration) 
or glycine (30 mM final concentration). 
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2.8 Mammalian cells 
2.8.1 Cell lines and culturing conditions 
In this study, the mammalian cell lines HEK 293 (ATCC- The Global Biorecourse Centre, 
Manassas, USA) and CHO- K1 (kindly provided by the Ian Young group, JCSMR, 
Canberra, Australia) were used. The cells were grown at 37 °C in a 5 % C02 humidified 
atmosphere in a HERA cell 240 C02 incubator (Heraeus- Thermo Scientific, USA). HEK 
cells were cultured in RPMI media with 10% FCS, 2 mM Glutamine and lmL of 
penicillin-streptomycin solution (Sigma) and CHO cells were cultured in Dulbecco's 
modified eagle's media plus nutrient mixture F-12 HAM (Sigma) with 2 % FCS and lmL 
penicillin-streptomycin solution. The cells were subcultured when they were confluent, 
by washing with PBS and dislodging them using 0.25% trypsin EDTA (Invitrogen). The 
trypsin activity was neutralised with FCS-containing medium and the cells were 
centrifuged at 900 g for 5 min in a Beckman GS-6R centrifuge. The cells were 
resuspended in complete medium and subcultured into flasks, dishes or on microscope 
slides as required for the various experiments. 
2.8.2 Transient transfection of mammalian cells 
Cells were either subcultured on microscope slides (LabTek II Chamber System, Nunc) 
or on 56.2 cm2 petri dishes. Upon reaching 50 to 80% confluency they were used for 
transfection. For the transfection either the Lipocetamine LTX Reagent with addition of 
Plus reagent was used or Lipofectamine 2000 (both from Invitrogen) following the 
manufacturers' instructions. Briefly, for transfection on 8-well microscope slides, the 
transfection mixture containing 200 ng of DNA, 0.5 |iL of Lipofectamine LTX reagent 
and 0.2 ^L PLUS reagent in 40 \iL Opti-MEM medium (Invitrogen) was added to each 
well already containing 200 nL of Opti-MEM. 
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After incubation of the cells for 24 h at 37 °C in a 5 % C02, humidified atmosphere, the 
media was changed back to normal growth media and the cells were incubated for 
another 24 h. The cells were then used for immunofluorescence (Section 2.8.4) or 
were lysed for Western Blot analysis (Section 2.8.3). For each transfection controls 
were included, containing non-transfected cells and mock transfected cells (vector only 
control). 
2.8.3 Lysis of cells for Western Blot 
Protein expression in transfected mammalian cells was examined by Western Blot. 
Cells were washed twice with 10 mL PBS buffer, then scraped off the flask and taken 
up in ice-cold PBS buffer, centrifuged for 5 min at 900 g and washed again with 10 mL 
PBS. After centrifugation at 900 g for 5 min ice-cold Lysis buffer (usually 3-5 mL) was 
added to the cells and the mixture was incubated for 15 to 20 min on ice. The cells 
were centrifuged at 12,000 g at 4 °C and the supernatant was used to prepare samples 
for Western Blotting (Section 1.4.4.1 to 1.4.4.3). 
RIPA (Lysis) buffer: 50 mM Tris-HCI pH 7.8 
2.8.4 Immunofluorescence microscopy of mammalian cells 
Immunofluorescence microscopy was performed to analyse transfection efficiency and 
expression of the amino acid transporters in mammalian cells. 
Transfected cells and controls were washed with PBS. The cells were then fixed with 
either 3.5% paraformaldehyde in PBS for 10 min at RT or with pre-cooled 100% 
methanol at -20 °C for 10 min. After washing cells twice with PBS for 10 min they were 
incubated with 0.1 % glycine in PBS for 5 min at RT. 
150 mM 
0.5 % 
0 . 1 % 
1% 
l x 
NaCI 
SDS 
Sodium deoxycholate 
Triton X-100 
complete EDTA-free protease inhibitor (Roche) 
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Subsequently, the cells were permeabilised with 0.3 % Triton X-100 in PBS for 10 min. 
The cells were then incubated for 2 h at 37 °C in a humidified environment with 
primary antibody in various dilutions and different blocking reagents depending on the 
mammalian cells and antibody. To remove non-specific binding, the cells were washed 
twice with 0.1 % Triton X-100 in PBS for 10 min and incubated for 1 h at 37 °C in a dark, 
humidified environment with the secondary antibody in appropriate dilution. After 
washing the cells twice with 0.1% Triton X-100 in PBS for 10 min the cells were 
mounted with the anti- fade reagent ProLong Gold (Invitrogen) and examined under 
the confocal microscope Leica TCS SP5 (Section 2.5.3). 
2.9 Statistical Analysis 
Statistical analysis was performed using Origin Statistical program (Origin Version7 
0300, 1991-2002 Origin Lab Corporation Ma, USA). Student's t test was used to 
compare samples. 
Additional statistical analysis, including one-way Analysis of Variance (ANOVA) and 
post hoc Bonferroni tests were conducted using the GraphPad InStat program (InStat 
Version 3.06 32bits for windows, GraphPad Sofware Inc., La Jolla, USA). A p- value < 
0.05 was considered as significant and was marked with asteriks in the figures. 
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3.1 Introduction and aim of this study 
In previous studies, the tissue biodistribution of B°AT1 and ASCT2 has been analysed 
(Avissar et al., 2001; Broer et al., 2004; Green et al., 2004). It has been determined that 
B°AT1 is localised in the early segments of the proximal tubule and in the apical 
membrane of the whole intestine except the colon. 
ASCT2 has either been detected apically in the early segment of the proximal tubule 
and in all segments of the intestine or controversially was shown to be in the 
basolateral membrane of the proximal tubules (Green et al., 2004). The study by 
Avissar et al. further suggested that ASCT2 is the main apical transporter for neutral 
amino acids in intestine and kidney. 
To clarify the relative roles of B°AT1 and ASCT2, the localisation of both transporters 
was determined with antibodies designed against an ASCT2 peptide in our own 
laboratory. In addition, the localisation of B°AT2 in the kidney was determined. 
Because the antibodies had not been used before, their specificity needed to be 
characterised prior to immunofluorescence studies on mouse tissue. 
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3.2 Results 
The immunofluorescence studies with tissue sections described in this chapter had to 
be optimised depending on the antibody used, particularly for the antibody against 
B°AT2. This antibody showed high non-specific binding to mouse tissue. The optimised 
protocol is shown in detail below: 
3.2.1 Immunofluorescence protocol 
o It is important for this protocol that throughout the whole procedure the slides 
never dry out. 
o Slides were first deparaffinised by sequential 10 min immersion in HistoClear, 
100 % ethanol and 95 % ethanol in a Coplin jar. 
o The slides were then washed three times for 5 min with PBS followed by three 
washes with distilled water each for 5 min in a Coplin jar. 
o The deparaffinised slides were immersed using a slide holder in 600 ml of boiling 
1 mM sodium citrate buffer (pH 6.0) in a 2 L beaker. The sodium citrate buffer was 
kept boiling for 15 min and then removed from the hot plate, 
o The submerged slides were incubated in the buffer for a further 20 min as it cooled 
down. 
o The slides were then taken out and washed with PBS three times for 5 min in a 
Coplin jar. 
o The tissue sections on the slides were outlined with a Pap Pen (Invitrogen). 
o 150 to 200 |iL of blocking solution in PBS was applied to each section until the 
sections were totally covered, 
o The slides were then incubated in a humidified incubation chamber at 37 °C for 1.5 
to 2.5 h. 
o After incubation, the blocking solution was removed and 150 to 200 [xl of primary 
antibody diluted in PBS was applied immediately to the sections until completely 
covered. 
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o The slides were incubated in a humidified incubation chamber at 37 °C for 0.5 to 
1.5 h. 
o After incubation, the primary antibody was removed and the slides were washed 
three times for 5 min in PBS in a dark Coplin jar to remove any unbound antibodies, 
o After washing, the PBS buffer was removed as much as possible and where 
necessary, the Pap Pen was applied again, 
o 150 to 200 \il of the secondary antibody diluted in PBS was applied to the sections 
immediately. 
o The slides were incubated in a humidified incubation chamber in the dark at 37 °C 
for 0.5 h. 
o After incubation, the secondary antibody was removed and the slides were washed 
three times for 5 min with PBS in a Coplin jar in the dark, 
o The PBS buffer was removed completely from the slides, which were then mounted 
with ProLong Gold antifade reagent (Invitrogen) to preserve the fluorescence of the 
section. The antifade reagent was allowed to set over night, 
o Digital images were obtained using the x40 or x60 oil objective with a LAS-AF 
system installed on a Leica TSC SP5 confocal microscope using the lasers according 
to the fluorochrome used, 
o Control sections were stained with secondary antibody only. 
o Images were, if necessary, processed using Adobe Photoshop CS3 Extended Version 
10.0.1 (Adobe Systems, San Jose, CA, USA) to enhance contrast. Images of controls 
and treated sections were processed using the same settings. 
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3.2.2 Characterisation of the B°AT1 antibody 
The neutral amino acid transporter gene for B°AT1 had been predicted to have a 
molecular mass of 71 kDa. The antibody against mouse B°AT1 was raised against a 
GST-fusion protein of the N-terminus. 
To elucidate whether the B°AT1 antibody was suitable for immunofluorescence studies 
on tissues, Western Blot analysis of B°AT1 injected oocytes was conducted first. 
Oocytes were injected with mouse B°AT1 cDNA and after 3 to 5 days, proteins were 
prepared for Western Blot analysis. Non-injected oocytes were used as a control. 
B°AT1 was detected as a 65 kDa band in the injected oocytes, but no band was visible 
in the control oocytes. 
Western blot analysis conducted with the pre-immune serum from the antibody 
production revealed a faint protein band at 95 kDa (Figure 3.1), which was only 
detected with the final serum after a long exposure time. 
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Figure 3.1: Evaluation of the mouse B°AT1 antibody in oocytes. 
B°AT1 cRNA injected oocytes (B°AT1) and non-injected oocytes (ni) were lysed, the lysates 
were then separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The 
membrane was incubated either with rabbit anti-mB°ATl (Bl) or pre-immune serum isolated 
from the same rabbit (S) during antibody production. The bands were visualised using a 
chemiluminescent Western Blot detection kit. B°AT1 was detected in the injected oocytes only. 
Another faint protein band was only detected in the pre-immune serum control as well. 
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To test whether the antibody was suitable for immunostaining, oocytes were injected 
with human and mouse B°AT1 cRNA. Non-injected oocytes were used as a control. 
Four days after injection, the oocytes were fixed with 4 % paraformaldehyde and 
subsequently detected with either chicken anti-human B°AT1 antibody stained by goat 
anti-chicken secondary antibody conjugated to Alexa Fluor® (AF) 488, a green 
fluorophore, or rabbit anti-mB°ATl antibody detected by donkey anti-rabbit secondary 
antibody conjugated to AF 488. 
Staining was then observed using a confocal microscope. In the membrane, 
fluorescence was detected in oocytes injected with human and mouse B°AT1, while no 
or only negligible fluorescence was observed in non-injected oocytes (Figure 3.2). This 
indicates that both B°AT1 antibodies are suitable for immunofluorescence studies. 
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Figure 3.2: Evaluation of human and mouse B°AT1 in oocytes. 
Both human (A) and mouse (C) B°AT1 cRNA injected oocytes showed bright green fluorescence 
of the oocyte membrane. Non-injected oocytes (B, D) used as negative control show no (B) or 
very faint (D) fluorescence. Original magnification, xlO. 
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3.2.3 Characterisation of the B°AT2 antibody 
The neutral amino acid transporter gene for B°AT2 had been predicted to form a 
protein with a molecular weight of 81 kDa. Two antibodies were generated against 
mouse B°AT2 protein, one against a GST-fusion protein of the C-terminus, the other 
against a GST-fusion protein of the N-terminus of the protein. 
To investigate if these antibodies were suitable for immunofluorescence studies on 
tissues, Western Blots analysis were conducted. Oocytes were injected with mouse 
B°AT2 cRNA and after 3 to 5 days prepared for Western Blot analysis. Non-injected 
oocytes were used as controls. B°AT2 was detected as a band with the molecular 
weight of 81 kDa in the injected oocytes, but not in the controls. 
An additional protein with a higher molecular weight than 82 kDa was detected as a 
weaker band. This protein was present in both the control and injected oocytes. 
Western Blot analysis conducted with the pre-immune serum from the antibody 
production showed the same unknown protein band (Figure 3.3). 
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Figure 3.3: Evaluation of mouse B°AT2 N-terminal antibody in oocytes. 
B°AT2 cRNA injected oocytes (B°AT2) and the non-injected oocytes (ni) were lysed, the lysates 
were then separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The 
membrane was incubated either with B°AT2 (B2) or pre-immune serum isolated from the same 
rabbit (S). The bands were visualised using a chemiluminescent Western Blot detection kit. 
B°AT2 was detected in the injected oocytes only. Another unknown protein was detected, 
which was present in non-injected oocytes and albeit weaker in the pre-immune serum control 
as well. 
Chapter 3 - Distribution of the amino acid transporters B°AT1, B°AT2 and ASCT2 
in kidney and intestine 
In addition, B°AT2 transfected HEK-293 (HEK) cells were also examined using Western 
Blot analysis. Non-transfected HEK cells were used as control. The B°AT2 protein was 
detected as a strong band at 81 kDa in the B°AT2 transfected HEK cells, but was also 
present at lower intensity in the non-transfected HEK cells (Figure 3.4). 
As the HEK cell line is derived from kidney tissue, it appears possible that HEK cells 
express B°AT2 endogenously, which will be investigated further below. 
Figure 3.4: Western Blot analysis of mouse B°AT2 in HEK cells. 
B°AT2 transfected HEK cells, are denoted as '+' and the non transfected HEK cells are denoted 
as '-'. The protein lysates were separated by SDS-PAGE and transferred onto nitrocellulose 
membrane. The membrane was incubated with the B°AT2 N-terminal antibody. The bands 
were visualised using a chemiluminescent Western Blot detection kit. The 98 kDa and the 
62 kDa markers are indicated by black arrows. B°AT2 was detected as an 81 kDa protein 
enriched in transfected cells, but was also present in non-transfected HEK cells. 
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To test whether the antibody was useful for immunofluorescence microscopy, oocytes 
were injected with mouse B°AT2 cRNA. Non-injected oocytes were used as a control. 
After 4 days, the oocytes were fixed with 4% paraformaldehyde and subsequently 
stained with rabbit anti-B°AT2 C-terminal antibodies. The primary antibodies were 
detected by donkey anti-rabbit secondary antibody conjugated to AF 488. 
Flourescence was then observed using a confocal microscope. The membranes of both 
the injected and non-injected oocytes showed a bright fluorescence staining with the 
antibody. However, weak immunofluorescence was also detected in the non-injected 
oocytes (Figure 3.5). The fluorescence was fainter in the non-injected oocytes than the 
injected oocytes, but the results were not convincing enough to determine that the 
B°AT2 antibody was suitable for immunofluorescence studies. 
Figure 3.5: Evaluation of mouse B°AT2 antibody in oocytes. 
B°AT2 cRNA injected oocytes stained with C-terminus (A, B) and N-terminus (C, D) antibodies 
showed bright green fluorescence of the oocyte membrane. Non-injected oocytes (B, D) were 
used as negative controls and showed weak fluorescence in both experiments. Original 
magnification, xlO. 
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Further preliminary immunofluorescence studies to determine which antibody was 
most suitable for this project showed slightly better results for the N-terminus specific 
antibody (data not shown) than the C-terminus specific antibody. For this reason, the 
N-terminus specific antibody was chosen for all subsequent experiments. 
To investigate the B°AT2 antibody further, HEK cells were transfected with B°AT2 
cDNA. After 48 h the cells were fixed with 3.5 % paraformaldehyde and subsequently 
stained with rabbit anti-B°AT2 antibody detected by donkey anti-rabbit secondary 
antibody conjugated to AF 488. B°AT2 staining was detected in the cytosol of B°AT2 
transfected cells, but also weakly in non-transfected cells (Figure 3.6). 
Similar to the Western Blot results this suggested that HEK293 cells express B°AT2 
endogenously. This experiment also could not confirm the suitability of the antibody 
for immunofluorescence studies. 
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Figure 3.6: Evaluation of N-terminal B°AT2 antibody in HEK cells. 
A: Bright B°AT2 staining was detected in the cytosol of transfected HEK cells B: Weaker 
immunofluorescence was observed in the non-transfected HEK cells. Original magnification, 
xlO. 
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RT-PCR was used to test for the endogenous expression of B°AT2 in HEK cells. RNA 
from HEK cells was obtained and reverse transcribed into cDNA. The cDNA was then 
examined by PCR using various primer pairs. Actin was used as a positive control and 
two primer pairs spanning the C-and N-terminus were used to test for B°AT2 existence. 
Figure 3.7 shows the result of this RT-PCR reaction. RNA and water were used as 
templates in the controls. The actin primers produced a faint product in the RNA only 
control, implying a slight contamination of the RNA with genomic DNA. In the water 
only control no product was amplified, indicating the absence of DNA and RNA 
contaminations. The positive actin control showed a bright actin-specific product of 
100 bp. Only the primers for the C-terminus region of the B°AT2 cDNA generated a 
visible product. This indicates that HEK cells express B°AT2 endogenously explaining 
the results of the Western Blot analysis and the immunofluorescence microscopy. 
Figure 3.7: RT-PCR of HEK cells with actin, B°AT2 N- and C- terminal specific primers. 
Total RNA was isolated from HEK cells and reverse transcribed into cDNA. The 250 bp and the 
1 kb band of the lkb marker, denoted as M, are accentuated. RNA was used as a template in 
the negative control and tested with actin primers, denoted as 1. It generated a faint product 
of actin, indicating slight genomic DNA contamination. When water was used as a template, 
denoted as 2, no specific fragment was generated. The positive actin control, denoted as A, 
amplified a lkb actin-specific fragment. With the primer pairs of the N- and C-terminus of 
B°AT2, denoted as N and C only the C-terminus was amplified as 250bp specific fragment. 
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Further RT-PCR experiments showed that Chinese hamster ovary cells (CHO) did not 
express B°AT2 endogenously (data not shown). These cells were used for B°AT2 
transfection, and were fixed with 3.5 % paraformaldehyde 48 h after transfection. 
Subsequently the cells were treated with rabbit anti-B°AT2 antibody and the protein 
was detected by donkey anti-rabbit secondary antibody conjugated to AF 488. B°AT2 
fluorescence was detected in the cytosol of B°AT2 transfected CHO cells. No 
fluorescence was observed in non-transfected cells and only faint background 
fluorescence was detected in mock-transfected cells (cells transfected with pcDNA3.1+ 
vector only) (Figure 3.8). This indicates that the B°AT2 antibody was suitable for 
immunofluorescence studies with tissue sections. 
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Figure 3.8: Evaluation of mouse N-terminal B°AT2 antibody in CHO cells. 
A: Bright green B°AT2 staining was detected in the cytosol of the transfected CHO cells B: No 
fluorescence was revealed in the non-transfected CHO cells. C: Only a faint fluorescence was 
detected in the mock-transfected CHO cells. Original magnification, xlO 
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3.2.4 Characterisation of the ASCT2 antibody 
The neutral amino acid transporter gene for ASCT2 has been predicted to form a 
protein of 58 kDa. Two ASCT2-specific antibodies were investigated. One antibody, 
kindly provided by the Avissar laboratory, was raised against the human ASCT2 
C-terminus (characterised in Avissa et al., 2001), while the second was designed in our 
laboratory against the mouse ASCT2 peptide epitope N-REPSGDSSATC—COOH. The 
specificity of the antibody designed in our laboratory was already analysed in the 
honours thesis of Tobias Heckel (Heckel, 2002). He showed that the detection of 
ASCT2-like immunoreactivity is reduced in Western Blots when the antibody is 
incubated with the immunogenic peptide, indicating that the antibody is specific for 
ASCT2. 
The two primer sequences are 82% identical. The amino acid sequence of human 
ASCT2 is highly homologous to those of rat and mouse ASCT2 (Broer A. et al., 1999; 
Liao, K. and Lane, M.D., 1995). For instance, the amino acid sequence of mouse ASCT2 
is 83 % identical to rat ASCT2 sequence. Furthermore, the human amino acid sequence 
of ASCT2 possesses 42% similarity to the mouse amino acid sequence and 56% 
similarity to the rat amino acid sequence of ASCT2. The first step was to test which of 
the antibodies was more appropriate to detect ASCT2 in tissue of different species. 
Human, mouse and rat tissue samples were first analysed using Western Blot analysis. 
Protein samples were prepared identically, separated by SDS-PAGE and after transfer 
onto a nitrocellulose membrane, ASCT2 was detected by immunoblotting. The Avissar 
laboratory antibody detected a 47 kDa protein in human and mouse tissue, but no 
protein in rat tissue. Longer exposure time revealed a weak protein band at 58 kDa and 
63 kDa in all tissues (data not shown). 
Detection with our own ASCT2 antibody revealed a band at 53 kDa in human tissue. 
This protein was not detected in rat tissue, but was observed with longer exposure 
time in mouse tissue (data not shown). Furthermore, a protein of around 100 kDa was 
detected in mouse and rat tissue, consistent with the size of an ASCT2 dimer. With 
longer exposure time a protein band became visible in the 77 to 80 kDa range in all 
tissues (Figure 3.9). To resolve these discrepancies, further tests were performed. 
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Figure 3.9: Detection of ASCT2- like immunoreactivity in different tissues by anti-
human and anti-mouse antibody. 
The tissue samples from mouse (M), human (H) and rat (R) were prepared identically, 
subsequently separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The 
membrane was either incubated with anti-human ASCT2 antibody received from the Avissar 
laboratory, denoted with AA or with anti-mouse ASCT2 antibody generated in our own 
laboratory, denoted as OA. The bands were visualised using a chemiluminescent Western 
detection kit. The marker sizes are indicated by black arrows. ASCT2-like activity was detected 
as a distinct 47 kDa band with the AA antibody in human and mouse but not in rat tissue. 
ASCT2-like immunoreactivity detection with OA revealed a 53 kDa protein in human tissue, but 
not in mouse and rat, but recognised bands at 85 kDa and 105 kDa in rat and mouse tissue. 
Oocytes were injected with ASCT2 cRNA and non-injected oocytes were used as a 
control. After 3 to 4 days the oocytes were prepared for Western Blot analysis. Again, 
both ASCT2 antibodies were investigated. Surprisingly, ASCT2-like immunoreactivity 
was detected as a 47 kDa protein in both non-injected and injected oocytes with the 
antibody received from the Avissar laboratory. Similarly, our own antibody detected 
two proteins around 80 kDa and 100 kDa in both injected and non-injected oocytes 
(Figure 3.10). These results were inconclusive with respect to antibody specificity. 
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Figure 3.10: Detection of ASCT2-like activity in oocytes by anti-human and anti-
mouse antibody. 
ASCT2 cRNA injected oocytes (ASCT2) and non-injected oocytes (ni) were lysed, the proteins 
were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane 
was either incubated with anti-human ASCT2 antibody received from the Avissar laboratory, 
denoted with AA or with the anti-mouse ASCT2 antibody designed in the Broer laboratory, 
denoted as OA. The bands were visualised using a chemiluminescent Western Blot detection 
kit. The Avissar antibody detected a protein of 47 kDa in both injected and non-injected 
oocytes. With our own antibody two immunoreactive bands were detected at about 80 kDa 
and 100 kDa. 
Additional Western Blot analysis with transfected CHO cells was undertaken to 
investigate, which antibody against ASCT2 would be suitable for further experiments. 
CHO cells were transfected with either ASCT2 cDNA or mock (the pcDNA3.1+ vector 
only control). Non-transfected cells were used as a second control. The cells were lysed 
48 h after transfection, and the proteins were separated by SDS-PAGE. The Avissar 
antibody detected a 58 kDa protein after prolonged exposure in all three cell types. 
The transfected CHO cells did show an increase of the detected protein in comparison 
to non- or mock-transfected cells. With the antibody designed by our own laboratory a 
number of bands at 41, 47, 54, 62, 79, 98 and 178 kDa were detected in ASCT2-
transfected cells, but not in mock-transfected or non-transfected cells. 
Immunoreactivity was particularly strong at 98 kDa. These proteins appear as a result 
of ASCT2 transfection and therefore are likely to represent different isoforms or 
degradation products of ASCT2 as reported previously (Tailor et al., 2001). A protein of 
around 54 kDa was weakly detected in both mock- and ASCT2-transfected cells (Figure 
3.11). 
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Figure 3.11: Evaluation of anti human- and anti mouse-ASCT2 antibody in CHO cells. 
ASCT2 cDNA transfected CHO cells are denoted as '+', mock-transfected CHO cells are denoted 
as 'M' and non-transfected CHO cells are denoted as ' - ' . Protein lysates were separated by 
SDS- PAGE and transferred onto nitrocellulose membrane. The membrane was incubated with 
anti-human ASCT2 antibody received from the Avissar laboratory, denoted with AA and with 
an anti-mouse ASCT2 antibody designed in our own laboratory, denoted as OA. The bands 
were visualised using a chemiluminescent Western Blot detection kit. The 98 kDa, the 62 kDa 
and the 49 kDa size of the marker are indicated by black arrows. ASCT2-like immunoreactivity 
was detected as a weak band at 58 kDa protein with the Avissar antibody in all three cell types. 
The antibody designed in our own Laboratory detected several bands in ASCT2 cDNA 
transfected cells at 41, 47, 62, 79, 98 and 178 kDa, a weak band of 54kDa was detected in 
mock-transfected cells and no immunoreactivity was detected in non-transfected cells. 
In summary, the Avissar antibody failed to detect ASCT2-like immunoreactivity in two 
different expression systems. These results were confirmed by immunofluorescence 
studies of CHO cells. Cells were fixed with 3.5% paraformaldehyde 48 h after 
transfection, incubated with rabbit anti-human ASCT2 antibody (Avissar laboratory), 
which was subsequently detected by donkey anti-rabbit secondary antibody 
conjugated to AF 488. Immunofluorescence was detected in the cytosol of ASCT2 cDNA 
transfected CHO cells but fluorescence of similar intensity was detected in non-
transfected cells as well. Mock-transfected cells showed less fluorescence in 
comparison to ASCT2 transfected and non-transfected cells. However, the 
fluorescence observed with the secondary antibody only was as bright as in ASCT2 
cDNA transfected cells (Figure 3.12). 
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Figure 3.12: Evaluation of anti-human ASCT2 antibody for immunofluorescence in 
paraformaldehyde fixed CHO cell. 
Immunofluorescence studies were conducted with paraformaldehyde fixed ASCT2 transfected 
(A), non-transfected (B) and mock-transfected CHO cell (C). 
A: Bright green immunofluorescence was detected in the cytosol of ASCT2 transfected CHO 
cells. B: Similar levels of fluorescence were also observed in the non-transfected CHO cells. C: 
The mock-transfected CHO cells showed a fainter fluorescence than A and B. D: Staining with 
the secondary antibody only as a control resulted in similar fluorescence intensity as A and B. 
Original magnification, xlO. 
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The absence of a significant difference in fluorescence between transfected, non-
transfected cells and cells treated with secondary antibody only, suggested that the 
antibody was not suitable for immunofluorescence studies on paraformaldehyde-fixed 
tissue. Therefore, the fixation method of the cells was changed from 
paraformaldehyde to a less aggressive fixative, the organic solvent acetone. 
CHO cells were transfected with ASCT2 cDNA as described above and fixed after 48 h 
with acetone. The cells were then stained with both, rabbit anti-human ASCT2 
(Avissar) and rabbit anti-mouse ASCT2 (Broer) antibodies and the protein was detected 
by donkey anti-rabbit secondary antibody conjugated to AF488 as described above. 
With the antibody from the Avissar laboratory a faint fluorescence was detected in the 
cytosol and in the plasma membrane of the transfected CHO cells. Mock-transfected 
CHO cells showed only slight background staining (Figure 3.13). No staining was 
observed in non-transfected CHO cells (data not shown). 
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Figure 3.13: Evaluation of anti-human ASCT2 antibody for immunofluorescence in 
acetone fixed CHO cell. 
Immunofluorescence studies were conducted with the Avissar antibody, with acetone fixed 
ASCT2 transfected (A) and non-transfected (B) CHO cell. 
A: Faint green ASCT2-like immunoreactivity was detected in the cytosol and the plasma 
membrane of the transfected CHO cells. B: The mock-transfected CHO cells showed slight 
background staining. Original magnification, xlO. Scale bars represent 10 nm. 
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The antibody designed in our laboratory, by contrast, showed bright fluorescence in 
the cytosol of the transfected cells (Figure 3.14 A). In mock-transfected cells only a 
slight background staining was detected (Figure 3.14 B). No staining was noted in the 
non-transfected CHO cells (data not shown). 
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Figure 3.14: Evaluation of anti-mouse ASCT2 antibody in acetone fixed CHO cells. 
Immunofluorescence studies were conducted with the Broer antibody, with acetone fixed 
ASCT2 transfected (A) and non-transfected (B) CHO cell 
A: Strong ASCT2-like immunoreactivity was detected in the cytosol of the transfected CHO 
cells. B: The mock-transfected CHO cells showed slight background staining. Original 
magnification, xlO. Scale bars represent 10 i^m. 
In summary, only the antibody designed in our laboratory detected ASCT2-like bands 
and immunofluorescence in transfected cells and was therefore chosen for further 
analysis. 
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3.2.5 Immunofluorescence of B°AT1, B°AT2 and ASCT2 in mouse kidney and 
intestine 
3.2.5.1 Confirmation of B°AT1 localisation in mouse kidney and intestine 
C57BI/6 adult mouse kidney and intestine specimens were pre-fixed with 10% NBF, 
then embedded in paraffin, sectioned and de-paraffined. Boiling sodium citrate (1 mM) 
buffer at pH 6 was subsequently applied to retrieve the cross-linked antigenic sites 
formed during the fixation. Subsequently, the sections were incubated with rabbit 
anti-mB°ATl antibody detected by donkey anti-rabbit secondary antibody conjugated 
to AF 488. The kidney proximal tubules were identified by incubation with biotinylated 
lotus tetragonobolus lectin (LTL), which was detected by Strepavidin-Texas Red. B°AT1 
fluorescence was observed in the mouse kidney in the S I segment and the S2 segment 
of the proximal tubule. The staining was only observed in the apical membrane of the 
cells. In the intestine, B°AT1 was detected in the apical membrane of the villi showing a 
gradual decrease from the top of the villi towards the crypt cells of the intestine 
(Figure 3.15). B°AT1 was observed in nearly all parts of the intestine (data not shown). 
Figure 3.15: Localisation of B°AT1 in C57BI/6 mouse kidney and intestine. 
B°AT1 was identified using a rabbit primary antibody, detected by a donkey anti-rabbit 
secondary antibody conjugated to AF 488 (green). Kidney proximal tubules were visualised 
using biotinylated Lotus Tetragonobolus Lectin (LTL), detected with Strepavidin-Texas Red 
(red). G represents a glomerulus. A: B°AT1 was detected on the apical membrane of the early 
proximal tubulus segments S I (i.e. near the glomerulus), denoted as 1, and S2, denoted as 2. 
B: B°AT1 staining was detected in the apical membrane of the villi. It was more strongly 
expressed at the tip of the villi, gradually decreasing towards the crypt cells. Original 
magnification, x40. Bars represent 10 nm. 
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3.2.5.2 Determination of B°AT2 localisation in mouse kidney and intestine 
To determine the B°AT2 localisation, the same procedure was used as with B°AT1, as 
described above. B°AT2 immunofluorescence was observed in the apical membrane of 
the later segments of the proximal tubulus, namely S2 and S3. Furthermore, B°AT2 was 
only noted in a very small percentage of cells. B°AT2 was not detected in the intestine. 
Only a faint background staining was observed (Figure 3.16). 
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Figure 3.16: Localisation of B°AT2 in C57BI/6 mouse kidney and intestine. 
B°AT2 was detected using a rabbit primary antibody and a donkey anti-rabbit secondary 
antibody conjugated to AF 488 (green). Kidney proximal tubules were visualised with 
biotinylated LTL and SA-Texas Red (red) as marker. A: B°AT2 was detected on the apical 
membrane of the later proximal tubulus segments S2, denoted with 1, and S3, denoted as 2 B: 
B°AT2 was detected in a more distinct manner on the apical membrane of the renal S2 
segment, denoted with 1. C: B°AT2 staining was not detected in the intestine. Original 
magnification, x40. Bars represent 10 nm. 
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3.2.5.3 ASCT2 localisation in human kidney and intestine 
The ASCT2 staining was undertaken by our collaborator Jessica Vanslambrouck in 
Sydney with human specimens. Kidney and intestine specimens were pre-fixed with 
10% NBF, followed by paraffin embedding and sectioning. Using the procedure 
explained above, the kidney sections were stained with peanut agglutinin (PNA), a 
distal tubule marker conjugated to AF 568 (red) and an anti-human ASCT2 antibody. 
The ASCT2-specific antibodies were detected by goat anti-rabbit secondary antibody 
conjugated to AF 488. ASCT2-like immunoreactivity was detected on the apical 
membrane of the proximal tubulus and also on the basolateral membrane of the distal 
tubulus. In these experiments of B°AT1, and ASCT2 in the proximal tubulus revealed 
co-localisation of B°AT1 and ASCT2-like immunoreactivity in the S2 segment, while only 
ASCT2-like immunoreactivity was expressed in the S3 segments (proximal straight 
tubules, data not shown). For this co-staining B°AT1 was identified using a chicken 
primary anti-B°ATl antibody detected by goat anti-chicken secondary antibody 
conjugated to AF 594. ASCT2 was identified using a rabbit anti-ASCT2 primary antibody 
detected by goat anti-rabbit secondary antibody conjugated to AF 488 (Figure 3.17). 
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Figure 3.17: Localisation of ASCT2-like immunoreactivity in human kidney. 
A: ASCT2-like immunoreactivity was identified using a rabbit primary antibody stained by a 
goat anti-rabbit secondary antibody conjugated to AF 488 (green). Kidney distal tubules were 
co-stained with PNA conjugated to AF 568 (red) as marker. ASCT2-like immunoreactivity was 
detected on the basolateral membrane of the distal tubules (1), but also on apical membrane 
of some proximal tubules (2). B: Co-staining with B°AT1 stained with chicken primary antibody 
detected by AF 594 (red) (1), revealed co-localisation of both transporters on a proportion of 
the proximal tubule (S2-segment)(2) but also in the basolateral membrane of tubules were 
B°AT1 was absent (3). Original magnification, x40. Bars represent 30 nm. Figure kindly 
provided by J. Vanslambrouck, Sydney University. 
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To investigate ASCT2 localisation in the intestine, ASCT2 was identified using a rabbit 
primary antibody detected by goat anti-rabbit secondary antibody conjugated to 
AF488. ASCT2-like expression was limited to the basolateral membrane of the base of 
the crypt cells. These cells mainly consist of Paneth cells (Figure 3.18). However, a 
positive staining was also obtained in goblet cells further up the villi. This staining of 
mucin within the goblet cells is most likely a result of non-specific binding by the rabbit 
anti-ASCT2 antibody. Antibodies raised in rabbits possess a well recognised attribute to 
generate high levels of non-specific binding to mucin in goblet cells (Rogers et al., 
2006). 
Figure 3.18: Localisation of ASCT2-like immunoreactivity in human intestine. 
ASCT2-like immunoreactivity was localised using a rabbit primary antibody and detected by a 
goat anti rabbit secondary antibody conjugated to AF 488 (green). B°AT1 was localised with 
chicken primary antibody and detected by a goat anti chicken antibody conjugated to AF 594 
(red). A-B: B°AT1 staining was detected in the apical membrane of enterocytes of the intestinal 
villi. However, ASCT2-like staining was restricted to the basolateral membrane of the crypt 
cells (arrow). Staining of mucin within the goblet cells by rabbit anti-ASCT2 antibody is most 
likely an artefact. Original magnification, x40 (A) and xlOO (B). Bars represent 30 |im. Figure 
kindly provided by J. Vanslambrouck, Sydney University. 
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3.3 Discussion and future directions 
3.3.1 Characterisation of the B°AT1 antibody 
The characterisation of the antibody against B°AT1 demonstrated the suitability of the 
antibody for immunofluorescence studies. Western Blot analysis detected a clear 
signal for a protein of the size reported for B°AT1. Staining of B°ATl-injected oocytes 
revealed clear fluorescence signals confirming the suitability of the antibody for 
immunofluorescence. 
3.3.2 Characterisation of the B°AT2 antibody 
The characterisation of the antibody against B°AT2 confirmed the suitability of the 
antibody for immunofluorescence studies. Comparable to the B°AT1 results, Western 
Blot analysis detected a clear signal for a protein of a size consistent with B°AT2, 
alongside a weaker non-specific protein in oocytes. This protein proved to be part of 
the pre-immune response of the rabbit in which the antibody was raised. Other 
smaller proteins were also detected, which could be either detection of B°AT2 splice 
variants reported previously (Sakata et ai, 1999) or unspecific labelling. The oocyte 
expression studies suggested however, that the antibody might not be as useful for 
immunofluorescence studies. 
Due to the weak immunofluorescence observed in B°AT2 cRNA injected oocytes, cell 
lines were used to express the transporter. Firstly, HEK cells were chosen as they have 
been shown to be easily transfected. Both Western Blot analysis and 
immunofluorescence studies suggested that HEK cells express B°AT2 endogenously, 
which was confirmed by RT-PCR. It is well known that reverse-transcription may 
terminate prematurely (Kotewicz et ai, 1988; Lodish, 2000) and the whole cDNA might 
not be generated. For this reason, detection of the B°AT2 N-terminus via RT-PCR may 
not have been successful. 
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As an alternative, CHO cells were chosen to test the antibody because B°AT2 has not 
been reported to be expressed in ovaries. Immunofluorescence studies of this cell line 
proved the suitability of the antibody for immunofluorescence studies using mouse 
tissue with staining observed in the cytosol of the cells, but not on the cell surface. 
It has been reported that B°AT1 needs to form a heterodimer with collectrin in kidney 
or ACE2 in intestine to be trafficked into the cell membrane (Danilczyk and Penninger, 
2006; Malakauskas et al., 2007; Kowalczuk et al., 2008). Due to the similarity of B°AT1 
and B°AT2, co-expression of one of these auxiliary proteins might be required for 
surface expression in a transfection system. Thus, a further step in this investigation 
would be to co-transfect CHO cells with B°AT2 and either collectrin or ACE2. This 
experiment could establish if B°AT2 needs to form a heterodimer with one of the 
protein homologues to be trafficked into the cell membrane, although this was not 
observed to be a requirement in the oocyte expression system (Kowalczuk et al., 
2008). 
3.3.3 Characterisation of the ASCT2 antibody 
Two different ASCT2 antibody properties were tested in this thesis. Although the 
antibody received from the Avissar laboratory has been characterised recently (Avissar 
etal., 2001), this study indicated a different result. 
The molecular weight of ASCT2 has been analysed in various studies (Avissar et al., 
2001; Bungard and McGivan, 2004; Choudry et al., 2006; Lim et al., 2006; Avissar et al., 
2008). However, these studies have reported different molecular weights for ASCT2. 
(Avissar et al., 2001; Bungard and McGivan, 2004; Lim et al., 2006). 
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Avissar et al. characterised two custom-made polyclonal antibodies raised against 
either rabbit ASCT2 or human ASCT2 peptide. The antibody against rabbit-ASCT2 
detected one band between 57 and 65 kDa in ASCT2 cDNA transfected cervical cancer 
cells retrieved from Henrietta Lacks (HeLa) cells, but several bands of 78, 88 and 
94 kDa in rabbit renal tissue as well as a band between 80 and 90 kDa in different parts 
of the gastrointestinal tract of rabbits. 
The antibody against human ASCT2 detected a 57 to 63 kDa protein in transfected 
HeLa cells and two proteins at 57 and 94 kDa in human C2BBel cells, but also 
additional proteins at 88 and 130 kDa. The 57 and 94 kDa proteins were demonstrated 
to be the ASCT2 specific proteins. Different protein glycosylation states were assumed 
to be the reason for some of the variations. Alternatively, different splice variants were 
hypothesised as a possible explanation (Avissar et al., 2001). 
Bundard and McGivan characterised an ASCT2 antibody raised against an ASCT2 
peptide. A band of 58-60 kDa was detected in non-transfected COS cells, which 
increased with transfection (Bungard and McGivan, 2004). In 2006, Lim et al. used an 
amino terminal tail isoform-specific ASCT2 antibody to detect the protein. Multiple 
bands at 70, 85 and 120 kDa were detected in membranes prepared from rat brain, 
which the study explained as due to different glycosylation (Lim et al., 2006). In the 
same year, ASCT2 was detected as a 54 kDa band in BBMV derived from rat jejunum 
(Choudry et al., 2006). Recently, ASCT2 was detected with a molecular weight of 
81 kDa in CaCo and C2 cells (Avissar et al., 2008). 
In Western Blot analysis, the Avissar antibody detected mostly a protein of lower 
molecular weight as reported previously for ASCT2, while our antibody detected either 
a molecular weight that corresponds to the predicted ASCT2 molecular weight or sizes 
that are consistent with a dimer or trimer of ASCT2. In 2001, Tailor et al. reported 
truncated forms of ASCT2. They are thought to result from imprecise recognition of the 
first start codon. Therefore, the smaller protein could have been the result of 
translation initiation at a later methionine codon (Tailor et al., 2001). 
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The most likely explanation for the different size detected by the Avissar antibody 
could be the specific detection of one of those truncated ASCT2 proteins. It is also 
generally known, that the detection quality of antibodies declines with repeated freeze 
and thaw cycles, which could indicate another possibility for the different size 
detection. Furthermore, the differences in fluorescence intensity in with transfected 
cells indicated a higher quality of ASCT2 antibody designed in the Broer laboratory. 
Interestingly, with different fixation methods for transfected CHO cells, different 
results were generated. Paraformaldehyde is a cross-linking reagent, which forms 
intermolecular bridges normally through the free amino groups and therefore creates 
a system of linked antigens. Acetone on the other hand removes lipids and dehydrates 
the cell, thus it precipitates the proteins at the cellular level. Cross-linking reagents 
preserve the structure of the cells better than organic solvents, but also may reduce 
the antigenicity of some cell components since cell membrane membranes are still 
intact and therefore requires the addition of a permeabilisation step, which allows the 
antibody access to the target (Oliver, 2010). 
It appears likely that the same restriction of the fixative applies to tissue samples in the 
same way as to transfected cells. ASCT2 was found mainly within the cytosol in 
transfected cells and not in the plasma membrane similar to a previous study 
(Gegelashvili et al., 2006). In 2006, Gegelashvili et al. observed that ASCT2 trafficking is 
dependent on the pH value of the surrounding media. 
In 2005, Holmseth et al. investigated systematically the quality of antibodies generated 
against a peptide along the primary sequence of the membrane protein. In this report 
antibodies raised to synthetic peptides did not always recognise the native protein 
(Holmseth et al., 2005), hence detection with these antibod ies might not be accurate. 
Furthermore, it seemed the ability of a peptide antibody to recognise the parent 
protein is a property of the peptides and not of the immunisation protocol used. 
Additionally, the specificity of such an antibody is hard to predict because cross-
reactivity to unrelated proteins is frequently observed. 
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All these results will be considered in the discussion of the localisation of the neutral 
amino acid transporters in Chapter 6. The ASCT2 antibody used in this chapter was 
raised against a synthetic peptide. Hence the results should be observed with caution. 
For future experiments an ASCT2 antibody against a full length GST-fusion protein 
might be more suitable. 
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4.1 Introduction and aim of this study 
The substrate specificity of the three neutral amino acid transporters B°AT1, B°AT2 and 
ASCT2 has been investigated intensely in previous studies. B°AT1 was reported to 
transport all neutral amino acids with low affinity (Bohmer et al., 2005; Camargo et al., 
2005), while B AT2 was characterised to transport neutral, branched chain amino acids 
and methionine with high affinity (Takanaga et al., 2005; Broer et al., 2006). Both 
transporters operate with a Na+-dependent symporter mechanism. ASCT2, by contrast, 
is a Na+-independent antiporter. It has been identified as a transporter accepting 
neutral amino acids with high affinity except aromatic amino acids (Kekuda et al., 
1996; Kekuda et al., 1997; Avissar et al., 2001). Despite the individual 
characterisations, little is known about the different contribution to neutral amino acid 
transport in vivo. Nevertheless, controversial speculations have been made about 
which of these transporters is the main contributor to the uptake of neutral amino 
acids in the intestine and in the kidney (Kekuda et al., 1996; Avissar et al., 2001). To 
clarify the contribution of each transporter, uptake was determined using mouse 
kidney brush border membrane vesicles after confirming the substrate specificity of 
each transporter. 
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4.2 Results 
The preparation of and transport studies with brush border membrane vesicles 
(BBMV) in this chapter were optimised to generate reproducible results with the 
vesicles. The optimised protocol is shown in detail below: 
4.2.1 Preparation of brush border membrane vesicle from mouse kidney: 
o It is important for this procedure that every solution and material is pre-cooled on 
ice before use. Furthermore, it is essential to work quickly and consistently, 
o After killing the animal, both kidneys were taken out and placed into a pre-cooled 
glass dish with ice-cold buffer A. 
o The kidneys were cut into small pieces and added into a 2 mL Eppendorf test tube 
containing 0.8 mL of ice-cold buffer A. 
o The kidney pieces were homogenated with a Polytron mixer at the highest setting 
for 1 min. During the homogenisation the Eppendorf test tube was cooled on ice. 
o An aliquot (approximately 100 nL) was removed and kept on ice in an Eppendorf 
test tube for alkaline phosphatase and Bradford tests, 
o 1.12 mL of ddH20 was added to the lysate and mixed by inverting the Eppendorf 
test tube five times. 
o 22 |iL of a 1 M MgCI2 stock solution was added to the mix for a final concentration 
of 1 mM. The Eppendorf test tube containing the mixture was inverted five times, 
o The Eppendorf test tube was incubated on ice for 15 min with occasional mixing, 
o The solution was centrifuged at l,500g for 15 min at 4 °C in a table top centrifuge, 
o Afterwards, the supernatant was decanted into a new pre-cooled tube and was 
centrifuged again in a Sorvall RC5C Plus centrifuge at 30,000 g for 30 min at 4 °C. 
o The supernatant was discarded and the remaining pellet was resuspended in a small 
amount of (150 nL) buffer B using a 1 mL syringe with a 25 G needle, 
o After resuspension, a further 4 mL of buffer B was added to the mixture. 
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o The resuspended pellet was then transferred into a tight-fitting glas potter (15 mL 
total volume) and homogenised with 10 strokes on ice. If the vesicles needed to be 
preloaded for ASCT2 analysis, ATP at a final concentration of 4 mM buffered with 
4 mM MgCI2 and unlabelled glutamine or leucine at a final concentration of 10 mM 
was added before the homogenisation. 
o Subsequently, the resuspended pellet was transferred into a SS-34 centrifuge tube 
and 50 pL of a 1M MgCI2 stock solution (for a final concentration of 12 mM) was 
added to the homogenised solution into the potter, 
o The homogenate was incubated for 15 min on ice followed by centrifugation at 
1,500 g for 15 min at 4 °C in a Sorvall RC5C Plus centrifuge, 
o The supernatant was decanted into a new cooled tube and centrifuged at 30.000 g 
for 30 min at 4 °C. 
o The resulting supernatant was discarded and the pellet was resuspended in 150 pL 
buffer C using a 1 mL syringe with a 25 G needle, 
o The suspension was filled into a chilled glass potter, which already contained 4 mL 
of buffer C and the whole mixture was homogenised with 10 strokes. If the vesicles 
needed to be preloaded for ASCT2 analysis, ATP up to a final concentration of 4 mM 
buffered with 4 mM MgCI2 and unlabelled glutamine or leucine at a final 
concentration of 10 mM was added to the buffer before the homogenisation. For 
preloding with valinomycin K2S04 buffer was used for dilution, containing 
valinomycin (O.lmg/ml). 
o The homogenate was transferred into a new cold centrifuge tube and the vesicles 
were collected by centrifugation at 48,000 g for 30 min at 4 °C in a SS-34 rotor, 
o The supernatant was discarded and the resulting pellet was resuspended in the 
desired volume of buffer C (for two kidneys the end volume was no greater than 
120 pL) using a 1 mL syringe with a 25 G needle, 
o The vesicles were kept on ice for immediate use. 
Buffer A: 300 mM D-Mannitol 
5 mM EGTA 
12 mM Tris- HCI titrated with HCI to pH 7.1 
Buffer B: 150 mM D-Mannitol 
2.5 mM EGTA 
6 mM Tris-HCI titrated with HCI to pH 7.1 
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Buffer C: 280 mM D-Mannitol 
10 mM HEPES 
10 mM Tris- HCI titrated with HCI to pH 7.3 
4.2.2 Substrate specificity measured with the usage of Xenopus leavis expression 
4.2.2.1 Substrate specificity of B°AT1 
The B°AT1 substrate specificity has been extensively analysed in our laboratory in 
previous studies. Broer et al. used flux measurements to determine the substrate 
specificity of B°AT1 (Broer et al., 2004). The data from this study are reproduced here 
for confirmation (Figure 4.1). Additionally, Bohmer et al. used two electrode voltage-
clamp techniques in the Xenopus laevis oocyte expression system to measure the 
leucine induced current (Bohmer et al., 2005). 
Uptake of [14C]leucine was inhibited by all neutral amino acids. B°AT1 was strongly 
inhibited (>80%) by cysteine, methionine, alanine, isoleucine, valine, leucine, 
asparagine, serine, glutamine, phenylalanine and alanine. Medium inhibition (50 to 
80%) was observed with threonine, glycine, proline, histidine, tyrosine, tryptophan 
and the amino acid analogue 2-Aminobicyclo[2,2,l]heptane-2-carbocylic-acid (BCH). 
No significant inhibition was observed with addition of arginine, lysine, aspartate, 
glutamate and N-Methyl-a-aminoisobutyric acid (MeAiB) (Figure 4.1). 
Confirmation of B°AT1 substrate specificity was obtained by flux measurements. All 
neutral amino acids produce an inward current (Bohmer et al., 2005). 
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Figure 4.1: Substrate specificity of mouse B°AT1. 
Oocytes expressing mB°ATl cRNA were incubated for 4 days. [14C]leucine uptake (100 |iM) was 
determined in the presence or absence of 20 mM unlabelled amino acids or their analogues. 
Each bar represents the mean + standard deviation of 10 oocytes. Data are compiled from 
three different experiments. The transport activity of non-injected oocytes was subtracted in 
each case as a control. The three-letter code is used for amino acids: MeAiB, N-Methyl-a-
aminoisobutyric acid; BCH, 2-Aminobicyclo[2,2,l]heptane-2-carbocylic-acid. The B°AT1 
substrates have been highlighted in light blue, the uninhibited control is shown in magenta. 
(Figure adapted from (Broer eta!., 2004). 
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4.2.2.2 Substrate specificity of B°AT2 
The B°AT2 substrate specificity has also been extensively analysed in our laboratory in 
a previous study. Broer A. et al. (2006) used flux measurements and two electrode 
voltage-clamp recordings in B°AT2-expressing Xenopus laevis oocytes to characterise 
the substrate specificity. The data from this study are reproduced here for comparison 
(Figure 4.2). 
Uptake of [14C]proline was strongly (>90%) inhibited by methionine, leucine, 
isoleucine, valine, proline and the amino acid analogue aminoisobutyric acid (Aib). A 
partial (40 to 90%) inhibition was observed with phenylalanine, serine, threonine, 
glutamine, asparagine, histidine, hydroxyproline (HO-Pro) and the amino acid 
analogues BCH and nipicotic acid (Nip). No significant inhibition was determined with 
glycine, tyrosine, tryptophan, cysteine, arginine, lysine, aspartate or glutamate. 
Additionally, a number of amino acid related compounds such as MeAib, P-alanine, 
GABA and betaine (Bet) also did not inhibit the uptake of [14C]proline (Figure 4.2). 
Confirmation of B°AT2 substrate specificity was obtained by flux measurements. The 
amino acids proline, leucine, methionine and alanine produced an inward current as 
well as the amino acid analogue Aib. 
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Figure 4.2: Substrate specificity of mouse B°AT2. 
Oocytes expressing mB°AT2 cRNA were incubated for 4 to 6 days. [14C]proline uptake (50 nM) 
was determined in the presence or absence of 5 mM unlabelled amino acids or their 
analogues. Each bar represents the mean ± standard deviation of 10 oocytes. Data are 
compiled from three different experiments. The transport activity of non-injected oocytes was 
subtracted in each case as a control. The B°AT2 substrates have been highlighted in light blue, 
the uninhibited control is shown in magenta. 
(Figure adapted from Boer A. et al., 2006) 
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4.2.2.3 Substrate specificity of ASCT2 
The ASCT2 substrate specificity has previously been analysed by Utsunomiya-Tate et 
al., using transport studies in the Xenopus laevis oocyte expression system 
(competition and exchange experiments), but also by Kekuda et al. and Pollard et al., 
using competition experiments on transfected cells (Kekuda et al., 1996; Pollard et al., 
2002), obtaining different results. 
Utsunomiya-Tate et al. measured in inhibition experiments 10 nM [14C]alanine uptake 
was measured in the presence of 1 mM unlabelled amino acids or related compounds. 
Strong inhibition was observed for alanine, serine, threonine, cysteine, glutamine and 
asparagine, while weaker inhibition was detected for methionine, leucine, glycine and 
valine. All amino acids were transported in an L-stereospecific manner. The additional 
uptake experiment was consistent with the competition experiment. 
In contrast, the study by Kekuda et al. showed inhibition of alanine uptake with the 
amino acids alanine, serine, cysteine, threonine, methionine, leucine, valine, 
tryptophan, glutamine and asparagine (Kekuda et al., 1996). The study by Pollard 
showed inhibition of alanine uptake with the amino acids serine, glutamine and to a 
lesser extent leucine. Additionally, inhibition was observed with phenylalanine in 
neuroblastoma cells (NBL-1) cells but not in human cariocarcinoma (JAR) cells (Pollard 
et al., 2002). 
To validate these observed variations in ASCT2 transport for human ASCT2, human 
ASCT2 substrate specificity was analysed. Human ASCT2 was chosen since it was not 
been analysed previously, whereas the mouse ASCT2 is well characterised 
(Utsunomiya-Tate et al., 1996). Oocytes were injected with human ASCT2 cRNA and 
non-injected oocytes were used as controls. Four to six days after injection, groups of 
seven to ten oocytes were used to determine the substrate specificity of human (h) 
ASCT2 by challenging the uptake of 50 |iM [14C]glutamine with a 100 fold excess of 
unlabelled L-amino acids as described in Chapter 2. 
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[14C]glutamine uptake was strongly inhibited (>90%) by threonine, serine, glutamine, 
asparagine and valine. Weaker inhibition (70 to 85%) was observed with leucine, 
methionine, cysteine and glycine. The inhibition by these amino acids was highly 
significant (p<0.001). All other amino acids tested showed inhibition of less than 40 % 
(Figure 4.3) (p<0.01 to not significant). 
1 2 0 -
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Figure 4.3: Substrate specificity of human ASCT2. 
Oocytes expressing hASCT2 cRNA were incubated for 4 to 6 days. [14C]glutamine uptake 
(50 nM) was determined in the presence or absence of 5 mM unlabelled amino acids. Each bar 
represents the mean ± standard deviation of seven to ten oocytes. * indicates the statistical 
significance with *** (p<0.001) and ** (p<0.01). Data are compiled from three different 
experiments. The ASCT2 substrates have been highlighted in light blue, the control is shown in 
magenta. 
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Amino acids competing with the uptake of [14C]glutamine, may or may not be 
substrates of the transporter as mentioned above. As a result exchange experiments 
were conducted with [14C]glutamine preloaded oocytes to demonstrate translocation 
via ASCT2. Oocytes were injected with hASCT2 cRNA and incubated for four to five 
days. 
Batches of seven to ten oocytes were washed twice with ND96 buffer and 
subsequently pre-incubated for 10 min in 90 pL ND96 containing 50 pM [14C] 
glutamine. The preloading reaction was stopped with three washes with ice-cold 
ND96. After the washing step the buffer was removed and 1 mL of ND96 containing 1 
mM unlabelled amino acid was added to the oocytes. 150 pL samples were taken from 
the supernatant at 5, 10, 20 and 30 min. After the last time point the efflux was 
stopped by washing the oocytes three times with ice-cold ND96 buffer. Oocytes that 
were pre- incubated with [14C]glutamine and subsequently incubated in substrate-free 
ND96 buffer were used as a control. 
High glutamine efflux (60 to 90 % of the preloaded [14C]glutamine) was observed with 
nearly all neutral, non-aromatic amino acids, namely alanine, asparagine, cysteine, 
glutamine, glycine, leucine, methionine, serine, threonine and valine. The efflux of 
these was highly significant (p<0.001) in comparison to the control. The only exception 
was isoleucine (p>0.05). Only very weak efflux (0 to 15 % of the preloaded radioactive 
glutamine) was detected with all other tested amino acids, including the ND96 control 
(Figure 4.4). No significance could be shown (p>0.05). 
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Figure 4.4: Substrate specificity of human ASCT2 determined by exchange activity. 
Oocytes expressing hASCT2 cRNA were incubated for four to five days. The oocytes were 
preloaded for 10 min with [14C]glutamine (50 pM) and subsequently efflux of the radioactively 
labelled glutamine was determined in the presence or absence of 1 mM unlabelled amino 
acids over 30 min. Each bar represents the mean transport activity of seven to ten oocytes. 
*** indicates the statistical significance at p<0.001. The experiment represents one of four 
repeated experiment with different batches of oocytes. The ASCT2 substrates have been 
highlighted in light blue. The control efflux in ND96 buffer is depicted in magenta. 
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4.2.3 Analysis of the amino acid transport contribution in brush border 
membrane vesicles 
After determining the substrate specificity of the amino acid transporters B°AT1, B°AT2 
and ASCT2, their contribution to neutral amino acid transport in the kidney was 
determined using BBMV. The vesicles were first analysed using Western Blot analysis 
for enrichment of the three amino acid transporters B°AT1, B°AT2 and ASCT2 from 
homogenate to BBMV. The vesicles were also tested for 4F2, a marker protein of the 
basolateral membrane. Kidney homogenate and BBMV samples were prepared and 
separated by SDS-PAGE. After transfer onto a nitrocellulose membrane, the proteins 
were observed by immunodetection. 
The basolateral membrane protein 4F2 has been reported to have a molecular mass of 
80 kDa (Nakamura et al., 1999). Here, the 4F2 protein was detected as a 78 kDa band 
protein in kidney homogenate and in BBMV (Figure 4.5). Thus, the vesicles seem to 
have a significant basolateral membrane contamination. The protocol was later 
optimised and the amount of basolateral contamination was still present but varied 
(data not shown). 
B°AT1 was observed as a 63 kDa protein in the homogenate and was also enriched in 
the BBMV. B°AT2 was detected as an 82 kDa protein in both the homogenate and the 
BBMV. However, no enrichment was discovered from homogenate to vesicle. The 
ASCT2 antisera detected a protein band at 47 kDa in homogenate and a 53 kDa protein 
in BBMV. Longer exposure time revealed a faint detection of the 53 kDa band in the 
homogenate as well (data not shown). The 53 kDa protein was enriched in BBMV in 
comparison to the homogenate. 
Chapter 4 - Contribution to epithelial amino acid transport by the transporters 
B°AT1, B°AT2 and ASCT2 
H V H V H V H V 
98 kDa — 
62 kDa 
49 kDa 
• • 
1 1 
4F2 
1 1 1 1 1 1 
Bl B2 A 
Figure 4.5 Detection of 4F2, B°AT1, B°AT2 and ASCT2 in kidney homogenate and 
brush border membrane vesicles. 
Kidney homogenate, denoted as H and BBMV samples, denoted as V, were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was either incubated 
with rabbit-anti B°AT1 (Bl), rabbit-anti B°AT2 (B2), rabbit-anti ASCT2 (A) or 4F2 antibody. The 
characterisation of the antibodies is described in Chapter 3. The BBMV preparation had a 10-
fold AP enrichment. The bands were visualised using a chemiluminescent western detection 
kit. 
4.3 Uptake experiments with brush border membrane vesicles 
The Western Blot analysis showed that all three proteins are expressed in kidney. To 
investigate whether the proteins are functionally active, uptake of [3H]labelled amino 
acid substrates was determined in the absence or presence of unlabelled amino acids. 
For these experiments only BBMV that showed more than a twelve fold enrichment of 
the brush border membrane marker enzyme alkaline phosphatase were used. Since all 
three transporters are Na+-dependent, the experiments were conducted in 
Na+-based buffer, while K+-based buffer was used as control and reference. 
As shown above, leucine is a major substrate for the transporters B°AT1 and B°AT2 and 
was therefore chosen for BBMV uptake. The time point for amino acid transport 
(15 sec) was chosen after evaluation of a preliminary time course (data not shown) and 
is similar to time points chosen in previous studies (Ganapathy and Leibach, 1982; 
Chesney et a!., 1986). An equilibrium time point was taken after 4 to 10 min. 
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To start the uptake experiment, 20 pL of vesicle solution was added into 80 pL uptake 
buffer (Na+- or K+-based) containing 100 pM [3H]leucine. After 15 sec, a sample was 
taken and the reaction was stopped by diluting the sample into 4 mL ice-cold stop 
buffer. The solution was immediately filtered through a pre-wetted nitrocellulose filter 
and washed with additional stop buffer. An equilibrium time point was taken after 4 to 
10 min. The radioactivity on the filter was counted using a Beckman LS 6500 
scintillation counter. 
Uptake in Na+-based buffer showed a higly significant 6.5 fold increase of leucine 
uptake (p<0.001) in comparison to the K+-based buffer (Figure 4.6). The transport at 15 
sec was 0.65 ± O.lpmol/mg protein in Na+-based buffer in contrast to 0.09 ± 0.001 
pmol/mg protein in the absence of Na+. After 10 min, a transport activity of 0.21 ± 0.01 
pmol/mg protein was observed in Na+-based buffer and of 0.33 ± 0.02 pmol/mg 
protein in K+-based buffer. 
15 sec 10 min 
Figure 4.6: [sH]leucine transport into mouse renal brush border membrane vesicles 
in Na+-based and K*-based buffer. 
Renal BBMV were incubated with [3H]leucine (10 pM) over a period of 10 min in Na+-based 
buffer (blue bars) and K+-based media (black bars). Each bar represents the average of 
duplicate measurements ± standard deviation, *** indicates statistical significance at p<0.001. 
Similar results were obtained in six different experiments. A 6.5 fold increase of [3H]leucine 
uptake was observed with Na+-based buffer in comparison to K+-based buffer. 
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This transport is most likely to be facilitated only by the B°AT1 or B°AT2 transporters, 
because ASCT2 would require substrate inside the vesicles for its antiport mechanism. 
To detect ASCT2 activity, it was essential to preload the BBMV with an amino acid 
substrate. Furthermore, Oppedisano et al. reported an increase of the Vmax of the 
transporter, decreasing the Km of the transporter for external Na+, in the presence of 
intra-vesicular ATP. For this reason, the BBMV were preloaded with ATP (4 mM) as 
well, which was complexed with MgCl2(4 mM). 
First, the preloading process had to be validated. To this end the vesicles were 
preloaded with KCI. Preloading with K+ can be verified by using the K+-ionophore 
valinomycin. When vesicles are preloaded with K+, the addition of valinomycin will 
render the membrane selectively permeable to K+. Dilution of the vesicles into K+-free 
buffer will generate a K+-gradient, which in turn will generate a potassium diffusion 
potential. This method has frequently been used to identify rheogenic transport 
processes (Ganapathy and Leibach, 1982). Since the BBMV contain rheogenic I n -
dependent B°AT1 transporters, a potassium diffusion potential (inside negative) will 
enhance uptake of amino acids via this transporter. 
Therefore, BBMV were preloaded with buffer containing potassium (K2S04) and 
valinomycin (0.1 mg/ml) and subsequently [3H]leucine uptake was analysed. Non-
preloaded vesicles were used as a control. 
The non-preloaded, renal BBMV showed a higly significant, close to 4 fold increase of 
leucine uptake (p<0.001) in comparison to the control in the absence of Na+ (Figure 
4.7). The transport at 15 sec was0.95 ± 0.003 pmol/mg protein in Na+-buffer in 
contrast to 0.25 ± 0.002 pmol/mg protein in the absence from Na+ (K+-buffer). The 
valinomycin preloaded vesicle showed a higly significant 12 fold increase of leucine 
uptake (p<0.001) with a transport of 2.31 ± 0.1 pmol/mg protein in Na+-based buffer in 
contrast to 0.19 ± 0.01 pmol/mg protein in K+-based buffer. 
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Figure 4.7: Effect on [3H]leucine transport in mouse renal brush border membrane 
vesicles preloaded or not preloaded with valinomycin in Na+-based and K+-based 
buffer. 
Non-preloaded renal BBMV were diluted into Na+-based buffer, denoted as 1, or K+-based 
buffer, denoted as 2, and [3H]leucine (100 |iM) was measured over a period of 0.25 min. 
Similarly, renal BBMV preloaded with K2S04 and treated with valinomycin (0.1 mg/ml) were 
diluted into Na+-based buffer, denoted as 3, or K+-based buffer, denoted as 4. Each bar 
represents the average of duplicates ± standard deviation; *** indicates statistical significance 
at p<0.001). A 3.8 fold increase of [3H]leucine uptake was observed with Na+ buffer in 
comparison to K+-based buffer for non-preloaded vesicles and a 12 fold increase was observed 
for preloaded BBMV. 
This result confirmed that the procedure was suitable for preloading of the vesicles. In 
addition, it should be noted that the vesicles contain B°AT1 transporters, which allow 
preloading with neutral amino acids. Preloading of vesicles with a substrate of ASCT2 
would then allow determination of whether an ASCT2-like antiport activity is present 
in renal BBMV. It was expected that uptake into preloaded BBMV would reveal an 
additional activity not observed in non-preloaded vesicles. 
To test for ASCT2 activity, renal BBMV preloaded with glutamine (30 mM) and ATP (4 
mM) were added to uptake buffer containing 100 pM [3H]leucine. As described above, 
non-preloaded vesicles were used as controls. A sample was taken after 15 sec and 
processed as described previously. Likewise, an equilibrium time point sample (data 
not shown) was processed. 
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The renal BBMV showed a significant 2.2 fold increase of leucine uptake in Na+-based 
buffer (p<0.01) in comparison to their counterparts in K+-based buffer. The preloaded 
BBMV, if anything, showed a smaller (1.8 fold) stimulation of leucine uptake in 
comparison to preloaded BBMV in K+-based buffer (Figure 4.8). The transport at 15 sec 
was 0.72 ± 0.05 pmol/mg protein in Na+-based buffer in contrast to 0.32 ± 0.03 
pmol/mg protein in the absence of Na+for non-preloaded BBMV. For preloaded BBMV, 
a leucine transport of 0.57 ± 0.001 pmol/mg protein in Na+-based buffer in contrast to 
0.31 ± 0.07 pmol/mg protein in K+-based buffer was detected. Thus no additional 
transport activity was detected in vesicles preloaded with ATP and glutamine. 
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Figure 4.8: [3H]leucine transport (15 sec time point) into mouse renal brush border 
membrane vesicles (preloaded with 30 mM glutamine and 4 mM ATP or non-
preloaded) in Na+-based and K+-based buffer. 
Non-preloaded renal BBMV were incubated with [3H]leucine (100 |iM) over a period of 15 sec 
in Na+-based buffer), denoted as 1 or K+-based buffer (2). Alternatively, renal BBMV were 
preloaded with 30 mM glutamine and [3H]leucine uptake was determined in the same way in 
Na+-based buffer(3), or K+-based buffer(4). Each bar represents the average of duplicates ± 
standard deviation, ** indicates statistical significance at p<0.01. Similar results were obtained 
in five different experiments. A 2.2 fold increase of [3H]leucine uptake was observed with Na+-
based buffer in comparison to K+-based buffer in non-preloaded vesicles. In preloaded BBMV a 
1.8 fold increase was observed for leucine uptake between the two buffers. 
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Since no additional leucine transport was observed in preloaded BBMV, it appears 
unlikely that ASCT2 contributes to leucine transport in mouse kidney. However as 
mentioned above, leucine is not a major substrate for ASCT2. Therefore the 
experiments were also conducted with glutamine, the major substrate of ASCT2, to 
fully confirm the lack of ASCT2 activity for neutral amino acid transport in mouse 
kidney. 
Preloaded BBMV (glutamine (30 mM) and ATP (4 mM) complexed with 4 mM MgCl2) 
were added to uptake buffer containing 100 |iM [3H]glutamine. As described above, 
non-preloaded vesicles were used as control. A sample was taken after 15 sec and 
processed as described previously. Likewise, an equilibrium time point sample (data 
not shown) was processed. 
The non-preloaded BBMV showed a 3 fold increase of glutamine uptake in comparison 
to their counterparts in K+-based buffer (p<0.001). In contrast the preloaded BBMV 
showed only a 2 fold increase of glutamine uptake in comparison to BBMV in K+-based 
buffer (Figure 4.9) (p<0.01). The transport at 15 sec was 1.34 ± 0.07 pmol/mg protein 
in Na+-based buffer in contrast to 0.41 ± 0.02 pmol/mg protein in K+-based buffer. For 
preloaded BBMV a glutamine transport of 0.87 ± 0.02 pmol/mg protein was observed 
in Na+-based buffer, in contrast to 0.38 ± 0.03 pmol/mg protein in K+-based buffer. 
Thus, no additional glutamine transport was observed in glutamine-preloaded BBMV in 
comparison to non-preloaded vesicles. 
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Figure 4.9: [3H]glutamine transport (15 sec time point) into mouse renal brush border 
membrane vesicles (preloaded with 30 mM glutamine and 4 mM ATP or non-
preloaded) in Na+-based and K+-based buffer. 
Non-preloaded BBMV were incubated with [3H]glutamine (100 nM) over a period of 15 sec in 
Na+-based buffer (1) or K+-based buffer (2). Glutamine uptake in BBMV preloaded with 30 mM 
glutamine was measured in the same way in Na+-based buffer (3) or K+-based buffer (4). Each 
bar represents the average of duplicates ± standard deviation. Statistical significance is 
indicated as *** (p<0.001) and ** (p<0.01). Similar results were obtained in five separate 
experiments. A 3 fold increase of [3H]glutamine uptake was observed in Na+-based buffer in 
comparison to K+-based buffer for non-preloaded vesicles and a 2 fold increase was observed 
for preloaded BBMV. 
The results of the previous experiments suggested that ASCT2 did not contribute to 
neutral amino acid transport in mouse kidney. In the following experiments, the 
relative contributions of B°AT1 and B°AT2 were investigated. In uptake experiments 
with [3H]leucine, different non-labelled amino acid substrates were used to compete 
for leucine transport. Due to the overlapping substrate specificity of B°AT1 and B°AT2, 
substrates that discriminate between the two had to be chosen carefully. Leucine, 
glutamine and phenylalanine were chosen as substrates for both transporters. Glycine 
is only transported by B°AT1, and not by B°AT2 and hence was chosen as the substrate 
for B°AT1 only, and proline is a better substrate for the B°AT2 than for the B°AT1 
transporter as indicated in inhibition experiments (90% inhibition with B°AT2, Figure 
4.2 while B°AT1 only showed 60% inhbition). 
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Renal BBMV (not preloaded) were used to examine the contribution of B°AT1 and 
B°AT2 transport by challenging the uptake of 100 pM [3H]leucine with 30 mM of 
different unlabelled amino acids. The BBMV in Na+-based buffer showed a 3.5 fold 
increase of leucine transport (p<0.001) in comparison to the potassium control. 
[3H]leucine uptake was strongly inhibited (> 91%) by leucine itself, phenylalanine and 
glycine (p<0.001). Weaker inhibition (79%) was observed with glutamine (p<0.01). 
Proline inhibited 55% of leucine uptake (Figure 4.10) (p>0.5). The strong inhibition of 
leucine transport by glycine, suggests that a B°AT1-Iike transport activity is dominant in 
renal BBMV. Since proline inhibited leucine uptake is only partially, there could be 
another transporter involved in this uptake, for instance XT2. 
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Figure 4.10: [3H]leucine transport into mouse renal brush border membrane vesicles 
in the presence and absence of unlabelled amino acids in Na+-based and K+-based 
buffer. 
BBMV were incubated with [3H]leucine (100 |iM) in the absence or presence of 30 mM 
unlabelled amino acids for 15 sec. [3H]leucine uptake in Na+-based buffer, denoted as Leu Na 
and in K+-based buffer, denoted as Leu K were used as a control. [3H]leucine uptake was then 
challenged by an excess of leucine (Leu), gutamine (Gin), proline (Pro), phenylalanine (Phe) and 
glycine (Gly) in Na+-based buffer. Each bar represents the average of duplicates ± standard 
deviation. Statistical significance is indicated as *** (p<0.001) and ** (p<0.01). Similar results 
were obtained in five different experiments. 
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4.4 Discussion 
4.4.1 Substrate specificity 
As a first step, the substrate specificity of B°AT1, B°AT2 and ASCT2 was analysed to 
provide guidance for the selection of substrates used for competition experiments in 
BBMV. Since B°AT1 and B°AT2 have been characterised previously in our laboratory 
(Bohmer et al., 2005; Broer et al., 2006), these experiments were not repeated. 
As mentioned above, ASCT2 substrate specificity was analysed by Utsunomiya-Tate et 
al. using competition and exchange experiments (Utsunomiya-Tate et al., 1996). These 
results were confirmed, the results obtained in this thesis being consistent with 
Utsunomiya-Tate et al. cited above. This suggested that ASCT2 prefers neutral amino 
acids without bulky or branched side chains. 
However, substrate specificity of ASCT2 was also analysed using competition 
experiments by Kekuda et al. and Pollard et al. (Kekuda et al., 1996; Pollard et al., 
2002). The basic principle for competition experiments is to use an additional substrate 
to a normal labelled susbstrate. This additional substrate reacts as a competitive 
inhibitor since both substrates compete for binding and transport. In most cases the 
competing inhibitor is also a substrate of the transporter. However, it is know that in 
some cases the competitive inhibitor may not be a substrate of the transporter and 
hence may not be transported (Van Winkle, 1999). An example for this situation was 
observed by Thomas and Christensen where cationic amino acids are a competitive 
inhibitor of amino acid transport by system ASC but they are not transported by it 
(Thomas and Christensen, 1970). Another example was observe by van Winkle et al. 
where D-tryptophan competitively inhibits L-tryptophan transport by system T but D-
tryptophan does not appear to be a susbtrate for system T (Van Winkle et al., 1990). In 
the case of ASCT2 alanine transport was inhibited in the presence of phenylalanine in 
transfected HeLa cells (Kekuda et al., 1996), indicating that phenylalanine is a 
preferred substrate of ASCT2. Pollard et al. showed that ASCT2 transport is inhibited 
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by phenylalanine transfected NBL-1 cells. In contrast, the inhibition of alanine 
transport with phenylalanine in JAR cells was not observed (Pollard et al., 2002). As 
experienced here, inhibition and active uptake do not always correlate. 
Therefore, to characterise a transporter both parts inhibition and active uptake should 
be measured in order to exclude discrepancies. In the case of ASCT2, the inhibition 
with phenylalanine obtained by Kekuda et al. caused the assumption that the 
transporter also transports aromatic amino acids and therefore could be the main B° 
activity in kidney and in the intestine (Avissar et al., 2001; Sundaram et al., 2007). 
Almost all B°AT2 substrates are also substrates of B°AT1, and therefore it is difficult to 
find substrates for distinct competition experiments. To see the total activity of both 
transporters, leucine was chosen as a substrate which is accepted by both 
transporters. Phenylalanine and glutamine were chosen as competitors because they 
inhibit both transporters (Bohmer et al., 2005; Broer et al., 2006). 
Glycine was chosen since it inhibits only B°AT1, while proline is a better inhibitor for 
B°AT2 than for B°AT1 (Broer et al., 2006). Therefore, the key substrate to distinguish 
between B°AT1 and B°AT2 transport activity is glycine. If glycine inhibits the amino acid 
uptake, B°AT1 is the active transporter and if glycine does not inhibit the amino acid 
uptake, B°AT2 is the active transporter. 
Since glutamine seems to be the preferred ASCT2 substrate over leucine, it was chosen 
to analyse ASCT2 transport activity. Additionally, the antiport mechanism of ASCT2 has 
to be considered when undertaking uptake experiments, meaning that BBMV have to 
contain amino acids in order to show transport activity. To discriminate between 
B°AT1, B°AT2 and ASCT2, glutamine uptake with non-preloaded vesicles has to be 
conducted as reference. If additional glutamine transport occurs with amino acid 
preloaded vesicles, ASCT2 is responsible for this additional transport. 
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4.4.2 Western Blot analysis of brush border membrane vesicles 
The Western Blot analysis showed that all three transporters were present in renal 
BBMV. Romeo et al. showed that B°AT1, having a calculated relative molecular weight 
of 71 kDa, runs at about 60 kDa, probably due to the hydrophobic nature of transport 
proteins (Romeo et al., 2006). The B°ATl-specific band detected in Figure 4.5 is thus 
consistent with the literature. 
B°AT2 has a calculated relative molecular weight of 82 kDa. Due to different 
glycosylation states it was observed to run between 85 to 96 kDa (Takanaga et al., 
2005). Thus, the protein detected as B°AT2 in BBMV had the same weight as described 
in this previous study. Interestingly, B°AT2 was not enriched in the BBMV suggesting 
that B°AT2 is not located in the apical membrane. The lack of B°AT2 enrichment in 
BBMV is at variance with the results obtained with immunofluorescence in Chapter 3, 
where B°AT2 was detected in the apical membrane of the renal S2 and S3 segment. 
The principle of BBMV preparation is an enrichment of the apical membrane (Biber et 
al., 2007). Therefore, if the transporter is located in the apical membrane of the 
tubulus, it would be enriched in BBMV, even when it is not very abundant in the 
kidney, as observed with B°AT2 in Chapter 3. 
To further address this problem, in situ biotinylation could be used to biotinylate the 
extracellular surfaces of renal cells and examine apically targeted transporters after 
membrane solubilisation. To this end, kidneys are perfused in situ with biotinylation 
solution containing sulfosuccinimidobiotin (sulfo-NHS-biotin), a cell-impermeant biotin 
derivative that attaches covalently to free amino acid groups on lysines. After 
solubilisation and fractionation of the membranes, labelled proteins can be isolated 
using streptavidin beads and analysed using immunoblotting (Frindt et al., 2008; Frindt 
and Palmer, 2009). This experimental method could help to determine if B°AT2 is 
located in the apical membrane. 
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The different reported molecular weights of ASCT2 have been discussed before in 
Chapter 3. ASCT2 has a predicted theoretical relative molecular weight of 57 kDa. A 
band consistent with these findings was enriched in BBMV as depicted Figure 4.5 and 
therefore is likely to be ASCT2. Surprisingly, the 60 kDa band was not detected in 
kidney homogenate, where instead a 49 kDa protein was detected. This band has the 
same size as the protein detected with the antibody received from the Avissar 
laboratory. As discussed previously, truncated forms of ASCT2 have been reported 
(Tailor et al., 2001), resulting from imprecise recognition of the first start codon. The 
lack of enrichment of this protein in BBMV suggests that it is not trafficked to the 
apical membrane. Another alternative would be that the homogenate was partially 
degraded and hence ASCT2 was detected at a different molecular weight. The first 
option appears more likely since the homogenate was used as a starting material to 
prepare the BBMV, which contained the higher molecular weight band. 
The 4F2 heavy-chain of heterodimeric amino acid transporters forms a protein with a 
relative molecular weight of 80 kDa (Nakamura et al., 1999). It is established a marker 
protein for the basolateral membrane. The presence of 4F2 in renal BBMV suggests a 
significant cross-contamination with basolateral membrane. This contamination has 
been reported before (Murer, 1984; Chung et al., 1999; Lim et al., 2005) and is difficult 
to avoid due to the procedure how BBMV are obtained. As mentioned above, the 
procedure makes use of the different composition of apical and basolateral 
membranes (Murer, 1984). The Mg2+-precipitation plays an important role in the 
procedure. 
The positive charge of the Mg2+ neutralises the negative charge of the membrane, 
allowing formation of cell membrane aggregates. However, the apical membrane is 
highly glycosylated (Lodish, 2000) and therefore would not form aggregations because 
the membranes cannot come into contact. Apical membranes can therefore be 
separated from basolateral and intra-cellular membranes and cell debris. 
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However, several components in the basolateral membrane also possess 
glycosylations, for instance 4F2 (Pineda et al., 1999). Sometimes these glycosylations 
are sufficient enough to prevent aggregations with the rest of the basolateral 
membrane, resulting in the cross-contamination. Additionally, during the 
homogenisation process cells are disrupted at different parts of the membrane. 
Especially in the location around the tight junctions, which divides apical and 
basolateral compartments, contamination of the apical membrane by small pieces of 
basolateral membrane can occur. 
4.4.3 Transport studies in BBMV 
Under optimal conditions, [3H]leucine uptake in BBMV showed a 6.5 fold higher uptake 
in Na+-based buffer than in K+-based buffer, indicating the presence of Na+-dependent 
transport in those vesicles. It is not possible to determine just from this [3H]leucine 
uptake experiment which of the two SLC6 family members is responsible for the 
transport since they display similar transport characteristics (Broer et al., 2006). 
[3H]leucine uptake in valinomycin-treated vesicles showed that the Na+-dependent 
transporter was also electrogenic. It further showed that the preloading procedure 
was useful for the analysis of ASCT2 activity. Valinomycin has been used extensively in 
previous studies to determine electrogenicity of transporters (Ghishan and Wilson, 
1985; Sugawara et al., 1992; Endo et al., 1998). Since valinomycin is an ionophore 
selective to K+ only, the vesicles could be successfully preloaded with K+, resulting in an 
increase of [3H]leucine uptake with K+-preloaded vesicles. 
Glutamine-preloaded vesicles were generated to examine ASCT2 contribution since 
the transporter requires amino acid on the inside of the vesicles for its obligatory 
antiport mechanism (Broer et al., 2000). Since ASCT2 activity would be an additional 
transport activity on top of the symport activity of B°AT1 and B°AT2, an increase of 
leucine transport would be expected. However, [3H]leucine transport in amino-acid 
free vesicles is higher (2.2 fold in comparison to uptake in K+-based buffer) than in the 
preloaded vesicles (1.8 fold increase in comparison to uptake in K+-based buffer). 
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The system L amino acid transporter LAT2/4F2 is located in the basolateral membrane 
and has an obligatory antiport mechanism as well. It transports a wide variety of 
neutral amino acids including leucine and glutamine in an ion-independent manner 
(Rossier et al., 1999; Wagner et al., 2000; Babu et al., 2003; Bodoy et al., 2005). If 
LAT2/4F2 had been present in the BBMV due to the cross-contaminations, leucine 
uptake would increase in glutamine-preloaded vesicles. 
Glutamine is the preferred substrate for ASCT2. The [3H]glutamine uptake was 
therefore analysed to further test for the presence of ASCT2. The same conditions 
were chosen as in [3H]leucine uptake. [3H]glutamine transport in amino acid-free 
vesicles was higher (3 fold in comparison to uptake in K+-based buffer) than in the 
glutamine-preloaded vesicles (2 fold increase in comparison to uptake in K+-based 
buffer), providing additional evidence for the lack of ASCT2 transport activity in kidney. 
Similar to the experiments performed in the oocyte expression system, BBMV can be 
used to determine radioactive amino acid transport in the presence of unlabelled 
amino acids. The 3 fold increase of [3H]leucine uptake under normal conditions 
showed that the vesicles were suitable for the experiment. The experiment showed 
that maximal inhibition of [3H]leucine by unlabelled leucine amounted to 91 %, which 
is similar to previous studies of B°AT1 and B°AT2 transport activity in heterologous 
expression systems (Broer et al., 2006). 
Given that phenylalanine strongly inhibits both transporters, the 91% inhibition by 
phenylalanine further validates the presence of B°-like amino acid transporters. 
Glutamine, is a weak inhibitor of B°AT2, but a good substrate of B°AT1, and inhibited 
the transport less strongly than leucine and phenylalanine (79 % inhibition). 
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Proline is a substrate for both transporters but shows a preference for B°AT2 (Broer et 
al., 2006). The partial inhibition (55%) therefore suggests that B°AT1 prevails over 
B°AT2 activity. Glycine is a substrate for B°AT1 only. Thus, the inhibition of [3H]leucine 
uptake by 91% in the presence of glycine, provides strong evidence for leucine 
transport being predominantly mediated by B°AT1. To fully confirm this analysis, the 
B ATI-deficient mouse was generated and its properties are analysed in Chapter 5. 
Over the past decades, the mechanism of renal transport has been extensively studied 
by the use of BBMV (reviewed in (Murer and Gmaj, 1986). Those studies usually have 
been performed with membrane vesicles from whole cortex. However, some studies 
also have been performed with separated BBMV from the proximal convoluted part 
(pars convoluta) and the proximal straight part (pars recta) of proximal tubule (Kragh-
Hansen etal., 1984; Jorgensen etal., 1990; Jessen and Sheikh, 1992). 
For those studies, renal tissue has been examined using microscopes and the two parts 
of the tubule were separated by their anatomical localisation. Subsequently, tissue 
sections of the two parts of the proximal tubule were obtained and further processed 
to BBMV (Kragh-Hansen et al., 1984). Transport studies with these BBMV showed the 
presence of different amino acid transport systems in the different part of the 
proximal tubulus consistent with the reported axial distribution of different amino acid 
transporters in the kidney (Scriver and Tenenhouse, 1985). 
The BBMV studies in this thesis were conducted with vesicle of whole kidney cortex 
and therefore are a mixture of BBMV obtained from pars convoluta and pars recta. It 
would be interesting to investigate whether all neutral amino acid transport takes 
place via B°AT1 in the early segments of the proximal tubule (as suggested in this 
chapter) or if some other activity is still observed in the S3 segment, where B°AT1 is 
not located. 
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5.1 Introduction and aim of the study 
To investigate the contribution to neutral amino acid of the amino acid transporters 
B°AT1, B°AT2 and ASCT2 further, a B°ATl-deficient mouse was employed and studied. 
The B°ATl-deficient mouse was established by the biotech company Deltagen. To 
achieve this gene targeting in mouse embryonic stem cells was used. The method is 
based on the fact that homologous DNA sequences can align with genomic DNA and 
undergo recombination in low frequencies. Thus, directed mutation at any locus in the 
mouse genome can be generated (Torres, 1997). A cassette containing the E. coli 
P-galactosidase (LacZ) and a neomycin resistance gene (Neo) as selective markers, was 
inserted in to exon 3, resulting in a 28 bp deletion of the SLC6A19 gene in exon 3. Thus, 
no functional B°AT1 protein can be translated. The principle is depicted in 
Figure 5.1. Subsequent PCR analysis and Southern Blot detection undertaken by 
Deltagen confirmed the deletion of the B°AT1 gene (data not shown). 
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Figure 5.1: Principle of B°ATl-deficient mouse generation. 
The B°AT1 gene is depicted with its coding sequences (red) and untranslated regions in blue. 
Boxes mark exons of the gene. A LacZ/Neo cassette was inserted into exon 3, disrupting the 
B°AT1 gene and deleting 28 bp of the exon 3 sequence. Note, the Figure is not drawn to scale. 
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The phenotype of the B°ATl-deficient mice showed a significant difference in size 
compared to wild type (wt) mice (Figure 5.2). An adult B°ATl-deficient mouse was 
smaller in size than the wt sibling. Weight measurements and urine amino acid analysis 
were not available at the time this thesis was written.. 
Figure 5.2: Phenotype of wild type C57/BI6 and B°ATl-deficient mouse. 
The smaller size of the B°ATl-deficient mouse (B) in comparison to the wt mouse (A) is shown 
by the measuring tape (Figure kindly provided by Angelika Broer) 
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The aim of this chapter was to study amino acid transport in the B°ATl-deficient 
mouse. Firstly, the lack of the B°AT1 protein was confirmed by immunofluorescence 
studies. Paraffin embedded kidney and intestinal sections of B°ATl-deficient mice 
were stained in parallel with sections of wt mice. Secondly, vesicle experiments were 
conducted with vesicles derived from B°ATI-deficient mice kidneys. These experiments 
were undertaken in order to investigate changes in neutral amino acid transport and 
possible compensations for the lack of B°AT1. 
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5.2 Results 
5.2.1 Determination of B°AT1 localisation in mouse kidney and intestine 
B°ATl-deficient mouse kidney and intestine were investigated using 
immunofluorescence microscopy to confirm whether B°AT1 was lacking or not. The 
mouse kidney and intestine specimens were pre-fixed with 10 % NBF, then embedded 
in paraffin, sectioned and de-paraffined. Boiling sodium citrate buffer (1 mM) at pH 6 
was subsequently applied to retrieve the cross-linked antigenic sites formed during the 
fixation. Subsequently, the slides were incubated with rabbit anti-mB°ATl antibody, 
which was detected by donkey anti-rabbit secondary antibody conjugated to AF 488. 
The kidney proximal tubules were identified, as described in Chapter 3 by co-staining 
with biotinylated LTL, which was detected by Steptavidin-Texas Red. No marker was 
used in intestinal staining. 
Immunofluorescence staining of the B°ATl-deficient mouse kidney sections detected 
no signal for B ATI (Figure 5.3 A). Positive controls consisted of wt mouse kidney 
sections stained in parallel with the B ATI-deficient mouse kidney slides. The positive 
control showed B°AT1 staining in the SI and S2 segments of the mouse kidney 
(Figure 5.3 B), as described in Chapter 3. A negative control consisting of stained wt 
mouse sections with the secondary antibody only demonstrated no distinct staining 
(Figure 5.3 C). 
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Figure 5.3: Localisation of B°AT1 in B°ATl-deficient and wt C57BI/6 mouse kidney. 
Slides were stained using a rabbit primary B°AT1 antibody detected by a donkey-anti rabbit 
secondary antibody conjugated to AF 488 (green). Kidney proximal tubules were co-stained 
with biotinylated Lotus Tetragonobolus lectine as marker followed by detection with 
Streptavidine-Texas Red (red). The glomeruli are denoted as G. A: No B°ATl-specific 
immunoreactivity was detected in the B°ATl-deficient mouse kidney sections. Only the marker 
was visible. B: B°AT1 staining was detected in the wt mouse slides as described above in the SI 
and S2 segments of the kidney proximal tubule. C: No specific staining of mouse tissue was 
observed with the usage of only secondary antibody. Original magnification, x40. Bars 
represent 10 nm. 
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Immunofluorescence staining of intestinal sections from B°ATl-deficient mice also 
failed to detect a signal for B°AT1 (Figure 5.4 A). As with the experiments on kidney 
sections, wt mouse intestine sections were stained in parallel with sections from the 
B°ATl-deficient mouse. The positive control showed B°AT1 staining in the apical 
membrane of the intestinal villi with more B°AT1 being expressed at the top of the villi 
gradually decreasing to the crypts (Figure 5.4 B). 
Figure 5.4: Localisation of B°AT1 in B°ATl-deficient and wt mouse intestine. 
B°AT1 was stained using a rabbit primary antibody detected by donkey-anti rabbit secondary 
antibody conjugated to AF 488 (green). A: No distinct B°ATl-specific immunoreactivity was 
detected in the B°ATl-deficient mouse sections. B: B°AT1 staining was detected in the apical 
membrane of the villi of wt mouse sections. Original magnification, x40. Bars represent 10 nm. 
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5.2.2 Amino acid transport of leucine and glutamine in B°AT1-deficient mice 
After confirmation of B°AT1 deletion in the B°ATl-deficient mice, the amino acid 
transport in the B°ATl-deficient mice was examined to determine the contribution to 
neutral amino acid transport by other proteins and a possible compensation for the 
lack of B°AT1. Renal BBMV were generated as described in Chapter 4 and immediately 
used for radioactive uptake studies as described in Chapter 4. Uptake was measured in 
NaCI-based and KCI-based buffer. Furthermore, the uptake studies were undertaken 
with and without preloading of the vesicles in order to examine the contribution of 
ASCT2 transport due to the antiport mechanism of ASCT2. 
As before [3H]leucine uptake (100 nM) was measured in BBMV generated from 
B°ATl-deficient mice not preloaded or preloaded with 30 mM glutamine and 4 mM 
ATP. 
In contrast to BBMV from wt kidneys, [3H]leucine uptake was the same under all 
conditions. (Figure 5.5). The transport at 15 sec was 0.24 ± 0.01 pmol/mg protein in 
Na+-based buffer in contrast to 0.25 ± 0.01 pmol/mg protein in the absence of Na+for 
non-preloaded BBMV. For preloaded BBMV a leucine transport of 
0.28 ± 0.02 pmol/mg protein in Na+-based buffer in contrast to 
0.23 ± 0.003 pmol/mg protein in K+-based buffer was detected. A small additional 
leucine transport was observed in preloaded BBMV in comparison to non-preloaded 
vesicles. 
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Figure 5.5: [3H]leucine transport into mouse renal brush border membrane vesicles 
(preloaded with 30 mM glutamine or not preloaded) in NaCI-based and KCI-based 
buffer. 
Non-preloaded renal BBMV were incubated with [3H]leucine (100 |iM) for 15 sec in NaCI-based 
buffer, denoted as 1 or KCI-based buffer, denotes as 2. The transport activity of BBMV 
preloaded with 30 mM glutamine was determined in the same way in NaCI-based buffer, 
denoted as 3, or KCI-based buffer, denoted as 4. Each bar represents the average of duplicates 
± standard deviation. Similar results were obtained in four different experiments. No increase 
of [3H]leucine uptake was observed with NaCI-based buffer in comparison to KCI-based buffer 
for non-preloaded vesicles and a 1.2 increase was observed for preloaded BBMV. 
Additionally, [3H]glutamine uptake was investigated, since it is the main substrate for 
ASCT2 (Figure 4.3). Preloaded and non-preloaded I BBMV were added to NaCI-based or 
KCI-based uptake buffer containing [3H]glutamine (100 pM). Non-preloaded vesicles 
were used as controls. A sample was taken after 15 sec and processed as described 
above. 
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The renal BBMV from B ATI-deficient mice showed a 1.5 fold increase of glutamine 
uptake in Na+-based buffer to KCI-based buffer control (p<0.05). Preloaded BBMV 
showed only a marginal, not significant increase of glutamine uptake in NaCI-based 
buffer to preloaded BBMV in KCI-based buffer (Figure 5.6) (p>0.05). The transport at 
15 sec was 0.36 ± 0.02 pmol/mg protein in Na+-based buffer in contrast to 0.24 ± 0.01 
pmol/mg protein in the absence from Na+for non-preloaded BBMV. Preloaded BBMV a 
glutamine transport of 0.29 ± 0.04 pmol/mg protein in NaCI-based buffer in contrast to 
0.25 ± 0.008 pmol/mg protein in K+-based buffer was detected. No additional 
glutamine transport was observed for preloaded BBMV in comparison to non 
preloaded vesicles (p>0.05). 
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Figure 5.6: [3H]glutamine transport into mouse renal brush border membrane 
vesicles (preloaded with 30 mM glutamine or non-preloaded) in NaCI and KCI buffer. 
Non-preloaded BBMV were incubated with [3H]glutamine (100 piM) for of 15 sec in NaCI-based 
buffer, denoted as 1 and KCI-based buffer, denoted as 2. Renal BBMV preloaded with 30 mM 
glutamine were treated in the same way in NaCI-based buffer are denoted as 3, and 4 in KCI-
based media. Each bar represents the average of duplicates ± standard deviation; * indicates 
statistical significance at p<0.05. Similar results were obtained in five different experiments. A 
1.5 fold increase of [3H]glutamine uptake was observed in NaCI-based buffer in comparison to 
KCI-based buffer for non-preloaded vesicles and a 1.16 fold increase was observed for 
preloaded BBMV. 
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5.3 Discussion 
5.3.1 Localisation of B°AT1 in B°ATl-deficient mice: 
Immunofluorescence studies with B°ATl-deficient mice in comparison to wt mice 
confirmed the lack of B°AT1 in B°ATl-deficient mice. No B°AT1 staining was observed 
in all segments of the kidney while in B°AT1 wt mice staining was detected in the SI 
and S2 segments as observed in Chapter 3. This represents the first characterisation of 
an SLC6A19-deficient mouse. A B°AT2-deficient mouse has been characterised by 
Drgonova et al., however, this study only focused on the localisation of B°AT2 in brain 
and not in kidney (Drgonova et al., 2007). Therefore, it would be very interesting to 
investigate the B°AT2-defient mouse in this matter to compare the B°AT2-deficient 
mouse to the B°ATl-deficient mouse. Furthermore it would be interesting to 
investigate the localisation of B°AT2 in the B°ATI-deficient mouse. 
The amino acid uptake into renal BBMV derived from B°ATI-deficient mice will be 
discussed in Chapter 6. 
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Amino acids are one of the basic building blocks for life and are crucially involved in 
most if not all biological processes. As a result, it is important to understand amino 
acid transport and reabsorption in organisms. In the last 10 to 15 years nearly all 
physiologically described amino acid transport systems (outlined in Table 1.1) in the 
kidney and the intestine have been identified at on the molecular level and 
characterised in different expression systems in some detail. By contrast, much less is 
known about their physiological contribution to amino acid transport in vivo. 
As outlined in the introduction, this thesis focuses on the neutral amino acid transport 
and reabsorption in mammals in the kidney and the intestine. More precisely, it 
investigates the relative contribution to neutral amino acid uptake of the transporters 
B°AT1, B°AT2 and ASCT2. 
Mutations in neutral amino acid transporters have been linked to diseases such as 
Hartnup Disorder (Kleta et al., 2004; Seow et al., 2004; Kowalczuk et al., 2008). A 
thorough analysis of epithelial amino acid transporters could not only elucidate the 
molecular correlation to diseases but also identify routes for drug delivery. 
Previous studies by Kleta et al. and Romeo et al. have examined the localisation of 
B°AT1 in mouse tissue via the use of immunofluorescence (Kleta et al., 2004; Romeo et 
al., 2006). They reported the presence of the transporter in the apical membrane of 
mouse proximal tubules. Both studies suggested expression of B°AT1 in the S I 
segment, but not in other segments of the kidney. 
These data are in agreement with earlier in-situ hybridisation studies by Broer et al. 
(2004), which reported expression of B°AT1 being restricted to S I and S2 segments of 
the kidney nephron. Finally, high levels of B°AT1 mRNA in mouse kidney were 
confirmed with RT-PCR (Romeo etai, 2006). 
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The results in Chapter 3 are consistent with this literature in terms of identifying the 
apical expression of the amino acid transporter B°AT1 in the SI and S2 segment of the 
mouse proximal nephron. B°AT1 was not observed in the S3 segment. These results 
are at variance with an RT-PCR analysis, where B°AT1 mRNA was detected in all 
segment of the mouse nephron except the glomerulus, the thick ascending limb and 
the distal tubules (Kleta et a!., 2004). The tissue isolation required for RT-PCR analysis 
does not provide the same cellular resolution as in s/'tu-hybridisation and 
immunofluorescence. As a result the discrepancy is likely to result from technical 
problems rather than refuting the more detailed localisation studies generated in this 
thesis and other more recent publications. 
In contrast to B°AT1, very little information was available about the B°AT2 
biodistribution in kidney. Previously, it was assumed that B°AT2 is a brain-specific 
transporter (Takanaga et a!., 2005). However, RT-PCR analysis revealed the presence of 
B AT2 mRNA not only in mouse brain but also in mouse kidney and lung (Broer et ai, 
2006). Thus a central question of this thesis was to determine the possible activity of 
B°AT2 in kidney. Utilising immunofluorescence techniques and proximal tubule specific 
markers, expression of B°AT2 protein was detected in the proximal tubule. Based on 
cell anatomy, expression was confined to the S2 and S3 segment (Figure 3.17). 
However, my results suggest low expression levels of B°AT2 in the kidney overall. The 
transporter is not expressed in the intestine. 
In comparison to B°AT1, B°AT2 seems to have a less important role due to the lower 
expression level and the more distal localisation along the proximal tubule. It has been 
known that amino acids transporters have a distinct distribution along the axis of the 
proximal tubule (Scriver and Tenenhouse, 1985). Transporters in the earlier segments 
of the proximal tubule tend to have higher capacity and broader specificity but lower 
affinity for their substrates, while transporters in the later segments of the proximal 
tubule possess lower capacity but higher affinity for a more select group of substrates. 
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B°AT1 and B°AT2 fit this pattern. B°AT1 accepts all neutral amino acids, has a low 
affinity for its substrates and is abundantly expressed in the S1/S2 segment of the 
proximal tubule. B°AT2, by contrast prefers branched-chain amino acids, has a higher 
affinity for its substrates and is expressed in smaller amounts in the S2/S3 segment of 
the proximal tubule. 
It has been suggested that in the early segments, where amino acid concentration is 
similar to that found in plasma, the reabsorption by transporters needs to be 
controlled or limited in order to protect the cells from osmotic overload. In later 
segments of the kidney, where the substrate concentration is lower, the transporters 
need to be of higher affinity in order to effectively retrieve the amino acids from the 
primary urine (Verrey, 2003). 
Similar to B°AT2, limited information was available about the ASCT2 expression in the 
kidney. Avissar et al. localised ASCT2 in rabbit kidney via immunohistochemistry in the 
apical membrane of the S I segment of the proximal convoluted tubule (Avissar et al., 
2001). In contrast, studies undertaken by Green et al. suggested localisation of ASCT2 
in the basolateral membrane of the proximal tubule in human kidney (Green et al., 
2004). 
In the study conducted by Vanslambrouck (2006) immunofluorescent techniques were 
used in combination with segment specific markers of the human nephron to clarify 
previous contradictions (Breedan, 2006). ASCT2 expression was detected in the apical 
membrane of the S2 and the S3 segments of the proximal convoluted tubule. 
Furthermore, the presence of the transporter was also observed in the basolateral 
membrane of the distal convoluted tubule. 
The observed localisation in the apical membrane is contrary to the observations of 
Avissar et al. (2001). However, the results of this study suggest that the ASCT2 
antibody does not recognise a specific epitope in paraformaldehyde-fixed tissue and 
therefore the results need to be interpreted with caution. In addition it has to be 
considered that the antibody for ASCT2 was raised against a synthetic peptide. 
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Holmseth et al. (2005) showed that with the use of these antibodies cross-reactivity to 
unrelated proteins is frequently observed and therefore interpretation of 
immunolocalisation should be done with caution. 
Previous investigations also showed that the cell surface expression of ASCT2 was 
significant higher at lower pH values of 6.2 to 6.7 in rat lenses (Lim et al., 2005) and 
foetal astrocytes (Gegelashvili et al., 2006). It is known that the pH of the kidney 
ultrafiltrate changes gradually from 7.4 to approximately 6.8 and therefore could 
explain the different localisations of ASCT2 on the apical membrane. Although these 
results would not explain the basolateral expression of ASCT2 and therefore the results 
should be interpreted with caution. 
As an amino acid exchanger ASCT2 is unlikely to have a prominent role in 
transepithelial transport of amino acids. A possible role of ASCT2 at the basolateral 
membrane of the distal tubules could be to equilibrate cytoplasmatic amino acids by 
releasing excess amino acids. This role has been discussed, but experimental proof is 
missing and needs further investigation (Verrey et al., 2005). Future experiments could 
be conducted using transwell plates. These plates allow the cells to differentiate and 
form apical and basolateral sides to the cell layer as they polarise allowing access to 
investigate expression and functional activity of the transporters on both sides of the 
membrane. OK is a cell line derived from possum kidney, showing characteristics of the 
proximal tubule, such as Na+-dependent transport systems and enzymes located in the 
apical membrane such as alkaline phosphatase (Koyama et al., 1978; Cheng et al., 
1988) and could be used for these experiments. 
The detection of ASCT2 in the basolateral membrane of crypt cells in the intestine is 
also at variance to the report of Avissar et al. (2001), where ASCT2 was suggested to be 
expressed in the apical membrane of the ileum but only weakly in the crypt cells. An 
ASCT2-like transport activity has been detected in rabbit small intestine and has been 
suggested to contribute to L-glutamate uptake. This is consistent with uptake of 
L-glutamate transport via ASCT2 at lower pH (Utsunomiya-Tate et al., 1996). 
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Thus, it appears likely that ASCT2 corresponds to the glutamate transport activity 
described in rabbit ileum (Munck and Munck, 1999). With the localisation in the 
intestinal crypt cells, ASCT2 cannot accomplish this transport. 
According to the results obtained with the different fixation methods it would be 
worthwhile to repeat the immunofluorescence experiments with specimens fixed in 
acetone instead of paraformaldehyde to exclude possible damage of the antigens. It 
also has to be considered, that the ASCT2 localisation conducted by Vanslambrouck 
was conducted with human specimens. Therefore, it would be interesting to 
investigate, if localisation studies in different species obtain different results. 
As outlined above, the biodistribution data did not provide an unambiguous answer as 
to the role of ASCT2 in amino acid reabsorption. The substrate specificies of all three 
neutral amino acid transporters have been characterised in the Xenopus laevis 
expression system in some detail (Utsunomiya-Tate et al., 1996; Bohmer et al., 2005; 
Broer et al., 2006). However, to date no study has been conducted to reveal their 
contribution to neutral amino acid transporter in vivo. However, studies with BBMV 
have been conducted for amino acid transport without knowing the substrate 
specificity of the different systems (Murer and Kinne, 1980; Murer and Gmaj, 1986; 
Satoh et al., 1989). 
In particular both B°AT1 (Verrey et al., 2005; Broer, 2008) and ASCT2 (Kekuda et al., 
1996; Avissar et al., 2001) have been suggested to represent the main Na+-dependent 
transport activity for neutral amino acids in kidney and intestine (system B°). Chapter 4 
thus analysed the contribution to epithelial neutral amino acid transport by B°AT1, 
B°AT2 and ASCT2 using BBMV derived from mouse kidney. 
The lack of stimulation of [3H]leucine or [3H]glutamine uptake in preloaded vs non-
preloaded vesicles, was inconsistent with a significant contribution of ASCT2 to neutral 
amino acid transport. This result refutes the suggestion of Avissar et al. that ASCT2 
represents the B° activity in kidney and intestine (Avissar et al., 2001). 
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Further weight to this argument was added by the use of BBMV derived from kidneys 
of B°ATI-deficient mice. The reduction of Na+-dependent glutamine transport by more 
than 70% in comparison to BBMV derived from wildtype mice (Figure 4.9) confirms 
that B°AT1 is the main Na -dependent glutamine transporter in kidney. 
However, the slight increase in glutamine uptake with non-preloaded, renal BBMV 
indicated the possible presence of another Na+-dependent glutamine transporter. 
Since no additional transport is.observed in preloaded BBMV, ASCT2 is unlikely to be a 
candidate for this transporter. 
To discriminate between the contribution of B°AT1 and B°AT2, [14C]leucine-uptake was 
challenged by unlabelled substrates The key substrate in this experiment was glycine, 
which is a substrate for B°AT1 only. The strong inhibition of leucine uptake by glycine 
further confirms that B°AT1 is the predominant neutral amino acid transporter in the 
apical membrane of the kidney proximal tubule. The lack of B°AT2 activity was 
confirmed in BBMV derived from B°ATl-deficient mice, showing a lack of 
Na+-dependent [3H]leucine uptake. Recently a B°AT2-deficient mouse was 
characterised by Drgonova et al. However, only amino acid uptake in synaptosomes 
was studied in these mice (Drgonova et al., 2007). Transport studies with this mouse 
using kidney BBMV or sections of intestine were unfortunately missing but would be 
interesting to investigate the possible role of B°AT2. 
In summary the results of this thesis strongly support the notion that B°AT1 is the 
major if not only Na+-dependent, broad neutral amino acid transport activity in kidney 
cortex. However, another possible candidate is B°AT3 because recent investigations 
showed it is mainly an alanine and glycine transporter (Vanslambrouck et al., 2010) 
that is expressed in the kidney. It could therefore, be involved in transport of those 
neutral amino acids. It would be worthwhile conducting transport experiments with 
BBMV derived from B°ATl-deficient mice with the different substrate for 
B°AT3. Na+-dependent transport of those substrates would be likely to be from B°AT3 
since B°AT2 and ASCT2 were excluded in this thesis. 
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Leucine uptake into renal BBMV derived from B°ATl-deficient mice showed no 
evidence of Na+-dependent leucine transport. Therefore, B°AT1 seems to be the only, 
functional Na+-dependent leucine transporter in the kidney. However, it needs to be 
analysed if the low levels of leucine transport observed in both NaCI- and KCI-based 
buffer reflects Na+-independent transport or binding of radioactive substrate to the 
vesicles. 
A possible candidate for the remaining leucine transport is B°AT3. As described 
previously, B°AT3 is mainly an alanine and glycine transporter but also shows low 
transport activity for leucine (Vanslambrouck et al., 2010). To investigate the role of 
B°AT3, leucine uptake in competition with glycine should be measured in BBMV 
derived from B°ATl-deficient mice. Another possible candidate for the remaining 
transport activity is the system L-like transporter LAT2/4F2 arising from cross-
contamination of the vesicles with basolateral membrane fragments. 
As described in the introduction, LAT2/4F2 is a Na+-independent transporter for large 
neutral amino acids, which in the kidney is made up of a heterodimer of the LAT2 light 
chain and the 4F2 heavy chain. However, its activity would only be revealed in 
preloaded vesicles because it catalyses an antiport mechanism (Kanai et al., 1998; 
Pineda et al., 1999). This would also be consistent with the marginal increase of 
leucine transport in preloaded BBMV. However, only LAT2/4F2 would explain this 
transport activity but not the non-identified uniporter with system L activity. One 
possibility to investigate the involvement of LAT2/4F2 is to test radio-labelled leucine 
uptake in the presence of system L inhibitors, such as BCH. 
In contrast to leucine uptake, BBMV derived from B°ATl-deficient mice still showed a 
significant amount of Na+-dependent glutamine uptake. A possible candidate for this 
Na+-dependent glutamine transporter in the kidney could be SNAT2. The 
Na+-dependent, system A transporter SNAT2 is a symporter and has been found in the 
kidney, but is not known to be expressed in the apical membrane. (Hatanaka et al., 
2000; Reimer et al., 2000; Sugawara et al., 2000; Yao et al., 2000; Hatanaka et al., 
2001; Armano et al., 2002; Chaudhry et al., 2002; Mackenzie et al., 2003). 
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Uptake experiments with the system A substrate analogue MeAlB could provide 
indication for the presence of SNAT2 in the apical membrane. LAT2/4F2 can be 
excluded as a possible candidate since it is Na+- independent and therefore would 
show similar levels of activity in NaCI-based and KCI-based buffer (Rossier et a!., 1999). 
In summary, the studies presented in this thesis have determined the distribution and 
contribution of neutral amino acid transporter B°AT1, B°AT2 and ASCT2 in vivo. It is 
now without doubt that the neutral amino acid transporter B AT I is the main, 
Na+-dependent neutral amino acid transporter in the kidney. Therefore, B ATI and not 
ASCT2, as suggested by Avissar et al., is the actual B° activity in the kidney (Avissar et 
a!., 2001). 
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Antibody Description Raised in Supplier 
Primary antibodies 
Anti-mouse B°AT1 
N-term 
Anti-mouse B°ATlN-term 
(against GST fusion protein) rabbit Pineda 
Anti-human B°AT1 
N-term 
Anti-mouse B°ATlN-term 
(against GST fusion protein) chicken Pineda 
Anti-mouse B°AT2 N-
term 
Anti-mouse B°AT2 N-term 
(against GST fusion protein) rabbit Pineda 
Anti-mouse B°AT2 C-
term 
Anti-mouse B°AT2 C-term 
(against GST fusion protein) rabbit Pineda 
Anti-mouse ASCT2 N-
term 
Anti-mouse ASCT2 
(against a ASCT2 N-term 
peptide) 
rabbit Pineda 
Anti-human ASCT2 C-
term 
Anti-human ASCT2 
(against a ASCT2 C-term 
peptide) 
rabbit Avissar laboratory 
Anti-mouse CD98 Anti-mouse rat Pharmingen 
LTL Biotinylated Lotus 
Tetragonolobus lectin 
Vector 
Laboratories 
Secondary antibodies 
Alexa Fluor 488 
(AF488) donkey anti-
rabbit IgG 
Alexa Fluor 488 conjugated 
to an anti-rabbit IgG 
donkey Invitrogen 
Alexa Fluor 488 
(AF488) goat anti-
chicken IgG 
Alexa Fluor 488 conjugated 
to an anti-chicken IgG 
goat Invitrogen 
Texas Red Strepavidin 
Texas Red conjugated to 
Strepavidin 
Vector 
Laboratories 
ECL Anti-rabbit IgG, 
horseradish 
peroxidise (HRP) 
Horseradish peroxidase 
conjugated to a mouse IgG 
mouse Amersham 
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Dilution for Western Blot analysis 
Detected protein Primary antibody Secondary antibody 
B°AT1 Anti-mouse B°AT1 N-term Anti-rabbit HRP 
1:3,000 1:5,000 
B°AT2 Anti-mouse B°AT2 N-term Anti-rabbit HRP 
1:3,000 1:5,000 
ASCT2 Anti-mouse ASCT2 N-term Anti-mouse HRP 
1:500 1:2,000 
ASCT2 Anti-human B°AT1 N-term Anti-mouse HRP 
1:1,000 1:5,000 
4F2 Anti-mouse CD98 Anti-mouse HRP 
1:500 1:10,000 
Dilution for immunofluorescence studies with oocytes 
Detected protein Primary antibody Secondary antibody 
B°AT1 Anti-mouse B°ATlN-term 
1.200 
AF488 donkey anti-rabbit 
1:1000 
B°AT1 Anti-human B°AT1 N-term 
1:200 
AF488 goat anti-chicken 
1:1000 
B°AT2 Anti-mouse B°AT2 N-term 
N/C1:200 
AF488 donkey anti-rabbit 
1:800 
Dilution for immunofluorescence studies on cells 
Detected protein Primary antibody Secondary antibody 
B°AT2 Anti-human B°AT1 N-term 
1:50 
AF488 donkey anti-rabbit 
1:600 
ASCT2 Anti-mouse ASCT2 N-term 
1:50 
AF488 donkey anti-rabbit 
1:800 
ASCT2 Anti-human B°AT1 N-term 
1:50 
AF488 donkey anti-rabbit 
1:800 
Dilution for immunofluorescence studies on tissue 
sections 
Detected protein Primary antibody Secondary antibody 
B°AT1 B°AT1 Nterm 
1:500 
AF488 donkey anti-rabbit 
1:800 
B°AT2 B°AT2 N-term 
1:60 
AF488 donkey anti-rabbit 
1:800 
LTL Biotinylated Lotus 
Tetragonolobus lectin 
1:400 
Texas Red Streptavidin 
1:300 
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Primer name Sequence (5' 3') Purpose 
Primers used for PCR 
B°AT2 with *Hind\\\s CAGAAGCTTCCACCATGCCTAAGA Generating B0AT2 with 
Hind\\\ at 5'-end 
B°AT2 with Xfaola CAGTCTAGACTACAAGTCAGACTC Generating B0AT2 with Xba\ 
at 3'-end 
Primers used for RT PCR 
Actin-sense GCTCACCATGGATGATGATATCGC Generating actin (lkb) 
Actin antisense GGAGGAGCAATGATCTTGATCTTC Generating actin (lkb) 
Mv7-3Ntermls ATGCCTAAGAATAGCAAAGTG Generating B°AT2 N-term 
Mv7-3Ntermla TTGCAGCTTACTGTTCCAGGC Generating B°AT2 N-term 
Mv7-3Ctermls CGTCGCTGCAACCTCATAGAT Generating B°AT2 C-term 
Mv7-3Ctermla CAAGTCAGACTCTGGCATATC Generating B°AT2 C-term 
Primers used for sequencing 
B02 into pcDNAa CTCAGTGGAAGAGGTTTCTAAGAAG Sequencing B°AT2-pcDNA 
B02 into pcDNAs CAAGTGGTTCCCCAACACTGG Sequencing B°AT2-pcDNA 
B02 in pcDNA seq s GACTCAGTGGAAGAGGTTTCTAAG Sequencing B°AT2-pcDNA 
pcDNA3.1 rev TAGAAGGCACAGTCGAGG Sequencing pcDNA 
SP6 ATTAGGTGACACTATAG Sequencing from the SP6 
promotor 
T7 TAATACGACTCACTATAGGG Sequencing from the T7 
promotor 
